Tetrahydro-1H-cyclopenta [CD] indene derivatives as hypoxia inducible factor-2 (alpha) inhibitors
By developing tetrahydro-1H-cyclopentadiene and [CD] indene derivatives as HIF-2α inhibitors, the problem of HIF-2α activity is solved, and a variety of diseases such as cancer, inflammatory bowel disease and Effective treatment of pulmonary hypertension.
Patent Information
- Application Number
- CN202411099450.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-12-10
- Filing Date
- 2020-04-16
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively inhibit the activity of HIF-2α, resulting in challenges in the treatment of related diseases such as cancer, inflammatory bowel disease, pulmonary hypertension and iron load disorders.
A class of tetrahydro-1H-cyclopentadiene [CD]indene derivatives were developed as inhibitors of hypoxia-inducible factor-2(α) to inhibit HIF-2α and thus treat related diseases.
By inhibiting HIF-2α, it significantly reduces tumor growth, immunosuppression and inflammation response, improves pulmonary vascular remodeling and iron absorption, providing a potential multidisease treatment strategy.
Smart Images

Figure BDA0004988964610000061 
Figure BDA0004988964610000071 
Figure BDA0004988964610000091
Abstract
Description
[0001] This application is a divisional application of an invention patent application with an application date of April 16, 2020, application number 202080027716.4, and invention name “Tetrahydro-1H-cyclopenta[CD]indene derivatives as hypoxia-inducible factor-2(α) inhibitors”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application is an international application claiming the benefit of U.S. Provisional Application No. 62 / 836,019, filed on April 18, 2019, and U.S. Provisional Application No. 62 / 946,191, filed on December 10, 2019, the contents of which are incorporated herein by reference in their entirety. Technical Field
[0004] The present disclosure provides certain tetrahydro-1H-cyclopenta[cd]indene compounds that are hypoxia-inducible factor 2α (HIF-2α) inhibitors and are therefore useful for treating diseases that can be treated by inhibiting HIF-2α. Pharmaceutical compositions containing such compounds and methods for preparing such compounds are also provided. Background Art
[0005] Hypoxia is an important regulator of both physiological and pathological processes including various types of cancer, liver diseases such as nonalcoholic steatohepatitis (NASH), inflammatory diseases such as inflammatory bowel disease (IBD), lung diseases such as pulmonary arterial hypertension (PAH), and iron overload disorders.
[0006] It is well known that hypoxia drives cancer progression and is associated with poor patient prognosis, resistance to chemotherapy and radiation therapy. With the progress in the past decades in clarifying the molecular mechanisms that enable cells to adapt to chronic hypoxia, there is a strong focus on developing drugs that can effectively block hypoxia response pathways in tumors. Among the signal transduction modules that have been developed as therapeutic targets for treating cancer and involve hypoxia response, HIF-α proteins continue to attract attention because they provide the possibility of extensive inhibition of downstream hypoxia effects in both tumors and tumor microenvironments. Therefore, directly targeting HIF-α proteins provides an exciting opportunity to attack tumors on multiple fronts (see Keith et al., Nature Rev. Cancer [Cancer Natural Review] 12: 9-22, 2012).
[0007] Hypoxia-inducible factors (HIF-1α and HIF-2α) are key transcription factors in the hypoxic pathway and are therefore used as attractive targets for therapeutic intervention. The half-life of HIF-α proteins is tightly regulated by the oxidative state within the cell. Under normoxic conditions, HIF-specific prolyl-hydroxylases (PHDs) hydroxylate specific proline residues on HIF proteins, which are then recognized by the tumor suppressor von Rippel-Lindau (VHL). The binding of VHL further recruits the E3 ubiquitin-ligase complex that targets HIF-α proteins for proteasome-mediated degradation. Under hypoxic conditions, when PHDs are inhibited (because they require oxygen to function), HIF-α proteins accumulate and enter the nucleus to actively drive gene expression. In addition, genetic mutations in the VHL gene that cause loss of VHL function can result in constitutively active HIF-α proteins, regardless of oxygen content. Upon activation, these transcription factors stimulate the expression of genes that collectively regulate anaerobic metabolism, angiogenesis, cell proliferation, cell survival, extracellular matrix remodeling, pH homeostasis, amino acid and nucleotide metabolism, and genomic instability.
[0008] Both HIF-1α and HIF-2α dimerize with HIF-1β (also known as ARNT: aryl hydrocarbon receptor nuclear translocator), and the dimer then binds to the hypoxia response element (HRE) on the target gene. The expression of HIF-1β is independent of the oxygen content of the VHL state, and therefore, the transcriptional activity of the complex is mainly controlled by the availability of HIF-α protein. HIF-1α and HIF-2α differ in their tissue distribution, sensitivity to hypoxia, activation time course and target gene specificity (Hu et al., Mol. Cell Biol. [Molecular and Cell Biology] 23: 9361-9374, 2003 and Keith et al., Nature Rev. Cancer [Cancer Natural Review] 12: 9-22, 2012). However, HIF-1α mRNA is ubiquitously expressed, and the expression of HIF-2α mRNA is mainly found in renal fibroblasts, hepatocytes and intestinal epithelial cells. No HIF-α was detected in normal tissues except HIF-2α, which is expressed in macrophages (see Talks et al., Am. J. Pathol. [American Journal of Pathology] 157: 411-421, 2000). In response to hypoxia, HIF-1α exhibits a short acute transcriptional response. In contrast, HIF-2α exhibits a more prolonged transcriptional effect. In addition, HIF-2α has greater transcriptional activity than HIF-1α under moderate hypoxic conditions (such as those encountered in terminal capillaries) (see Holmquist-Menge / bier et al., Cancer Cell [Cancer Cell] 10: 413-423, 2006). Although some hypoxia-regulated genes are regulated by both HIF-1α and HIF-2α, some genes only respond to specific HIF-α proteins. For example, lactate dehydrogenase A (LDHA), phosphoglycerate kinase (PGK), and pyruvate dehydrogenase kinase 1 (PDK1) are mostly controlled by HIF-1α, whereas Oct-4 and erythropoietin (EPO) are exclusively regulated by HIF-2α.
[0009] In general, the relative contribution of HIF-α protein to gene transcription is cell type specific and disease specific. In fact, there are reports supporting that HIF-α protein plays a contradictory role in tumorigenesis. An example is the regulation of MYC by HIF-α, which is an important transcription factor and frequently overexpressed in human cancers. It has been shown that HIF-2α activation increases MYC transcriptional activity, while HIF-1α inhibits MYC activity. Therefore, in MYC-driven tumors, HIF-2α inhibition reduces proliferation, while HIF-1α inhibition increases growth (see Gordan et al., Cancer Cell [Cancer Cell] 11: 335-347, 2007 and Koshiji et al., EMBO J. [Journal of the European Molecular Biology Association] 23: 1949-1956, 2004). Therefore, it is necessary to identify small molecules that specifically inhibit HIF-2α activity. Furthermore, HIF-2α was demonstrated to be an important driver of clear cell renal cell carcinoma (ccRCC) with VHL deficiency and several other pseudo-hypoxic tumors including but not limited to glioblastoma, neuroblastoma, somatostatinoma, leiomyoma / leiomyosarcoma, polycythemia vera, and retinal abnormalities, etc. Therefore, HIF-2α inhibitors would provide therapeutic benefits with limited toxicity compared to pan-HIF-α inhibitors.
[0010] In addition to its direct role in regulating growth-promoting genes in tumor cells (e.g., ccRCC), HIF-2α also mediates the immunosuppressive effects of hypoxia on the tumor microenvironment. Expression of HIF-2α has been detected in myeloid cells, and accumulation of HIF-2α protein has been readily detected in various human cancers (see Talks KL et al., Am J Pathol. [American Journal of Pathology] 2000; 157(2): 411-421). Overexpression of HIF-2α in tumor-associated macrophages (TAMs) is associated with high-grade human tumors and is associated with poor prognosis. Institutionally, HIF-2α promotes macrophage polarization into an immunosuppressive M2 phenotype and enhances migration and invasion of tumor-associated macrophages (see Imtiyaz HZ et al., J Clin Invest. [Clinical Research Journal] 2010; 120(8): 2699-2714). In addition, HIF-2α can indirectly promote other immunosuppressive pathways (e.g., adenosine and arginase, etc.) by regulating the expression of key signaling regulators (e.g., adenosine A2B / A2A receptors and arginase). These data suggest that HIF-2α may be a potential therapeutic target for treating a wider range of inflammatory disorders and cancers as a single agent or in combination with other therapeutic agents (e.g., immunotherapy).
[0011] Due to the role of HIF-α proteins in regulating the physiological response to changes in oxygen content, in addition to cancer, they are also causally related to many pathological processes associated with hypoxia. Inflammatory bowel disease (IBD) is a chronic relapsing inflammatory disease of the intestine. Normally, the intestine maintains dynamic and rapid fluctuations in cellular oxygen tension, in which the tip of the epithelial villi is hypoxic and the base of the epithelial villi is better oxygenated. Disturbance of epithelial oxygen tension plays a role in the regression of intestinal inflammation and IBD (see Shah YM, Molecular and Cellular Pediatrics [Molecular and Cellular Pediatrics], December 2016; 3 (1): 1). Although HIF-1α and HIF-2α can bind to the same typical HRE, various studies have confirmed that HIF-1α and HIF-2α regulate different subsets of genes, resulting in opposite effects in the symptoms of IBD. HIF-1α in intestinal epithelial cells is widely recognized as a major protective factor in IBD (see Karhausen J et al., J Clin Invest. 2004; 114(8): 1098-1106; Furuta GT et al., J Exp Med. 2001; 193(9): 1027-1034). However, HIF-2α activation contributes to IBD through multiple mechanisms, including direct regulation of multiple proinflammatory cytokines, such as tumor necrosis factor-α, to drive inflammation, and indirect disruption of intestinal barrier integrity by increasing turnover of tight junction protein occlusives (see Xue X et al., Gastroenterology. 2013; 145(4):831-841; Glover LE et al., Proc Natl Acad Sci USA. 2013; 110(49):19820-19825). Therefore, in IBD, HIF-2α inhibitors hold promise for inhibiting chronic activation of HIF-2α to restore proinflammatory responses and increase intestinal barrier integrity.
[0012] With the increasing prevalence of obesity and metabolic syndrome, NASH is becoming a common chronic liver disease, and the available treatment options are limited. Recent studies have confirmed a positive correlation between intestinal HIF-2α signaling and body mass index and hepatotoxicity, and further animal model studies support the causal relationship of this relationship (see Xie C et al., Nat Med. [Natural Medicine] November 2017; 23 (11): 1298-1308.). Therefore, targeting intestinal HIF-2α represents a novel therapeutic strategy for NASH.
[0013] PAH is a life-threatening disease with a very poor prognosis. Progressive pulmonary vascular remodeling (characterized by coaxial pulmonary artery wall thickening and occlusive intimal lesions) is one of the main causes of increased pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) in patients with PAH (see Aggarwal S et al., Compr Physiol. 2013 July; 3(3): 1011-34). Recently, HIF-2α was found to contribute to the process of hypoxic pulmonary vascular remodeling, reduce the plasticity of the vascular bed, and ultimately weaken PAH (see Andrew S et al., Proc Natl Acad Sci US A. 2016 August 2; 113(31): 8801-8806, Tang H et al., Am J Physiol Lung Cell Mol Physiol. 2018 February 1; 314(2): L256-L275). These studies have provided new insights into the role of pulmonary endothelial HIF-2α in regulating the pulmonary vascular response to hypoxia and offer a much-needed interventional therapeutic strategy by targeting HIF-2α.
[0014] Iron is an essential nutrient required for oxygen delivery and is used as a cofactor in many key enzymatic and redox reactions. HIF-2α regulates the expression of key genes that contribute to iron absorption, which, when iron absorption is disrupted, leads to iron load disorders. For example, a sophisticated study using mice lacking HIF-2α in the intestinal epithelium showed that HIF-2α knockout resulted in a significant reduction in the levels of Dmt1, Dcytb, and FPNmRNA (all important genes in iron transport and absorption) in the duodenum. More importantly, these effects are not compensated by HIF-1α (see Mastrogiannaki M et al., J Clin Invest. [Clinical Research Journal] 2009; 119 (5): 1159-1166). Therefore, small molecules targeting HIF-2α have the potential to improve iron homeostasis in patients with iron disorders. Therefore, it is necessary to identify small molecules that inhibit HIF-2α activity. The present disclosure meets this need and related needs. Summary of the invention
[0015] In a first aspect, there is provided a compound having formula (IA):
[0016]
[0017] in:
[0018] X 1 is CH or N;
[0019] R 1Hydroxyl, halogen, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 、-OCOOR 11 、-OCONR 12 R 13 、-OCHR 14 OCOR 15 or-OCHR 14 OCOOR 15a , where R 10 , R 11 , and R 15 and R 15a are independently alkyl or alkyl substituted by amino, carboxyl or hydroxyl, R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxyl, or hydroxyl, or R 12 and R 13 Together with the nitrogen atom to which it is attached, it forms an optionally substituted heterocyclic group, and each R 14 is hydrogen, alkyl or haloalkyl;
[0020] R 2 is hydrogen, deuterium, alkyl, halo, haloalkyl, alkenyl or alkynyl;
[0021] R 2a is hydrogen, halogenated or deuterated;
[0022] R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or
[0023] R 3 and R 4 together with the carbon to which it is attached, form oxo, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene;
[0024] R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy;
[0025] R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or
[0026] R 5 and R 6 together with the carbon to which it is attached, form oxo, alkyldienyl, 3-6 membered cycloalkylene, or 4-6 membered optionally substituted heterocyclylene; provided that R 5 With R 6 and R 3 With R 4together with the carbon to which it is attached, do not simultaneously form oxo, cycloalkylene, or optionally substituted 4- to 6-membered heterocyclylene;
[0027] R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl or haloalkoxy;
[0028] L is a bond, S, SO, SO2, O, CO or NR 16 , where R 16 is hydrogen or alkyl;
[0029] R 8 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl or heteroaralkyl, wherein aryl or heteroaryl (each by itself or as part of aralkyl or heteroaralkyl), or heterocyclyl (each by itself or as part of heterocyclylalkyl) is substituted by R a , R b , R c , R g and R h Substitution, where R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidene, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h are independently selected from hydrogen, deuterium and halo; and
[0030] R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl or heteroaryl, wherein the heteroaryl is optionally substituted by R independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo and cyano d , R e and R f replace; or
[0031] When R 9 and R 2 When attached to the same carbon atom, they may combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene;
[0032] R 9a is hydrogen, halogenated or deuterated;
[0033] or pharmaceutically acceptable salts thereof.
[0034] In a first embodiment of the first aspect, there is provided a compound having formula (I):
[0035]
[0036] in:
[0037] X 1 is CH or N;
[0038] R 1 Hydroxyl, halogen, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 、-OCOOR 11 、-OCONR 12 R 13 、-OCHR 14 OCOR 15 or-OCHR 14 OCOOR 15a , where R 10 , R 11 , and R 15 and R 15a are independently alkyl or alkyl substituted by amino, carboxyl or hydroxyl, R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxyl, or hydroxyl, or R 12 and R 13 Together with the nitrogen atom to which it is attached, it forms an optionally substituted heterocyclic group, and each R 14 is hydrogen, alkyl or haloalkyl;
[0039] R 2 is hydrogen, deuterium, alkyl, halo, haloalkyl, alkenyl or alkynyl;
[0040] R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or
[0041] R 3 and R 4 together with the carbon to which it is attached, form oxo, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene;
[0042] R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy;
[0043] R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or
[0044] R 5 and R 6 together with the carbon to which it is attached, form a 3- to 6-membered cycloalkylene or a 4- to 6-membered optionally substituted heterocyclylene; provided that R 5 and R 6 and R 3 and R 4 together with the carbon to which it is attached, do not simultaneously form a cycloalkylene or an optionally substituted 4- to 6-membered heterocyclylene;
[0045] R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl or haloalkoxy;
[0046] L is a bond, S, SO, SO2, O, CO or NR 16 , where R 16 is hydrogen or alkyl;
[0047] R 8 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl or heteroaralkyl, wherein aryl or heteroaryl (each by itself or as part of aralkyl or heteroaralkyl), or heterocyclyl (by itself or as part of heterocyclylalkyl) is independently selected from the following R a , R b and R c Substituted: hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidene, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl; and
[0048] R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl or heteroaryl, wherein the heteroaryl is optionally substituted by R independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo and cyano d , R e and R f replace; or
[0049] When R 9 and R 2 When attached to the same carbon atom, they may combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene;
[0050] or pharmaceutically acceptable salts thereof.
[0051] In a second aspect, there is provided a crystalline form of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (Compound 5), designated as polymorph Form A, having an X-ray powder diffraction pattern comprising peaks at angular positions 15.8 and 18.6, wherein these angular positions may vary by +0.2° 2θ, as determined by X-ray powder diffraction using (CuKα) In a first embodiment of the second aspect, the A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 15.8, 18.6, and 20.1, wherein these angular positions can vary by +0.2° 2θ. In a second embodiment of the second aspect, the A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 12.9, 15.8, 18.6, and 20.1, wherein these angular positions can vary by +0.2° 2θ. In a third embodiment of the second aspect, the A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 11.4, 12.9, 15.8, 18.6, and 20.1, wherein these angular positions can vary by +0.2° 2θ. In a fourth embodiment of the second aspect, the A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at angular positions 10.0, 11.4, 12.9, 15.8, 18.6, and 20.1, wherein the angular positions can vary by +0.2° 2θ. In a fifth embodiment of the second aspect, the A polymorph exhibits an X-ray powder diffraction pattern comprising peaks at the angular positions shown in Table A below, wherein the angular positions can vary by +0.2° θ. In a sixth embodiment of the second aspect, the A polymorph exhibits an X-ray powder diffraction pattern comprising at least one peak (in some embodiments, at least two peaks, at least three peaks, at least four peaks, or at least five peaks) at the angular positions shown in Table A below, wherein the angular positions can vary by +0.2° θ.
[0052]
[0053]
[0054] In a sixth embodiment of the second aspect, the A polymorph Form exhibits substantially Figure 1 The X-ray powder diffraction pattern shown in . Essentially for the sixth embodiment, ±0.2° 2θ is used. In the seventh embodiment of the second aspect and the first to sixth embodiments thereof, the peaks represented therein have an error margin of ±0.1° 2θ.
[0055] In a third aspect, the disclosure relates to a method of treating a disease treatable by inhibiting HIF-2α in a patient (preferably a patient in need of such treatment), the method comprising administering to the patient (preferably a patient in need of such treatment) a therapeutically effective amount of (i) a compound of formula (IA) or (I) (or any of its embodiments described herein) or a pharmaceutically acceptable salt thereof; or (ii) the Form A polymorph of Compound 5 as defined in the second aspect above or any of its embodiments.
[0056] In one embodiment of the third aspect, the disease is cancer, such as renal cancer, glioblastoma (see PNAS [Proceedings of the National Academy of Sciences of the United States of America] 2017, 114, E6137-E6146), renal cell carcinoma, neuroblastoma, pheochromocytoma and paraganglioma (see European Journal of Cancer [European Journal of Cancer] 2017, 86, 1-4), somatostatinoma, hemangioblastoma, gastrointestinal stromal tumor (GIST), pituitary tumor, leiomyoma, leiomyosarcoma, polycythemia or retinal tumor. In another embodiment, non-cancer diseases that may benefit from Hif-2α inhibition include VHL (Hippel-Lindau) disease (see Oncotarget, 2015, 6, 23036-23037), PAH (pulmonary arterial hypertension) (see Mol. Cell. Biol. 2016, 36, 1584-1594), reflux esophagitis (see Current Opinion in Pharmacology 2017, 37:93-99), hepatic steatosis (see Nature Medicine 2017, 23, 1298-1308), NASH, inflammatory diseases (such as inflammatory bowel disease (see Nature Reviewsgastroenterology&Hepatology [Nature Reviews, Gastroenterology and Hepatology] 2017, 14, 596)), autoimmune diseases (such as graft-versus-host disease (see Blood [Blood], 2015, 126, 1865)) or iron overload.
[0057] In a fourth aspect, the disclosure relates to a pharmaceutical composition comprising (i) a compound of Formula (IA) or (I) (or any of its embodiments described herein) or a pharmaceutically acceptable salt thereof; or (ii) the Form A polymorph of Compound 5 as defined in the second aspect above or any of its embodiments; and a pharmaceutically acceptable excipient. The disclosure relates to utilizing the Form A polymorph of Compound 5 as defined in the second aspect above or any of its embodiments; and a pharmaceutically acceptable excipient.
[0058] In a fifth aspect, the present disclosure relates to (i) a compound of formula (IA) or (I) (or any embodiment thereof as described herein) or a pharmaceutically acceptable salt thereof or (ii) a Form A polymorph of Compound 5 as defined in any one of the second aspect or embodiments thereof above, for use as a medicament. In one embodiment, a compound of formula (I) (and any embodiment thereof as described herein) or a pharmaceutically acceptable salt thereof or a Form A polymorph of Compound 5 as defined in any one of the second aspect or embodiments thereof above can be used to treat one or more of the diseases disclosed in the third aspect above.
[0059] In a sixth aspect, there is provided (i) a compound of formula (IA) or (I) or a pharmaceutically acceptable salt thereof (and any embodiments thereof disclosed herein); or (ii) the A-type polymorph of compound 5 as defined in any one of the second aspect or embodiments thereof above in the manufacture of a medicament for treating a disease in a patient, wherein the activity of HIF2α contributes to the pathology and / or symptoms of the disease. In one embodiment, the disease is one or more of the diseases disclosed in the third aspect above.
[0060] In a seventh aspect, a method for inhibiting HIF2α is provided, the method comprising contacting HIF2α with (i) a compound of formula (IA) or (I) (or any one of its embodiments described herein) or a pharmaceutically acceptable salt thereof; or (ii) the A-type polymorph of compound 5 as defined in any one of the second aspect or its embodiments above; or contacting HIF2α with a pharmaceutical composition comprising (i) a compound of formula (IA) or (I) (or any one of its embodiments described herein) or a pharmaceutically acceptable salt thereof; or (ii) the A-type polymorph of compound 5 as defined in any one of the second aspect or its embodiments above, and a pharmaceutically acceptable excipient.
[0061] In any of the above aspects relating to the treatment of cancer, further embodiments include administering (i) a compound of formula (IA) or (I) or a pharmaceutically acceptable salt thereof (or any embodiments thereof disclosed herein) or (ii) the Form A polymorph of compound 5 as defined in any of the above second aspect or embodiments thereof, in combination with at least one additional anticancer agent, such as the EGFR inhibitor gefitinib, erlotinib, afatinib, icotinib, neratinib, rociletinib, cetuximab, panitumumab, zalutumumab, nimotuzumab or matuzumab. In another embodiment, a compound of formula (IA) or (I) (and any embodiments thereof described herein), or a pharmaceutically acceptable salt thereof, or a polymorphic form of compound 5 as defined in any one of the second aspect or embodiments thereof above, is administered in combination with a HER2 / neu inhibitor, including lapatinib, trastuzumab, and pertuzumab. In another embodiment, a compound of formula (IA) or (I) (and any embodiments thereof described herein), or a pharmaceutically acceptable salt thereof, or a polymorphic form of compound 5 as defined in any one of the second aspect or embodiments thereof above, is administered in combination with a PI3k / mTOR inhibitor, including idelalisib, buparlisib, BYL719, and LY3023414. In another embodiment, a compound of Formula (IA) or (I) (and any embodiments thereof described herein), or a pharmaceutically acceptable salt thereof, or the A polymorphic form of compound 5 as defined in any of the second aspect or embodiments thereof above, is administered in combination with a VEGF inhibitor (such as bevacizumab), and / or a multi-tyrosine kinase inhibitor (such as sorafenib, sunitinib, pazopanib and cabozantinib).In another embodiment, a compound of formula (IA) or (I) (and any embodiments thereof described herein) or a pharmaceutically acceptable salt thereof, or a polymorphic form of compound 5 as defined in any one of the second aspect or embodiments thereof above, is administered in combination with an immunotherapeutic agent such as PD-1 and PD-L1 inhibitors, CTLA4 inhibitors, IDO inhibitors, TDO inhibitors, A2A agonists, A2B agonists, STING agonists, RIG-1 agonists, Tyro / Axl / Mer inhibitors, glutaminase inhibitors, arginase inhibitors, CD73 inhibitors, CD39 inhibitors, TGF-β inhibitors, IL-2, interferons, PI3K-γ inhibitors, CSF-1R inhibitors, GITR agonists, OX40 agonists, TIM-3 antagonists, LAG-3 antagonists, CAR-T therapy, and therapeutic vaccines. When a combination therapy is used, these agents may be administered simultaneously or sequentially.
[0062] In an eighth aspect, a method for preparing a compound of formula (IA) (wherein R 2 is hydrogen, R 9 is a hydroxyl group, and X 1 , R 2 is hydrogen, R 1 , R 3 To R 8 , L, R 2a and R 9a is as defined in the first aspect above, i.e. a method of formula (IA-1)):
[0063]
[0064] It comprises treating a compound of formula (IA) (wherein R 2 and R 9 Together with the carbon atom to which it is attached, it forms an oxo group, and X 1 , R 1 , R 3 To R 8 , L, R 2a and R 9a is as defined in the first aspect above, i.e., formula (IA-2)):
[0065]
[0066] Treat with a suitable reducing agent.
[0067] In a first embodiment of the eighth aspect, in each of the compounds of Formula (IA-1) and (IA-2), X 1 Yes CH, R 1 is hydroxyl, R 3 , R 4 , R5 and R 6 is fluorine, and R 7 , R 2a and R 9a is hydrogen, L is O, and R 8 It is 3-cyano-5-fluorophenyl.
[0068] In a ninth aspect, a method for preparing a compound of formula (IA) (wherein R 2 is hydrogen, R 9 is fluorine, and X 1 , R 1 , R 3 To R 8 , L, R 2a and R 9a is as defined in the first aspect above, i.e., a method of formula (IA-3)):
[0069]
[0070] It comprises a compound having formula (I) (wherein R 2 is hydrogen, and R 9 is a hydroxyl group, and X 1 , R 1 , R 3 To R 8 , L, R 2a and R 9a is as defined in the first aspect above, i.e., formula (IA-1)):
[0071]
[0072] Treat with a suitable fluorinating agent.
[0073] In a first embodiment of the ninth aspect, in each of the compounds of formula (IA-3) and (IA-1), X 1 Yes CH, R 1 is hydroxyl, R 3 , R 4 , R 5 and R 6 is fluorine, and R 7 , R 2a and R 9a is hydrogen, L is O, and R 8 It is 3-cyano-5-fluorophenyl.
[0074] In a tenth aspect, there is provided a method for preparing a crystalline form A polymorph of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile from a composition, the method comprising:
[0075] a) contacting 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile with one or more solvents selected from the group consisting of n-pentanol, heptane, methanol (MeOH), isopropyl alcohol (IPA), methyl tert-butyl ether (MTBE), ethyl acetate (EtOAc), isopropyl acetate (IPAc), toluene, acetone, acetonitrile (ACN), 1,4-dioxane and ethanol (EtOH); preferably selected from n-pentanol and heptane; at a temperature selected from about room temperature to about 60°C, preferably at about 50°C;
[0076] b) cooling the mixture to about room temperature; and
[0077] c) The Form A polymorph of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile was filtered from the mixture. BRIEF DESCRIPTION OF THE DRAWINGS
[0078] Figure 1 Depicted is a representative XRPD diffraction pattern of the Form A polymorph of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (Compound 5) crystallized from pentanol and hexanes according to the method described in Example 25. DETAILED DESCRIPTION
[0079] definition:
[0080] Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this application and have the following meanings:
[0081] "Alkyl" means a linear saturated monovalent hydrocarbon group of 1 to 6 carbon atoms or a branched saturated monovalent hydrocarbon group of 3 to 6 carbon atoms, for example, methyl, ethyl, propyl, 2-propyl, butyl, pentyl, etc. Those skilled in the art will appreciate that the term "alkyl" may include an "alkylene" group.
[0082] Unless otherwise specified, "alkylene" means a straight-chain saturated divalent hydrocarbon group of 1 to 6 carbon atoms or a branched-chain saturated divalent hydrocarbon group of 3 to 6 carbon atoms, for example, methylene, ethylene, propylene, 1-methylpropylene, 2-methylpropylene, butylene, pentylene, etc.
[0083] The "alkenyl group" means a straight-chain monovalent hydrocarbon group of 2 to 6 carbon atoms or a branched monovalent hydrocarbon group of 3 to 6 carbon atoms containing a double bond, for example, propenyl, butenyl and the like.
[0084] "Alkaldienyl" is an alkenyl group as defined above attached via a terminal divalent carbon. For example, in the following compound:
[0085] The arrow indicates an alkyldienyl group.
[0086] "Haloalkyldienyl" is an alkyldienyl substituted with one or two halo groups, each as defined herein.
[0087] The "alkynyl group" means a straight-chain monovalent hydrocarbon group of 2 to 6 carbon atoms or a branched monovalent hydrocarbon group of 3 to 6 carbon atoms containing a triple bond, for example, propynyl, butynyl and the like.
[0088] "Alkylthio" means a -SR group wherein R is alkyl as defined above, for example methylthio, ethylthio, and the like.
[0089] "Alkylsulfonyl" means a -SO2R group (wherein R is alkyl as defined above) such as methylsulfonyl, ethylsulfonyl, and the like.
[0090] "Alkyl sulfoxide" means a -SOR group wherein R is alkyl as defined above, for example, methyl sulfoxide, ethyl sulfoxide, and the like.
[0091] "Amino" means -NH2.
[0092] "Alkylamino" means a -NHR group (wherein R is alkyl as defined above), for example, methylamino, ethylamino, propylamino, or 2-propylamino and the like.
[0093] "Aminoalkyl" means a linear monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical of 3 to 6 carbon atoms substituted with -NR'R", wherein R' and R" are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl or alkylcarbonyl, each as defined herein, for example, aminomethyl, aminoethyl, methylaminomethyl, and the like.
[0094] "Alkoxy" means a -OR group where R is alkyl as defined above, for example, methoxy, ethoxy, propoxy or 2-propoxy, n-butoxy, iso-butoxy or tert-butoxy and the like.
[0095] "Alkoxyalkyl" means a linear monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical of 3 to 6 carbon atoms substituted with at least one alkoxy radical (one or two alkoxy radicals as defined above), for example, 2-methoxyethyl, 1-, 2- or 3-methoxypropyl, 2-ethoxyethyl, and the like.
[0096] "Alkoxycarbonyl" means a -C(O)OR group wherein R is alkyl as defined above, for example, methoxycarbonyl, ethoxycarbonyl, and the like.
[0097] "Alkylcarbonyl" means a -C(O)R group wherein R is alkyl as defined herein, for example, methylcarbonyl, ethylcarbonyl, and the like.
[0098] "Aryl" means a monovalent monocyclic or bicyclic aromatic hydrocarbon group of 6 to 10 ring atoms, for example, phenyl or naphthyl.
[0099] "Aralkyl" means an -(alkylene)-R group wherein R is aryl as defined above, for example, benzyl, phenethyl, and the like.
[0100] "Bicyclic cycloalkyl" means a fused bicyclic saturated monovalent hydrocarbon group of 6 to 10 carbon atoms, and is optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxyl and cyano. Examples include, but are not limited to, decalin, octahydro-1H-indene, etc.
[0101] "Cycloalkyl" means a monocyclic saturated monovalent hydrocarbon radical of 3 to 10 carbon atoms optionally substituted with one or two substituents independently selected from alkyl, alkyldienyl, halo, alkoxy, hydroxy, cyano, haloalkyldienyl, and cyanoalkyl. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 1-cyanocyclopropyl-1-yl, 1-cyanomethylcyclopropyl-1-yl, 3-fluorocyclohexyl, and the like. Cycloalkyl may include cycloalkylene as defined herein.
[0102] "Cycloalkylalkyl" means a -(alkylene)-R group wherein R is cycloalkyl as defined above, for example, cyclopropylmethyl, cyclohexylmethyl, and the like.
[0103] Unless otherwise indicated, "cycloalkylene" means a divalent cycloalkyl group as defined above.
[0104] "Cycloalkenyl" means a monocyclic monovalent hydrocarbon radical of 3 to 10 carbon atoms containing one or two double bonds, optionally substituted by one or two substituents independently selected from alkyl, halo, alkoxy, hydroxyl, cyano and cyanoalkyl. Examples include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl or cyclohexenyl, etc.
[0105] "Oxocycloalkenyl" means a monocyclic monovalent hydrocarbon group of 3 to 10 carbon atoms containing one or two double bonds, and optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, hydroxy, cyano and cyanoalkyl. Examples include, but are not limited to, 3-oxocyclohex-1-enyl, etc.
[0106] "Cyanoalkyl" means a linear monovalent hydrocarbon group of 1 to 6 carbon atoms or a branched monovalent hydrocarbon group of 3 to 6 carbon atoms substituted with a cyano group, for example, cyanomethyl, cyanoethyl, and the like.
[0107] "Carboxy" means -COOH.
[0108] "Dialkylamino" means a -NRR' group where R and R' are alkyl as defined above, for example, dimethylamino, methylethylamino, and the like.
[0109] "Disubstituted amino" means a -NRR' group where R and R' are independently alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, or alkylcarbonyl (each as defined herein), for example, dimethylamino, ethylmethylamino, bishydroxyethylamino, bismethoxyethylamino, diethylaminoethylamino, and the like.
[0110] "Halo" means fluorine, chlorine, bromine or iodine, preferably fluorine or chlorine.
[0111] "Haloalkyl" means an alkyl group as defined above, substituted with one or more halogen atoms (e.g., one to five halogen atoms, such as fluorine or chlorine), including those substituted with different halogens, for example, -CH2Cl, -CF3, -CHF2, -CH2CF3, -CF2CF3, -CF(CH3)2, etc. When the alkyl group is substituted only with fluorine, it may be referred to as a fluoroalkyl group in this application.
[0112] "Haloalkoxy" means a -OR group, wherein R is a haloalkyl group as defined above, for example, -OCF3, -OCHF2, etc. When R is a haloalkyl group (wherein the alkyl group is substituted only with fluorine), it may be referred to herein as a fluoroalkoxy group.
[0113] "Hydroxyalkyl" means a linear monovalent hydrocarbon radical of 1 to 6 carbon atoms or a branched monovalent hydrocarbon radical of 3 to 6 carbon atoms substituted with one or two hydroxyl groups, provided that if two hydroxyl groups are present, they are not on the same carbon atom. Representative examples include, but are not limited to, hydroxymethyl, 2-hydroxy-ethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl and 2-(hydroxymethyl)-3-hydroxypropyl, preferably 2-hydroxyethyl, 2,3-dihydroxypropyl and 1-(hydroxymethyl)-2-hydroxyethyl.
[0114] Unless otherwise specified, "heterocyclyl" means a saturated or unsaturated monovalent monocyclic radical of 4 to 8 ring atoms, one or two of which are selected from N, O or S(O). n(wherein n is an integer from 0 to 2) heteroatoms, the remaining ring atoms are C. In addition, one or two ring carbon atoms in the heterocyclic ring can be optionally replaced by -CO-groups. More particularly, the term heterocyclic includes but is not limited to pyrrolidinyl, piperidinyl, homopiperidinyl, 2-oxopyrrolidinyl, 2-oxopiperidinyl, morpholinyl, piperazinyl, tetrahydro-pyranyl, thiomorpholinyl, etc. When the heterocyclic ring is unsaturated, it can contain one or two ring double bonds, provided that the ring is not aromatic. When the heterocyclic group contains at least one nitrogen-atom, it is also referred to as heterocyclic amino in this article and it is a subset of heterocyclic groups.
[0115] "Heterocyclylalkyl" or "heterocycloalkyl" means a -(alkylene)-R radical where R is a heterocyclyl ring as defined above, for example, tetrahydrofuranylmethyl, piperazinylmethyl, morpholinylethyl, and the like.
[0116] Unless otherwise indicated, "heterocyclylene" means a divalent heterocyclyl as defined above. When the heterocyclylene contains 4, 5 or 6 ring atoms, it may be referred to herein as a 4- to 6-membered heterocyclylene.
[0117] Unless otherwise indicated, "heteroaryl" means a monovalent monocyclic or bicyclic aromatic group of 5 to 10 ring atoms, wherein one or more (in one embodiment, one, two or three) ring atoms are heteroatoms selected from N, O or S, and the remaining ring atoms are carbon. Representative examples include, but are not limited to, pyrrolyl, thienyl, thiazolyl, imidazolyl, furanyl, indolyl, isoindolyl, oxazolyl, isoxazolyl, benzothiazolyl, benzoxazolyl, quinolyl, isoquinolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazolyl, tetrazolyl, etc. As defined herein, the terms "heteroaryl" and "aryl" are mutually exclusive. When the heteroaryl ring contains 5 or 6 ring atoms, it is also referred to as a 5-yuan or 6-yuan heteroaryl herein.
[0118] "Heteroarylene" means a divalent heteroaryl group as defined above.
[0119] "Heteroaralkyl" means a -(alkylene)-R group, where R is heteroaryl as defined above, for example, pyridylmethyl, etc. When the heteroaryl ring in the heteroaralkyl contains 5 or 6 ring atoms, it is also referred to herein as a 5-membered or 6-membered heteroaralkyl.
[0120] The phrase “R 2 and R 9 Attached to a ring carbon atom that is located adjacent to the ring attached to R 1 "meta" means R 2 and R 9 The location is as follows:
[0121]
[0122] The term "oxo," as used herein, alone or in combination, refers to =(O).
[0123] When necessary, any definition herein can be used in combination with any other definition to describe a composite structural group. As a rule, any subsequent element defined in this way is an element attached to the parent part. For example, the composite group alkoxyalkyl means that the alkoxy group is attached to the parent molecule through the alkyl group.
[0124] The disclosure also includes protected derivatives of compounds of formula (IA) or (I). For example, when compounds of formula (IA) or (I) contain groups (such as hydroxyl, carboxyl, thiol or any group containing one or more nitrogen atoms), these groups may be protected by suitable protecting groups. A comprehensive list of suitable protecting groups can be found in TW Greene, Protective Groups in Organic Synthesis [protective groups in organic synthesis], 5th edition, John Wiley & Sons, Inc [John Wiley & Sons Publishing Company]. (2014), the disclosure of which is incorporated herein by reference in its entirety. The protected derivatives of the compounds of the disclosure can be prepared by methods well known in the art.
[0125] The present disclosure also includes polymorphic forms of compounds of formula (IA) or (I) or their pharmaceutically acceptable salts. Polymorphs are different crystalline forms of a compound that differ in their arrangement in the lattice among the molecules of the compound. Therefore, a single compound can produce various polymorphic forms. Polymorphs of a compound typically have different melting points, solubility, density, and optical properties. The polymorphic forms of a compound can be distinguished by many techniques such as X-ray diffraction, IR, or Raman spectroscopy.
[0126] "XRPD" means X-ray powder diffraction, an analytical technique that measures the diffraction of X-rays in the presence of a solid component. Materials that are crystalline and have a regularly repeating array of atoms produce a unique powder pattern.
[0127] As used herein, "anti-solvent" means a solvent in which the compound of Formula (IA) or (I) is less soluble.
[0128] The term "prodrug" refers to a compound that becomes more active in vivo. Certain compounds of formula (IA) or (I) may also exist as prodrugs, as described in Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology (Testa, Bernard and Mayer, Joachim M. Wiley-VHCA, Zurich, Switzerland 2003). Prodrugs of compounds of formula (IA) or (I) are structurally modified forms of the compound that are susceptible to chemical changes under physiological conditions to provide an active compound. Prodrugs are often useful because they are easier to administer than the compound or parent drug in some cases. For example, they can be bioavailable by oral administration, whereas the parent drug cannot. A variety of prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug. An example (but not limited to) of a prodrug is a compound that is administered as an ester (the "prodrug"), but then metabolically hydrolyzed to the carboxylic acid, the active entity. Other examples include peptidyl derivatives of compounds of formula (IA) or (I).
[0129] A "pharmaceutically acceptable salt" of a compound means a salt that is pharmaceutically acceptable and possesses the desired pharmacological activity of the parent compound. Such salts include:
[0130] Acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or acid addition salts formed with organic acids such as formic acid, acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, glucoheptanoic acid, 4,4'-methylenebis-(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, etc.; or
[0131] Salts formed when an acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion); or salts formed by coordination with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, etc.). It should be understood that pharmaceutically acceptable salts are non-toxic. Additional information on suitable pharmaceutically acceptable salts can be found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pennsylvania, 1985, which is incorporated herein by reference in its entirety.
[0132] Compounds of formula (IA) or (I) may have an asymmetric center. Compounds of formula (IA) or (I) containing asymmetrically substituted atoms can be separated in optically active forms or racemic forms. Individual stereoisomers of a compound can be prepared by synthesis from commercially available starting materials containing a chiral center, or by preparing a mixture of enantiomeric products followed by separation (e.g., conversion into a mixture of diastereomers followed by separation or recrystallization, chromatographic techniques, direct separation of enantiomers on a chiral chromatographic column, or any other suitable method known in the art). Unless a specific stereochemical form or isomeric form is specifically indicated, all chiral forms, diastereomeric forms, racemic forms are within the scope of the present invention. It will also be appreciated by those of ordinary skill in the art that when a compound is represented as an (R) stereoisomer, it may contain the corresponding (S) stereoisomer as an impurity, and vice versa.
[0133] Certain compounds with formula (IA) or (I) can exist as tautomers and / or geometric isomers. All possible tautomers and cis and trans isomers (as separate forms and mixtures thereof) are within the scope of this disclosure. In addition, as used herein, although only a few examples are listed, the term alkyl includes all possible isomeric forms of the alkyl group. In addition, when these cyclic groups (e.g., aryl, heteroaryl, heterocyclic) are substituted, although only a few examples are listed, they include all possible isomers. In addition, all hydrates of compounds with formula (IA) and (I) are within the scope of this disclosure.
[0134] Compounds of formula (IA) or (I) may also contain unnatural amounts of isotopes at one or more atoms that constitute such compounds. An unnatural amount of an isotope may be defined as an amount ranging from the amount found in nature to 100% of the atom in question, differing only in the presence of one or more isotopically enriched atoms. Exemplary isotopes that may be incorporated into compounds of formula (IA) or (I) (and any embodiments thereof disclosed herein, including specific compounds)) include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, and iodine, for example, 2 H. 3 H. 11 C. 13 C. 14 C. 13 N. 15 N. 15 O. 17 O. 18 O. 32 P. 33 P. 35 S. 18 F. 36 Cl, 123 I and 125 1. Isotope-labeled compounds (e.g., 3 H and 14 C-labeled compounds) can be used in compound or substrate tissue distribution assays. 3 H) and carbon-14 (i.e. 14 C) isotopes are useful because of their ease of preparation and detectability. In addition, heavier isotopes, such as deuterium (i.e., 2 H) substitution may provide certain therapeutic advantages resulting from greater metabolic stability (e.g., increased in vivo half-life or reduced dosage requirements). In some embodiments, in the compounds disclosed herein, including those in Table 1 below, one or more hydrogen atoms are replaced by 2 H or 3 H is replaced, or one or more carbon atoms are 13 C- or 14 C-enriched carbon substitution. Positron emitting isotopes (e.g. 15 O. 13 N. 11 C and 15 F) can be used in positron emission tomography (PET) studies to examine substrate receptor occupancy. Isotopically labeled compounds can generally be prepared by substituting an isotopically labeled reagent for a non-isotopically labeled reagent by following procedures similar to those disclosed in the Schemes or Examples herein.
[0135] Certain structures provided herein are drawn with one or more floating substituents. Unless otherwise provided or otherwise clear from the context, one or more substituents may be present on any atom of the ring to which they are attached, where chemically feasible and permitted by the rules of valence. For example, in the structure R 7 Substituents may replace any hydrogen on the benzo portion of the tricyclic ring. 1 When it is CH, the hydrogen of CH is included.
[0136] "Optionally substituted aryl" refers to aryl groups optionally substituted with one, two, or three substituents independently selected from alkyl, hydroxy, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, alkylthio, alkylsulfonyl, amino, alkylamino, dialkylamino, halo, haloalkyl, haloalkoxy, and cyano.
[0137] "Optionally substituted heteroaryl" refers to a heteroaryl group as defined above optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkylthio, alkylsulfonyl, hydroxy, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, alkoxy, halo, haloalkyl, haloalkoxy, amino, alkylamino, dialkylamino, and cyano.
[0138] Unless otherwise indicated, "optionally substituted heterocyclyl" refers to a heterocyclyl as defined above optionally substituted with one, two, or three substituents independently selected from the group consisting of alkyl, alkylthio, alkylsulfonyl, hydroxy, cycloalkyl, carboxy, alkoxycarbonyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy, and cyano.
[0139] "Optionally substituted heterocyclylene" is a divalent optionally substituted heterocyclyl as defined above.
[0140] "Pharmaceutically acceptable carrier or excipient" means a carrier or excipient useful in preparing a pharmaceutical composition that is generally safe, non-toxic and not biologically or otherwise undesirable, and includes carriers or excipients that are acceptable for veterinary as well as human pharmaceutical use. "Pharmaceutically acceptable carrier / excipient" as used in this specification and claims includes both one and more than one such excipient.
[0141] "Spiro cycloalkyl" refers to a saturated bicyclic ring with 6 to 10 ring carbon atoms, wherein these rings are connected only by an atom, and the connecting atom is also referred to as a spiral atom, most commonly a quaternary carbon ("spiro carbon"). The spiro cycloalkyl ring is optionally substituted with one or two substituents, and these substituents are independently selected from alkyl, halo, alkoxy, hydroxyl and cyano. Representative examples include but are not limited to spiral [3.3] heptane, spiral [3.4] octane, spiral [3.5] nonane, spiral [4.4] nonane (1:2:1:1) etc.
[0142] "Spiroheterocyclyl" refers to a saturated bicyclic ring having 6 to 10 ring atoms, one, two or three of which are selected from N, O or S(O). n (wherein n is an integer from 0 to 2) heteroatom, the remaining annular atoms are C, and these rings are connected only by an atom, and the connecting atom is also referred to as spiral atom, most commonly quaternary carbon ("spiro carbon"). Spiro heterocyclic ring is optionally substituted by one, two or three substituents, and these substituents are independently selected from alkyl, alkylthio, alkyl sulfonyl, hydroxyl, cycloalkyl, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, alkoxy, alkoxyalkyl, aminoalkyl, halo, haloalkyl, haloalkoxy and cyano. Representative examples include but are not limited to 2,6-diazaspiro [3.3] heptane, 2,6-diazaspiro [3.4] octane, 2-azaspiro [3.4] octane, 2-azaspiro [3.5] nonane, 2,7-diazaspiro [4.4] nonane etc.
[0143] As used herein, the term "about" is intended to qualify the numerical value it modifies, indicating that this value is a variable within the error range. When no specific error range is listed (e.g., the standard deviation of the mean value given in a data graph or table), the term "about" should be understood to mean a range covering ±10%, preferably ±5%, including the listed values and ranges.
[0144] In formula (I), R 9 In the definition of "heteroaryl", the phrase "heteroaryl, wherein the heteroaryl is optionally substituted with R independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, and cyano d , R e , and R f "substituted" (and similar phrases used to define other groups in formula (I)) is intended to encompass unsubstituted heteroaryl and heteroaryl groups substituted with R d , R e , and R f Any one of the substituted heteroaryl groups.
[0145] As used herein, the term "disease" is intended to be generally synonymous and may be used interchangeably with the terms "disorder," "syndrome," and "condition" (in the case of medical conditions), all of which reflect an abnormal condition of one of the parts of the human or animal body or of the body that impairs its normal functioning, typically manifests itself by distinctive signs and symptoms, and causes the human or animal to have a reduced life span or quality of life.
[0146] The term "combination therapy" means the administration of two or more therapeutic agents to treat the diseases or disorders described in the present disclosure. Such administration encompasses the co-administration of these therapeutic agents in a substantially simultaneous manner, such as administration in a single capsule with a fixed ratio of active ingredients or administration in multiple separate capsules of each active ingredient. In addition, such administration also encompasses the use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide a beneficial effect of the drug combination in treating the conditions or disorders described herein.
[0147] The term "patient" is often synonymous with the term "subject" and includes all mammals, including humans. Examples of patients include humans, livestock (e.g., cattle, goats, sheep, pigs, and rabbits), and pets (e.g., dogs, cats, rabbits, and horses). Preferably, the patient is a human.
[0148] “Treating” or “treatment” illnesses include:
[0149] (1) preventing the disease, that is, causing clinical symptoms of the disease to not develop in a mammal that may be exposed to or susceptible to the disease but does not yet experience or display symptoms of the disease;
[0150] (2) inhibiting the disease, that is, arresting or reducing the development of the disease or its clinical symptoms; or
[0151] (3) Alleviate the disease, that is, cause the disease or its clinical symptoms to subside.
[0152] "Therapeutically effective amount" refers to the amount of a compound of the present disclosure or a pharmaceutically acceptable salt thereof that, when administered to a patient for treating a disease, is sufficient to affect such treatment of the disease. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc. of the mammal to be treated.
[0153] The terms "inhibit" and "reduce" or any variants of these terms in relation to HIF-2α include any measurable reduction or complete inhibition to achieve the desired result. For example, reduction can be a reduction in HIF-2α activity by about, up to about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein, compared to normal activity.
[0154] Example:
[0155] In the following additional embodiments 1-30, the present disclosure includes:
[0156] 1A. In Embodiment 1A, the compound having formula (IA):
[0157] As described in the first aspect of the present invention. In a sub-embodiment of embodiment 1A, R 2a and R 9a is independently hydrogen or deuterium.
[0158] 1. In Example 1, the compound has the formula (I):
[0159] As described in the first embodiment of the aspect of the above summary of the invention.
[0160] In Embodiment 1A or the first subembodiment of 1 or a subembodiment within Embodiment 1A, the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 1 It's hydroxyl.
[0161] In Embodiment 1A or the second sub-embodiment of 1 or a sub-embodiment within Embodiment 1A, the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 1 is amino or halogenated, preferably R 1 It's amino.
[0162] In the third subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 1 Yes - OCOR 10 、-OCOOR 11 、-OCONR 12 R 13 、-OCHR 14 OCOR 15 or-OCHR 14 OCOOR 15a , where R 10 , R11 , R 15 and R 15a is as defined in the Summary of the Invention.
[0163] In a fourth sub-embodiment of Embodiment 1A or 1 or a sub-embodiment within Embodiment 1A, the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 1 It is -OP(O)(OH)2 or -OCH2OP(O)(OH)2.
[0164] In Embodiment 1A or the fifth subembodiment of 1 or subembodiments within Embodiment 1A, and subembodiments contained therein (i.e., the first, second, third, and fourth subembodiments above), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 6 is halogenated, preferably R 6 Those that are fluorine.
[0165] In Embodiment 1A or the sixth subembodiment of 1 or subembodiments within Embodiment 1A, and subembodiments contained therein (i.e., the first, second, third, and fourth subembodiments), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 6 is an alkyl group, preferably R 6 Those that are methyl.
[0166] In Embodiment 1A or the seventh subembodiment of 1 or a subembodiment within Embodiment 1A, and subembodiments contained therein (i.e., the first, second, third, and fourth subembodiments), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 6 Those that are hydrogen or deuterium.
[0167] In Embodiment 1A or the eighth subembodiment of 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first, second, third, and fourth subembodiments), the compound of Formula (1A) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 6 is a cycloalkyl group, preferably R 6 Those which are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0168] In Embodiment 1A or the ninth sub-embodiment of 1 or the sub-embodiments within Embodiment 1A, and the sub-embodiments contained therein (i.e., the first, second, third, fourth, fifth, sixth, seventh and eighth sub-embodiments above), the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 5 is halogenated or halogenated alkyl, preferably R 5 Those which are difluoromethyl or trifluoromethyl.
[0169] In Embodiment 1A or the tenth subembodiment of 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first, second, third, fourth, fifth, sixth, seventh, and eighth subembodiments above), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 5 is an alkyl group, preferably R 5 Those which are methyl or ethyl.
[0170] In the eleventh subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first, second, third, fourth, fifth, sixth, seventh, and eighth subembodiments), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 5 Those which are hydrogen or alkoxy.
[0171] In the twelfth subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first, second, third, and fourth subembodiments), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 5 and R 6 Together with the carbon to which it is attached, it forms a 3- to 6-membered cycloalkylene group, preferably R 5 and R 6 Those which, together with the carbon to which they are attached, form cyclopropylene, cyclobutylene or cyclopentylene, each optionally substituted with one or two fluorines.
[0172] In the thirteenth subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first, second, third, and fourth subembodiments), the compound of Formula (IA) or (I), or a pharmaceutically acceptable salt thereof, is wherein R 5 and R 6 Together with the carbon to which it is attached, it forms a 4- to 6-membered optionally substituted heterocyclylene, preferably R 5 and R 6 Those formed together with the carbon to which they are attached
[0173] In the fourteenth subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first to eleventh subembodiments), the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 3 and R 4 Those that are independently halogenated.
[0174] In the fifteenth subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first to eleventh subembodiments), the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein R 3 is halogenated and R 4 Those that are hydrogen.
[0175] In the sixteenth subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first to fifteenth subembodiments), the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein X 1 Is CH or CR 7 Those.
[0176] In the seventeenth subembodiment of Embodiment 1A or 1 or a subembodiment within Embodiment 1A, and the subembodiments contained therein (i.e., the first to fifteenth subembodiments), the compound of Formula (IA) or (I) or a pharmaceutically acceptable salt thereof is wherein X 1 Those that are N.
[0177] 2A. In Embodiment 2A, the compound of Embodiment 1A or a pharmaceutically acceptable salt thereof has a structure of Formula (IIa1) or (IIb1):
[0178]
[0179] In a first sub-embodiment of Embodiment 2A, the compound or a pharmaceutically acceptable salt thereof of the sub-embodiment of Embodiment 1A has a structure of Formula (IIa1). In a second sub-embodiment of Embodiment 2A, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIb1).
[0180] 2Aa. In Example 2Aa, the compound of Example 1A or a sub-example of Example 1A or a pharmaceutically acceptable salt thereof has a structure of Formula (IIa1') or (IIb1')
[0181]
[0182] In a first sub-embodiment of Embodiment 2Aa, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIa1′). In a second sub-embodiment of Embodiment 2Aa, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIb1′).
[0183] 2. In Example 2, the compound or a pharmaceutically acceptable salt thereof of Example 1 has a structure of formula (IIa) or (IIb):
[0184]
[0185] In the first sub-embodiment of Example 2, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIa). In the second sub-embodiment of Example 2, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIb).
[0186] 2a. In Example 2a, the compound of Example 1 or a pharmaceutically acceptable salt thereof has a structure of Formula (IIa') or (IIb'):
[0187]
[0188] In a first sub-embodiment of embodiment 2a, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (IIa'). In a second sub-embodiment of embodiment 2a, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (IIb').
[0189] 3A. In Embodiment 3A, the compound of Embodiment 1A or a sub-embodiment within Embodiment 1A or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIa1) or (IIIb1):
[0190]
[0191] In a first sub-embodiment of Embodiment 3A, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIa1). In a second sub-embodiment of Embodiment 3A, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIb1).
[0192] 3Aa. In Example 3Aa, the compound of Example 1A or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIa1') or (IIIb1'):
[0193]
[0194] In a first sub-embodiment of Embodiment 3Aa, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIa1′). In a second sub-embodiment of Embodiment 3Aa, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIb1′).
[0195] 3. In Example 3, the compound of Example 1 or a pharmaceutically acceptable salt thereof has a structure of formula (IIIa) or (IIIb):
[0196]
[0197] In a first sub-embodiment of Example 3, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIa). In a second sub-embodiment of Example 3, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (IIIb).
[0198] 3a. In Example 3a, the compound of Example 1 or a pharmaceutically acceptable salt thereof has a structure of formula (IIIa') or (IIIb'):
[0199]
[0200] In a first sub-embodiment of embodiment 3a, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (IIIa'). In a second sub-embodiment of embodiment 3a, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (IIIb').
[0201] 4. In Example 4, the compound of Example 1 or a pharmaceutically acceptable salt thereof has a structure of formula (IVa) or (IVb):
[0202]
[0203] Where R 5 and R 6 Together with the carbon to which it is attached, it forms a 3 to 6 membered cycloalkylene, preferably a cyclopropylene, cyclobutylene or cyclopentylene optionally substituted with one or two fluorines. In a first sub-embodiment of Embodiment 4, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (IVa). In a second sub-embodiment of Embodiment 4, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (IVb).
[0204] 5. In Example 5, the compound of Example 1 or a pharmaceutically acceptable salt thereof has a structure of formula (Va) or (Vb):
[0205]
[0206] Where R 5 and R 6 Together with the carbon to which it is attached, it forms a 4- to 6-membered optionally substituted heterocyclylene, preferably R 5 and R 6 Together with the carbon to which it is attached,
[0207] In a first sub-embodiment of Example 5, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (Va). In a second sub-embodiment of Example 5, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (Vb).
[0208] 6. In Example 6, the compound of Example 1 or a pharmaceutically acceptable salt thereof has a structure of Formula (VIa) or (VIb):
[0209]
[0210] Where R 5 and R 6 Together with the carbon to which it is attached, it forms a 3 to 6 membered cycloalkylene, preferably a cyclopropylene, cyclobutylene or cyclopentylene optionally substituted with one or two fluorines. In the first sub-embodiment of Embodiment 6, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (VIa). In the second sub-embodiment of Embodiment 6, the compound or a pharmaceutically acceptable salt thereof has a structure of formula (VIb).
[0211] 7A. In Embodiment 7A, the compound of Embodiment 1A or a pharmaceutically acceptable salt thereof has a structure of Formula (VIIa1) or (VIIb1):
[0212]
[0213] In a first sub-embodiment of Embodiment 7A, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (VIIa1). In a second sub-embodiment of Embodiment 7A, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (VIIb1).
[0214] 7. In Example 7, the compound of Example 1 or a pharmaceutically acceptable salt thereof has the structure of Formula (VIIa) or (VIIb):
[0215]
[0216] In a first sub-embodiment of Example 7, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (VIIa). In a second sub-embodiment of Example 7, the compound or a pharmaceutically acceptable salt thereof has a structure of Formula (VIIb).
[0217] 8. In Embodiment 8, the compound or pharmaceutically acceptable salt thereof of any one of Embodiments 1A to 7 and sub-embodiments contained therein (e.g., sub-embodiments within Embodiment 1A, the first to seventeenth sub-embodiments of Embodiments 1A and / or 1 and sub-embodiments of Embodiments 2A to 7) is wherein R 3 and R 4 In a first sub-embodiment, one of R 3 is fluorine and R 4 It's hydrogen.
[0218] 9. In Embodiment 9, the compound of any one of Embodiments 1A to 7 and the subembodiments contained therein (e.g., the subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and the subembodiments of Embodiments 2A to 7), or a pharmaceutically acceptable salt thereof, is wherein R 3 and R 4 is halogenated, preferably R 3 and R 4 It's fluorine.
[0219] 10. In Embodiment 10, the compound of any one of Embodiments 1A to 9 and subembodiments contained therein (e.g., subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1, and subembodiments of Embodiments 2A to 9), or a pharmaceutically acceptable salt thereof, is wherein L is O, S, SO, SO2, or NH. In a first subembodiment of Embodiment 10, L is O. In a second subembodiment of Embodiment 10, L is S. In a third subembodiment of Embodiment 10, L is NH. In a fourth subembodiment of Embodiment 10, L is SO or SO2.
[0220] 11. In Embodiment 11, the compound of any one of Embodiments 1A to 10 and sub-embodiments contained therein (e.g., sub-embodiments within Embodiment 1A, the first to seventeenth sub-embodiments of Embodiments 1A and / or 1 and sub-embodiments of Embodiments 2A to 10) or a pharmaceutically acceptable salt thereof is wherein R 8 is cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl or heteroaralkyl, wherein aryl or heteroaryl (each by itself or as part of aralkyl or heteroaralkyl), or heterocyclyl (by itself or as part of heterocyclylalkyl) is substituted by R a , R b and R c Replace the R a , R b and R c independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidene, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.
[0221] 12A. In Embodiment 12A, the compound of any one of Embodiments 1A, 2A, 2Aa, 3A, 3Aa, 7A, and 8 to 10 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 8 It is R a , R b , R c , Rg and R h Substituted phenyl, wherein R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h is independently selected from hydrogen, deuterium and halo. In a first sub-embodiment of Embodiment 12A, R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy, and cyano. a , R b and R c are independently selected from hydrogen, deuterium, methyl, methoxy, hydroxy, chlorine, fluorine, cyano, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy, and R g and R h is independently hydrogen or deuterium. In a third sub-embodiment of Embodiment 12A, R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-difluoromethylphenyl, or 3-cyano-5-fluoro-2,4,6-trideuteriophenyl. In a fourth sub-embodiment of embodiment 12A, R 10 It is 3-cyano-5-fluorophenyl or 3-cyano-5-fluoro-2,4,6-trideuterated phenyl.
[0222] 12. In embodiment 12, the compound of any one of embodiments 2, 2a, 3, 3a-6 and 7-10 and subembodiments contained therein (e.g., the first to seventeenth subembodiments of embodiment 1 and subembodiments of embodiments 2, 2a, 3, 3a-6 and 7-10) or a pharmaceutically acceptable salt thereof is wherein R 8 It is R a , R b and R c Substituted phenyl, the Ra , R b and R c is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. In a first sub-embodiment of Embodiment 12, R a , R b and R c is independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy and cyano. a , R b and R c is independently selected from hydrogen, methyl, methoxy, hydroxy, chloro, fluoro, cyano, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy. 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl or 3-cyano-5-difluoromethylphenyl. In the fourth sub-embodiment of embodiment 12, R 10 It is 3-cyano-5-fluorophenyl.
[0223] 13. In Embodiment 13, the compound of any one of Embodiments 1A to 10 and the subembodiments contained therein (e.g., the subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and the subembodiments of Embodiments 2A to 10) or a pharmaceutically acceptable salt thereof is wherein R 8 is cycloalkyl or cycloalkylalkyl, each optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano, alkyldienyl, haloalkyldienyl, and hydroxy. In a first sub-embodiment of Embodiment 13, R 8 is cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl or cyclohexylmethyl, each optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano and hydroxy. In a second sub-embodiment of Embodiment 13, R 6is cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclobutylethyl, cyclopentylmethyl, cyclopentylethyl or cyclohexylmethyl, each substituted with one or two substituents independently selected from hydrogen, methyl, methoxy, cyano and fluorine, preferably R 8 is cyclopropylmethyl, 1-cyanocyclopropylmethyl, cyclobutylmethyl, 2-fluorocyclopropylmethyl or 1-cyanocyclobutylmethyl. In the third sub-embodiment of Embodiment 13, R 8 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, each optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano and hydroxy. In a fourth sub-embodiment of Embodiment 13, R 8 is cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, each optionally substituted with one or two substituents independently selected from methyl, cyano, methoxy and fluorine, preferably, R 8 It is cyclobutyl, 3-fluorocyclobutyl, 3,3-difluorocyclobutyl, 3-cyanocyclobutyl, 3-fluorocyclohexyl or 3-cyano-3-methylcyclobutyl.
[0224] 14. In Embodiment 14, the compound of any one of Embodiments 1A to 10 and the subembodiments contained therein (e.g., the subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and the subembodiments of Embodiments 2A to 10), or a pharmaceutically acceptable salt thereof, is wherein R 8 It is R a , R b and R c Substituted heteroaryl, the R a , R b and R c is independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl. In a first sub-embodiment of Embodiment 14, R 8 is a 5-membered or 6-membered heteroaryl group, for example, pyridyl, pyridazinyl, pyrimidinyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl or pyrazinyl, each of which is substituted by R a , R b and R c Substitution, where R a and R b are independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy and cyano, and R c is selected from the group consisting of hydrogen, alkyl, halo, haloalkyl and haloalkoxy. 8is pyridin-3-yl, pyridin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, pyrimidin-2-yl, thiophen-2-yl, furan-2-yl, thiazol-5-yl, oxazol-5-yl, imidazol-5-yl, furan-3-yl, thiophen-3-yl, thiazol-4-yl, pyridin-4-yl, oxazol-2-yl, imidazol-2-yl, pyridin-2-yl, pyrazin-2-yl or thiazol-2-yl, each of which is substituted by R a , R b and R c Substitution, where R a and R b are independently selected from hydrogen, methyl, methoxy, hydroxy, chlorine, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy, and R c is selected from the group consisting of hydrogen, methyl, cyano, chlorine, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy. 8 It is 5-cyanopyridin-3-yl, 5-chloropyridin-3-yl or 5-fluoropyridin-3-yl.
[0225] 15. In Embodiment 15, the compound of any one of Embodiments 1A to 10 and the subembodiments contained therein (e.g., the subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and the subembodiments of Embodiments 2A to 10) or a pharmaceutically acceptable salt thereof is wherein R 8 It is R a , R b and R c A substituted bicyclic aryl group, wherein R a and R b are independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy and cyano, and R c is selected from the group consisting of hydrogen, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, and aminoalkyl.
[0226] 16. In Embodiment 16, the compound of any one of Embodiments 1A to 10 and the subembodiments contained therein (e.g., the subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and the subembodiments of Embodiments 2A to 10), or a pharmaceutically acceptable salt thereof, is wherein R 8 is a heterocyclic group, wherein the heterocyclic group is R a , R b and R c Substitution, where R a and R b are independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy and cyano, and R cis hydrogen, alkyl, halo, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl or aminoalkyl. 8 is tetrahydrofuranyl, tetrahydropyranyl or oxetanyl, each independently R a and R b Substitution, where R a and R b are independently selected from hydrogen, methyl and fluoro.
[0227] 17. In Embodiment 17, the compound of any one of Embodiments 1A to 10 and subembodiments contained therein (e.g., subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and subembodiments of Embodiments 2A to 10), or a pharmaceutically acceptable salt thereof, is wherein R 8 is a spiroheterocyclyl. In one embodiment, the spiroheterocyclyl ring contains at least one nitrogen atom. In a second embodiment, the spiroheterocyclyl ring contains at least one oxygen atom.
[0228] 18. In Embodiment 18, the compound of any one of Embodiments 1A to 17 and subembodiments contained therein (e.g., subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and subembodiments of Embodiments 2A to 17) or a pharmaceutically acceptable salt thereof is wherein R 7 is hydrogen, methyl, ethyl, methoxy, fluorine, trifluoromethyl or trifluoromethoxy. 7 It's hydrogen.
[0229] 19. In Embodiment 19, the compound of any one of Embodiments 1A to 18 and subembodiments contained therein (e.g., subembodiments within Embodiment 1A, the first to seventeenth subembodiments of Embodiments 1A and / or 1 and subembodiments of Embodiments 2A to 18) or a pharmaceutically acceptable salt thereof is wherein R 2 is hydrogen, fluorine, methyl or ethyl. In a first sub-embodiment, R 2 is hydrogen. In a second sub-embodiment, R 2 In a third sub-embodiment, R 2 It's fluorine.
[0230] 20. In Embodiment 20, the compound of any one of Embodiments 1A to 19 and sub-embodiments contained therein (e.g., sub-embodiments within Embodiment 1A, the first to seventeenth sub-embodiments of Embodiments 1A and / or 1 and sub-embodiments of Embodiments 2A to 19) or a pharmaceutically acceptable salt thereof is wherein R 9 is hydrogen, alkyl, halo, hydroxy or alkoxy. In a first sub-embodiment of Embodiment 20, R 9 is hydrogen, methyl, methoxy or fluorine.
[0231] 21. In Embodiment 21, the compound of any one of Embodiments 1A to 20 and sub-embodiments contained therein (e.g., sub-embodiments within Embodiment 1A, the first to seventeenth sub-embodiments of Embodiments 1A and / or 1 and sub-embodiments of Embodiments 2A to 20) or a pharmaceutically acceptable salt thereof is wherein R 2 and R 9 Attached to the same carbon atom. In a first sub-embodiment of Embodiment 21, R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0232] 22A. In Embodiment 22A, the compound of any one of Embodiments 1A, 2A, 2Aa, 3A, 3Aa, 7A, 8 to 10, 12A and 13 to 18 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 2 and R 9 Attached to a ring carbon atom that is attached to R 1 The ring carbon is in the meta position and R 2 is hydrogen or deuterium and R 9 is hydrogen, methyl or fluorine.
[0233] 22B. In Embodiment 22B, the compound of Embodiment 22A and sub-embodiments thereof or a pharmaceutically acceptable salt thereof is wherein R 2 is hydrogen or deuterium and R 9 It's fluorine.
[0234] 22C. In Embodiment 22C, the compound of Embodiments 22A and 22B and sub-embodiments contained therein or a pharmaceutically acceptable salt thereof is wherein R 2a and R 9a is independently hydrogen, deuterium or fluorine, preferably hydrogen or fluorine, more preferably hydrogen.
[0235] 22. In Embodiment 22, the compound of any one of Embodiments 1A to 18 and 22C and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form an oxo group. In a first sub-embodiment of Embodiment 22, R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0236] 23. In Embodiment 23, the compound of any one of Embodiments 1A to 18 and 22C and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 2and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form a 3 to 6 membered cycloalkylene. In a first subembodiment of Embodiment 23, R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form a cyclopropylene group. In a first subembodiment of Embodiment 23, R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0237] 24. In Embodiment 24, the compound of any one of Embodiments 1A to 18 and 22C and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form a 4- to 6-membered heterocyclylene. In a first subembodiment of Embodiment 23, R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form oxetan-4-yl. In a first sub-embodiment of Embodiment 24, R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0238] 25. In Embodiment 25, the compound of any one of Embodiments 1A to 18 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 2 and R 9 are attached to the same carbon atom and together with the carbon atom to which they are attached form an alkyldienyl group, preferably a vinyldienyl group. In a first sub-embodiment of Embodiment 22, R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0239] 26. In Embodiment 26, the compound of any one of Embodiments 1A, 2A, 2Aa, 12A, 13 to 20 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is a compound of Formula (VIIIa1) or (VIIIb1):
[0240]
[0241] (VIIIa1)(VIIIb1).
[0242] In one embodiment, the compound has Formula (VIIIb1).
[0243] 27. In embodiment 27, the compound of embodiment 26 and sub-embodiments contained therein or a pharmaceutically acceptable salt thereof is wherein R 2 is hydrogen or deuterium and R 9 is hydrogen, fluorine or methyl, preferably fluorine, and R 2a and R 9a are independently hydrogen, deuterium or fluorine. In a first sub-embodiment of Embodiment 26, R 2a and R 9a is independently hydrogen or deuterium. In a second sub-embodiment of Embodiment 26, R 2a and R 9a are independently hydrogen or fluorine.
[0244] 28. In Embodiment 28, the compound of any one of Embodiments 1, 2, 2a and 12 to 20 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is a compound of Formula (VIIIa) or (VIIIb):
[0245]
[0246] In one embodiment, the compound has Formula (VIIIb).
[0247] 29. In embodiment 29, the compound of embodiment 28 and sub-embodiments contained therein or a pharmaceutically acceptable salt thereof is wherein R 2 is hydrogen and R 9 is hydrogen, fluorine or methyl.
[0248] 30. In Embodiment 30, the compound of any one of Embodiments 26 to 29 and subembodiments contained therein, or a pharmaceutically acceptable salt thereof, is wherein R 7 is hydrogen and R 8 It is 3-cyano-5-fluorophenyl or 3-cyano-5-fluoro-2,4,6-trideuterated phenyl.
[0249] It should be understood that the embodiments and sub-embodiments described above include all combinations of the embodiments and sub-embodiments listed therein. 9 Can be independently combined with one or more of Embodiments 1A to 30 and / or the sub-embodiments contained therein.
[0250] In further embodiments 40 to 99, the disclosure comprises:
[0251] 40. A compound having formula (IA):
[0252]
[0253] in:
[0254] X1 is CH or N;
[0255] R 1 Hydroxyl, halogen, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 、-OCOOR 11 、-OCONR 12 R 13 、-OCHR 14 OCOR 15 or-OCHR 14 OCOOR 15a , where R 10 , R 11 , and R 15 and R 15a are independently alkyl or alkyl substituted by amino, carboxyl or hydroxyl, R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxyl, or hydroxyl, or R 12 and R 13 Together with the nitrogen atom to which it is attached, it forms an optionally substituted heterocyclic group, and each R 14 is hydrogen, alkyl or haloalkyl;
[0256] R 2 is hydrogen, deuterium, alkyl, halo, haloalkyl, alkenyl or alkynyl;
[0257] R 2a is hydrogen or deuterium;
[0258] R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or
[0259] R 3 and R 4 together with the carbon to which it is attached, form oxo, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene;
[0260] R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy;
[0261] R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or
[0262] R 5 and R 6 together with the carbon to which it is attached, form oxo, alkyldienyl, 3-6 membered cycloalkylene, or 4-6 membered optionally substituted heterocyclylene; provided that R 5 With R6 and R 3 With R 4 together with the carbon to which it is attached, do not simultaneously form oxo, cycloalkylene, or optionally substituted 4- to 6-membered heterocyclylene;
[0263] R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl or haloalkoxy;
[0264] L is a bond, S, SO, SO2, O, CO or NR 16 , where R 16 is hydrogen or alkyl;
[0265] R 8 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl or heteroaralkyl, wherein aryl or heteroaryl (each by itself or as part of aralkyl or heteroaralkyl), or heterocyclyl (by itself or as part of heterocyclylalkyl) is substituted by R a , R b , R c , R g and / or R h Substitution, where R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidene, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h are independently selected from hydrogen, deuterium, and halo; and
[0266] R 9 R is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, alkylsulfonyl or heteroaryl, wherein the heteroaryl is optionally substituted by R independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo and cyano d , R e and R f replace; or
[0267] When R 9 and R 2 When attached to the same carbon atom, they may combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene;
[0268] R 9a is hydrogen or deuterium;
[0269] or pharmaceutically acceptable salts thereof.
[0270] 41. A compound having formula (I):
[0271]
[0272] in:
[0273] X 1 is CH or N;
[0274] R 1 Hydroxyl, halogen, amino, -OP(O)(OH)2, -OCH2OP(O)(OH)2, -OCOR 10 、-OCOOR 11 、-OCONR 12 R 13 、-OCHR 14 OCOR 15 or-OCHR 14 OCOOR 15a , where R 10 , R 11 , R 15 and R 15a are independently alkyl or alkyl substituted by amino, carboxyl or hydroxyl, R 12 and R 13 are independently hydrogen, alkyl, or alkyl substituted with amino, carboxyl, or hydroxyl, or R 12 and R 13 Together with the nitrogen atom to which it is attached, it forms an optionally substituted heterocyclic group, and each R 14 is hydrogen, alkyl or haloalkyl;
[0275] R 2 is hydrogen, deuterium, alkyl, haloalkyl, alkynyl or alkenyl;
[0276] R 3 and R 4 is independently hydrogen, deuterium, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl; or
[0277] R 3 and R 4 together with the carbon to which it is attached, form oxo, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene;
[0278] R 5 is hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxy or alkoxy;
[0279] R 6 is hydrogen, deuterium, alkyl, cycloalkyl or halo; or
[0280] R 5 and R 6 together with the carbon to which it is attached, form a 3- to 6-membered cycloalkylene or a 4- to 6-membered optionally substituted heterocyclylene; provided that R 5 and R 6 and R 3 and R 4 together with the carbon to which it is attached, do not simultaneously form a cycloalkylene or an optionally substituted 4- to 6-membered heterocyclylene;
[0281] R 7 is hydrogen, deuterium, alkyl, alkoxy, cyano, halo, haloalkyl or haloalkoxy;
[0282] L is a bond, S, SO, SO2, O, CO or NR 16 , where R 16 is hydrogen or alkyl;
[0283] R 8 is alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl or heteroaralkyl, wherein aryl or heteroaryl (each by itself or as part of aralkyl or heteroaralkyl), or heterocyclyl (by itself or as part of heterocyclylalkyl) is substituted by R a , R b and / or R c Replace the R a , R b and / or R c are independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidene, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl; and
[0284] R 9 is hydrogen, alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, haloalkoxy, alkylsulfoxide, or alkylsulfonyl, or heteroaryl, wherein the heteroaryl is optionally substituted by R d , R e and R f Replace the R d , R e and R f are independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo and cyano; or
[0285] When R 9 and R 2When attached to the same carbon atom, they may combine to form oxo, alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene;
[0286] or pharmaceutically acceptable salts thereof.
[0287] 42. The compound of embodiment 40 or 41 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are independently halo.
[0288] 43. The compound of embodiment 40 or 41 or a pharmaceutically acceptable salt thereof, wherein R 3 is halogenated and R 4 It's hydrogen.
[0289] 44. The compound of embodiment 40, 41, 42 or 43 or a pharmaceutically acceptable salt thereof, wherein R 1 It's hydroxyl.
[0290] 45. The compound of embodiment 40, 41, 42 or 43 or a pharmaceutically acceptable salt thereof, wherein R 1 It's amino.
[0291] 46. A compound according to any one of embodiments 40 to 45, or a pharmaceutically acceptable salt thereof, wherein R 6 It is halogenated.
[0292] 47. A compound according to any one of embodiments 40 to 45, or a pharmaceutically acceptable salt thereof, wherein R 6 is an alkyl group, preferably R 6 It's methyl.
[0293] 48. A compound according to any one of embodiments 40 to 45, or a pharmaceutically acceptable salt thereof, wherein R 6 It's hydrogen.
[0294] 49. A compound according to any one of embodiments 40 to 45, or a pharmaceutically acceptable salt thereof, wherein R 6 is cycloalkyl, preferably cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
[0295] 50. A compound according to any one of embodiments 40 to 49, or a pharmaceutically acceptable salt thereof, wherein R 5 is halo, preferably fluoro.
[0296] 51. A compound according to any one of embodiments 40 to 49, or a pharmaceutically acceptable salt thereof, wherein R 5 is a haloalkyl group, preferably R 5 It is difluoromethyl or trifluoromethyl.
[0297] 52. A compound according to any one of embodiments 40 to 49, or a pharmaceutically acceptable salt thereof, wherein R 5 is an alkyl group, preferably R 5 It is methyl or ethyl.
[0298] 53. A compound as described in any one of Embodiments 40 to 49, or a pharmaceutically acceptable salt thereof, wherein R 5 is hydrogen or alkoxy.
[0299] 54. A compound according to any one of embodiments 40 to 45, or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 Together with the carbon to which it is attached it forms a 3 to 6 membered cycloalkylene, preferably a cyclopropylene, cyclobutylene or cyclopentylene optionally substituted with one or two fluorines.
[0300] 55. A compound according to any one of embodiments 40 to 54, or a pharmaceutically acceptable salt thereof, wherein X 1 Yes CR 7 .
[0301] 56. The compound of Example 40 or a pharmaceutically acceptable salt thereof, which has the structure of formula (IIa1) or (IIb1):
[0302]
[0303] 57. The compound of Example 40 or a pharmaceutically acceptable salt thereof, which has the structure of Formula (IIa1′) or (IIb1′):
[0304]
[0305] 58. The compound of Example 41 or a pharmaceutically acceptable salt thereof, which has the structure of formula (IIa) or (IIb):
[0306]
[0307] 59. The compound of Example 41 or a pharmaceutically acceptable salt thereof, which has the structure of Formula (IIa') or (IIb'):
[0308]
[0309] 60. The compound of Example 41 or a pharmaceutically acceptable salt thereof, which has the structure of formula (IVa):
[0310]
[0311] Where R 5 and R 6Together with the carbon to which it is attached it forms a 3 to 6 membered cycloalkylene, preferably a cyclopropylene, cyclobutylene or cyclopentylene optionally substituted with one or two fluorines.
[0312] 61. The compound of Example 41 or a pharmaceutically acceptable salt thereof, which has the structure of Formula (VIa) or (VIb):
[0313]
[0314] Where R 5 and R 6 Together with the carbon to which it is attached it forms a 3 to 6 membered cycloalkylene, preferably a cyclopropylene, cyclobutylene or cyclopentylene optionally substituted with one or two fluorines.
[0315] 62. The compound of Example 41 or a pharmaceutically acceptable salt thereof, which has the structure of Formula (VIIa) or (VIIb):
[0316]
[0317] 63. A compound as described in any one of Embodiments 40 to 62, or a pharmaceutically acceptable salt thereof, wherein R 3 It's fluorine.
[0318] 64. The compound of any one of embodiments 40 to 42 and 44 to 62, or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 It's fluorine.
[0319] 65. The compound of any one of Embodiments 40 to 64, or a pharmaceutically acceptable salt thereof, wherein L is O, S, SO, SO2 or NH.
[0320] 66. The compound of embodiment 65 or a pharmaceutically acceptable salt thereof, wherein L is O.
[0321] 67. A compound according to any one of embodiments 40 to 66, or a pharmaceutically acceptable salt thereof, wherein R 8 is cycloalkyl, cycloalkenyl, bicyclic cycloalkyl, oxocycloalkenyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, spirocycloalkyl, spiroheterocyclyl, heterocyclylalkyl, heteroaryl or heteroaralkyl, wherein aryl or heteroaryl (each by itself or as part of aralkyl or heteroaralkyl), or heterocyclyl (by itself or as part of heterocyclylalkyl) is substituted by R a , R b and R c Replace the R a , R b and R cindependently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, alkenyl, alkynyl, alkylidene, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.
[0322] 68. A compound or a pharmaceutically acceptable salt thereof as in any one of Embodiments 40, 42 to 57 and 63 to 66 and subembodiments contained therein, wherein R 8 It is R a , R b , R c , R g and R h Substituted phenyl, wherein R a , R b and R c is independently selected from hydrogen, deuterium, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl, and R g and R h are independently selected from hydrogen and halo.
[0323] 68A. A compound or a pharmaceutically acceptable salt thereof as in any one of Embodiments 40, 42 to 57 and 63 to 66 and subembodiments contained therein, wherein R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-difluoromethylphenyl or 3-cyano-5-fluoro-2,4,6-trideuteratedphenyl. In a first sub-embodiment of Embodiment 68A, R 10 It is 3-cyano-5-fluorophenyl or 3-cyano-5-fluoro-2,4,6-trideuterated phenyl.
[0324] 69. A compound or a pharmaceutically acceptable salt thereof as in any one of embodiments 41 to 55 and 58 to 66, wherein R 8 It is R a , R b and R c Substituted phenyl, the R a , Rb and R c independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.
[0325] 70. A compound or a pharmaceutically acceptable salt thereof as in any one of embodiments 41 to 55 and 58 to 66, wherein R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl or 3-cyano-5-difluoromethylphenyl. In the fourth sub-embodiment of embodiment 26, R 10 It is 3-cyano-5-fluorophenyl.
[0326] 71. A compound or a pharmaceutically acceptable salt thereof as in any one of Embodiments 40 to 66 and any subembodiments contained therein, wherein R 8 is cycloalkyl or cycloalkylalkyl, each optionally substituted with one or two substituents independently selected from alkyl, halo, alkoxy, cyano and hydroxy.
[0327] 72. A compound or a pharmaceutically acceptable salt thereof as in any one of Embodiments 40 to 66 and any subembodiments contained therein, wherein R 8 It is R a , R b and R c Substituted heteroaryl, the R a , R b and R c are independently selected from hydrogen, alkyl, haloalkyl, haloalkoxy, alkoxy, hydroxy, halo, cyano, hydroxyalkyl, alkoxyalkyl, aminoalkyl, optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted heterocyclyl.
[0328] 73. A compound as described in any one of Embodiments 40 to 66, or a pharmaceutically acceptable salt thereof, wherein R 8 is a 5-membered or 6-membered heteroaryl group (e.g., pyridyl, pyridazinyl, pyrimidinyl, thienyl, furanyl, thiazolyl, oxazolyl, imidazolyl or pyrazinyl), each of which is substituted by R a , Rb and R c Substitution, where R a and R b are independently selected from hydrogen, alkyl, alkoxy, hydroxy, halo, haloalkyl, haloalkoxy and cyano, and R c is selected from the group consisting of hydrogen, alkyl, halo, haloalkyl and haloalkoxy.
[0329] 74. A compound according to any one of embodiments 40 to 66, or a pharmaceutically acceptable salt thereof, wherein R 8 is pyridin-3-yl, pyridin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, pyrimidin-2-yl, thien-2-yl, furan-2-yl, thiazol-5-yl, oxazol-5-yl, imidazol-5-yl, furan-3-yl, thien-3-yl, thiazol-4-yl, pyridin-4-yl, oxazol-2-yl, imidazol-2-yl, pyridin-2-yl, pyrazin-2-yl or thiazol-2-yl, and R a , R b and R c Substitution, where R a and R b are independently selected from hydrogen, methyl, methoxy, hydroxy, chlorine, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy, and R c is selected from the group consisting of hydrogen, methyl, cyano, chlorine, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy.
[0330] 75. The compound of embodiment 74 or a pharmaceutically acceptable salt thereof, wherein R 8 It is 5-cyanopyridin-3-yl, 5-chloropyridin-3-yl or 5-fluoropyridin-3-yl.
[0331] 76. A compound as described in any one of Embodiments 40 to 75, or a pharmaceutically acceptable salt thereof, wherein R 7 is hydrogen, methyl, ethyl, methoxy, fluorine, trifluoromethyl or trifluoromethoxy, preferably R 7 It's hydrogen.
[0332] 77. A compound as described in any one of Embodiments 40 to 76, or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, fluorine, methyl or ethyl.
[0333] 78. A compound as described in any one of Embodiments 40 to 77, or a pharmaceutically acceptable salt thereof, wherein R 9 is hydrogen, alkyl, halo, hydroxy or alkoxy.
[0334] 79. A compound according to any one of embodiments 40 to 77, or a pharmaceutically acceptable salt thereof, wherein R 9 is hydrogen, methyl, methoxy or fluorine.
[0335] 80. A compound according to any one of embodiments 40 to 79, or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attached to the same carbon atom.
[0336] 81. The compound of embodiment 80 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0337] 82. A compound as described in any one of Embodiments 40 to 76, or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attached to the same carbon atom and together with the carbon atom to which it is attached form an oxo.
[0338] 83. A compound as described in any one of Embodiments 40 to 76, or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attached to the same carbon atom and together with the carbon atom to which it is attached form a 3- to 6-membered cycloalkylene group.
[0339] 84. The compound of embodiment 83 or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Together with the carbon atom to which it is attached it forms a cyclopropylene group.
[0340] 85. A compound as described in any one of Embodiments 40 to 76, or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attached to the same carbon atom and together with the carbon atom to which it is attached form a 4- to 6-membered heterocyclylene.
[0341] 85a. A compound as described in any one of Embodiments 40 to 76, or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attached to the same carbon atom and together with the carbon atom to which it is attached form an alkyldienyl, preferably a vinyldienyl.
[0342] 86. A compound as described in any one of embodiments 82 to 85a, or a pharmaceutically acceptable salt thereof, wherein R 2 and R 9 Attach to and Attach to R 1 The ring carbon of is a ring carbon atom in the meta position.
[0343] 87. A compound or a pharmaceutically acceptable salt thereof as in any one of embodiments 40, 42-57, 63-68A and 71-76, wherein R2 and R 9 Attach to and Attach to R 1 The ring carbon is in the meta position and R 2 is hydrogen or deuterium and R 9 is hydrogen, methyl or fluorine.
[0344] 88. The compound of embodiment 87 and sub-embodiments thereof or a pharmaceutically acceptable salt thereof is wherein R 2 is hydrogen or deuterium and R 9 It's fluorine.
[0345] 89. The compound of any one of Embodiments 40, 65-68A and 71-79 or a pharmaceutically acceptable salt thereof, which has the structure of Formula (VIIIa1) or (VIIIb1):
[0346]
[0347] The structure of formula (VIIIb1) is preferred.
[0348] 90. The compound of embodiment 89 or a pharmaceutically acceptable salt thereof, wherein R 2a and R 9a are independently hydrogen or deuterium, preferably R 2a and R 9a It's hydrogen.
[0349] 91. A compound according to any one of Embodiments 41, 65 to 67 and 69 to 79, or a pharmaceutically acceptable salt thereof, having a structure of Formula (VIIIa) or (VIIIb):
[0350]
[0351] Preferably it has the structure of formula (VIIIb).
[0352] 92. The compound of embodiment 91 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen and R 9 is hydrogen, fluorine or methyl.
[0353] 93. A pharmaceutical composition comprising a compound of any one of embodiments 40 to 92 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0354] 94. A method of inhibiting HIF2α, the method comprising contacting HIF2α with a compound of any one of Embodiments 40 to 92 or a pharmaceutically acceptable salt thereof, or with a pharmaceutical composition of Embodiment 93.
[0355] 95. A method for treating a disease mediated by HIF2α in a patient, the method comprising administering to a patient identified as needing the same a therapeutically effective amount of a pharmaceutical composition comprising a compound as described in any one of Examples 40 to 92, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient.
[0356] 96. A method of treating cancer in a patient, the method comprising administering to a patient identified as being in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound as described in any one of Examples 40 to 92, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0357] 97. The method of embodiment 96, wherein the compound of embodiments 40 to 92 or a pharmaceutically acceptable salt thereof is optionally administered in combination with at least one other anticancer agent.
[0358] 98. The method of embodiment 96 or 97, wherein the cancer is renal cancer or glioblastoma.
[0359] 99. The method of embodiment 95, wherein the disease is NASH, pulmonary hypertension, or inflammatory bowel disease.
[0360] The representative compounds prepared are disclosed in the following Compound Table 1:
[0361] Table I
[0362]
[0363]
[0364]
[0365]
[0366]
[0367] Additional representative compounds of formula (I) that can be prepared are shown in Table II below:
[0368]
[0369]
[0370] General synthetic scheme
[0371] The compounds of the present disclosure can be prepared by the methods depicted in the reaction schemes shown below.
[0372] Starting materials and reagents used to prepare these compounds can be obtained from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.) or prepared by methods known to those skilled in the art following the procedures set forth in, for example, Fieser and Fieser's Reagents for Organic Synthesis, Vols. 1-17 (John Wiley & Sons, 1991); Rodd's Chemistry of Carbon Compounds, Vols. 1-5 and Supplements (Elsevier Science Publishers, 1989); Organic Reactions, Vols. 1-40 (John Wiley & Sons, 1991); March's Advanced Chemistry, Vols. 1-41 (John Wiley & Sons, 1991); Organic Chemistry (John Wiley & Sons, 4th Edition) and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some of the methods by which the disclosed compounds may be synthesized, and various modifications may be made to these schemes and will be enlightening to those of ordinary skill in the art upon reading this disclosure. If desired, these starting materials and intermediates, as well as the final products of the reactions, may be separated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, and the like. Such materials may be characterized using conventional means, including physical constants and spectral data.
[0373] Unless indicated to the contrary, the reactions described herein occur at atmospheric pressure, at a temperature range from about -78°C to about 150°C, such as from about 0°C to about 125°C, and further such as at about room temperature (or ambient temperature), such as about 20°C.
[0374] Compounds of formula (I) can be prepared as illustrated and described in Scheme 1 below, wherein X 1 Yes CH, R 1 is hydroxyl, R 3 , R 4 , R 5 , R 6 , R 7 , and R8 As defined in the Summary of the Invention (or any embodiment thereof), and R 9 With R 2 Combine to form an alkyldiene group.
[0375] Solution 1
[0376]
[0377] An aldehyde having the formula 1-a (wherein R 7 is as described in the Summary of the Invention or a precursor thereof) and a compound having Formula 1-b (wherein X 1 is a halide, and R 3 A zinc metal-mediated Reformastky reaction between (as defined, for example, independently hydrogen, deuterium, alkyl, halo, haloalkyl, hydroxyalkyl, or alkoxyalkyl) provides a compound of formula 1-c. Compounds of formula 1-a and 1-b are commercially available or they can be prepared by methods well known in the art. For example, 2-bromo-4-fluorobenzaldehyde, ethyl 2-bromo-2,2-difluoroacetate, ethyl 2-bromo-2-methylpropionate, ethyl 2-bromopropionate, ethyl 2-bromoacetate are commercially available. The hydroxyl group in 1-c can be oxidized under oxidizing conditions (such as 2-iodobenzoic acid (IBX) or TPAP, NMO) to give a ketone of formula 1-d. By methods well known in the art, the ketone group in the compound of formula 1-d can be functionalized to provide a compound of formula 1-e, wherein R 5 and R 6 As described in the Summary of the Invention. For example, compounds of formula 1-e, wherein R 5 and R 6 is fluorine. Cyclization of 1-e can be achieved by treating it with an alkyl lithium reagent such as n-BuLi to give ketone 1-f. The carbonyl group in 1-f can be reduced with a reducing agent such as NaBH4 to provide alcohol 1-g.
[0378] Compounds of formula 1-g can be converted to compounds of formula 1-h by lithiation of 1-g followed by treatment of the lithium intermediate with CBr4. Oxidation of 1-h with an oxidant such as IBX provides ketones of formula 1-i. Addition of an allyl metal reagent such as allyl magnesium bromide to compounds of formula 1-i provides compounds of formula 1-j.
[0379] Alternatively, a compound of formula 1-j can be prepared from 1-f by adding an allyl metal reagent (such as allyl magnesium bromide) to a compound of formula 1-f as shown below:
[0380]
[0381] Lithiation of 1-g with a base (such as LDA) followed by treatment of the lithium intermediate with a brominating agent (such as CBr4 or 1,2-dibromotetrafluoroethane) provides compounds of formula 1-j. If desired, the enantioselective synthesis of compounds of formula 1-g can be achieved by adding 2-allyl-4,4,5,5-tetramethyl-1,3,2-dioxaborane to compounds of formula 1-f in the presence of a ligand (such as 1-m) and a suitable base (such as tBuONa) in an organic solvent (such as MeOH, toluene) as shown below:
[0382]
[0383] Compounds of formula 1-j can be cyclized in the presence of a Pd catalyst and a suitable ligand (such as Pd(dppf)Cl2CH2Cl2 or Pd(PPh3)2Cl2) to provide compounds of formula 1-k. Compounds of formula R can be cyclized by methods well known in the art. 8 -LH compound (wherein L is N, O, or S, and R 8 As defined in the Summary of the Invention), treating compound 1-k to convert the fluorine group in the compound of formula 1-k into a compound of formula -LR 8 A group (where L and R 8 As described in the Summary of the Invention). having the formula R 8 -LH compounds are commercially available or they can be prepared by methods well known in the art. For example, 3-fluoro-5-hydroxybenzonitrile, 3,5-difluorophenol, 3-chloro-5-fluorophenol, 3-chloro-5-hydroxy-benzonitrile, 5-fluoropyridine-3-ol, 5-chloropyridine-3-ol, 5-hydroxynicotinonitrile, 3-fluoro-5-mercaptobenzonitrile, 3-amino-5-fluorobenzonitrile, 3,3-difluorocyclobutane-1-ol, 3-amino-5-fluorobenzonitrile, 3-fluoro-5-mercaptobenzonitrile, 3-chloro-5-mercaptobenzonitrile, 3-amino-5-chlorobenzonitrile are commercially available.
[0384] A compound having formula (I) (wherein R 1 is hydroxyl, R 3 , R 4 , R 5 , R 6 , R 7 and R 8 is as defined in the Summary of the Invention (or any embodiment thereof), and R 9 and R 2 to form oxo) can be prepared as illustrated and described in Scheme 2 below.
[0385] Solution 2
[0386]
[0387] Compounds of formula 1-k can be converted to compounds of formula 1-1 by treating them with oxidative cleavage agents such as NaIO4 and RuCl3 hydrate under conditions well known in the art. 8 -LH compound to treat compound 1-1, the fluorine group in the compound of formula 1-1 is converted into a compound of formula -LR 8 A group (where L and R 8 as described in the Summary of the Invention).
[0388] Compounds of formula (I) may be converted to other compounds of formula (I) by methods well known in the art. For example, compounds of formula (I) (wherein R 9 With R 2 Combination to form oxo) to synthesize a compound having formula (I) (wherein R 1 is hydroxyl, R 2 is hydrogen, and R 9 is hydroxyl or fluorine).
[0389] Method (i)
[0390]
[0391] The compound of formula (I) (wherein R 1 is hydroxyl, R 9 With R 2 Combining to form an oxo group), converting it into a compound having formula (I) (wherein R 1 is hydroxyl, R 9 is a hydroxyl group).
[0392] Method (ii)
[0393]
[0394] Compounds of formula (I) (wherein R 1 is hydroxyl, R 9 is a hydroxyl group), which is converted into a compound having formula (I) (wherein R 1 is hydroxyl, R 9 is fluorine).
[0395] utility
[0396] The compounds disclosed herein can be used to treat HIF-2α mediated diseases, including but not limited to various types of cancer, liver diseases such as non-alcoholic steatohepatitis (NASH), inflammatory diseases such as inflammatory bowel disease (IBD), lung diseases such as pulmonary arterial hypertension (PAH), and iron overload disorders.
[0397] HIF-2α plays an important role in the development and progression of many human cancers. Many extensive studies have demonstrated the key role of increased HIF-2α activity in driving clear cell renal cell carcinoma (ccRCC) (see Shen and Kaelin for review, Seminars in Cancer Biology 23:18-25, 2013). Abnormal HIF-2α activity is mainly due to the loss of function of the tumor suppressor VHL. It is well known that more than 80% of ccRCC have defective VHL through deletion, mutation or disturbed post-translational modification. Defective VHL leads to constitutively active HIF-α protein, regardless of oxygen content. Various studies using gain-of-function and loss-of-function approaches in mouse models have demonstrated that HIF-2α is a key oncogenic substrate of VHL (see Kondo et al. Cancer Cell 1:237-246, 2002; Kondo et al. PLoS Biology 1:439-444, 2002; Maranchi et al. Cancer Cell 1:247-255, 2002; Zimmer et al. Mol. Cancer Res 2:89-95, 2004). For example, knockdown of HIF-2α in VHL-null tumors inhibits tumor formation; whereas reintroduction of VHL and overexpression of HIF-2α overcome the tumor suppressive effects of VHL. Furthermore, single nucleotide polymorphisms in HIF-2α are associated with resistance to PHD-mediated degradation and are associated with an increased risk of RCC. In addition to being a typical tumor initiation event in ccRCC, the VHL-HIF-2α axis is also involved in ccRCC tumor metastasis through its downstream CXCR4 and CYTIP (see Vanharanta et al. Nature Medicine 19:50-59, 2013; Peter Staller et al., Nature 2003 Sep 18; 425(6955):307-11). In summary, these studies strongly support the potential therapeutic utility of HIF-2α-targeted agents for the treatment of ccRCC.
[0398] Defective VHL not only predisposes patients to renal cancer (lifetime risk of 70%), but also to hemangioblastoma, pheochromocytoma, endolymphatic sac tumors, and pancreatic neuroendocrine tumors. Tumors derived from defective VHL are usually driven by constitutively active downstream HIF-α proteins, most of which depend on HIF-2α activity (see Maher et al. Eur. J. Hum. Genet [European Journal of Human Genetics]. 19: 617-623, 2011). Both genetic and epigenetic mechanisms can lead to loss of VHL function. Epigenetic inactivation of VHL expression and the constitutive activation of HIF-α protein have been found in many cancers, including RCC, multiple myeloma, retinoblastoma, NSCLC, pancreatic endocrine tumors, squamous cell carcinoma, acute myeloid leukemia, myelodysplastic syndrome, and esophageal squamous cell carcinoma (see the review by Nguyen et al. Arch. Phann. Res [Drug Research Literature] 36: 252-263, 2013). HIF-2α is also associated with retinal cancer, adrenal cancer, and pancreatic cancer through both VHL loss of function and activating mutations of HIF-2α. Recently, gain-of-function HIF-2α mutations have been identified in polycythemia and paraganglioma with polycythemia (see Zhuang et al., NEJM [New England Journal of Medicine] 367:922-930, 2012; Percy et al., NEJM [New England Journal of Medicine] 358:162-168, 2008; and Percy et al., Am. J. Hematol. [American Journal of Hematology] 87:439-442, 2012). It should be noted that many known HIF-2α target gene products (e.g., VEGF, PDGF, and cyclin D1) have been shown to play a key role in cancers originating from the kidney, liver, colon, lung, and brain. Therefore, HIF-2α targeted therapy may be beneficial for the above cancers when driven by these signaling events downstream of abnormal HIF-2α pathway activation. In addition to VHL loss of function and activating mutations in HIF-2α, HIF-α proteins are frequently upregulated in the intratumoral environment of rapidly growing tumors due to hypoxic conditions resulting from poor vascularization in large tumors. The activated HIF-α pathway further promotes tumor cell survival and proliferation by transcriptionally upregulating various essential factors.
[0399] Numerous studies have demonstrated a correlation between HIF-2α overexpression and poor prognosis in various cancers, including astrocytoma, breast cancer, cervical cancer, colorectal cancer, glioblastoma, glioma, head and neck cancer, liver cancer, non-small cell lung cancer, melanoma, neuroblastoma, ovarian cancer, and prostate cancer, supporting the pursuit of HIF-2α as a therapeutic target for the treatment of these cancers (see review by Keith et al., Nature Rev. Cancer 12:9-22, 2012). HIF-2α has been shown to promote the growth of APC mutant colorectal cancer by regulating genes involved in proliferation, iron utilization, and inflammation (see Xue et al. Cancer Res 72:2285-2293, 2012; and Xue and Shah, Carcinogenesis 32:163-169, 2013). In hepatocellular carcinoma (HCC), knocking down HIF-2α in preclinical models resulted in inhibition of in vitro cell proliferation and in vivo tumor growth by downregulating VEGF and cyclin D1 (see He et al. Cancer Sci [Cancer Science] 103: 528-534, 2012). In NSCLC, about 50% of patients show overexpression of HIF-2α protein, which is strongly associated with higher VEGF expression and, more importantly, reduced overall survival. Interestingly, although HIF-1α expression is also often increased, it is not associated with reduced overall survival in lung cancer patients (see Giatromanolaki et al. Br. J. Cancer [British Journal of Cancer] 85: 881-890, 2001). Extensive studies of mice engineered with both non-degradable HIF-2α and mutant KRAS tumors showed increased tumor burden and decreased survival compared to mice with mutant KRAS expression alone (see Kim, et al. J. Clin. Invest [Journal of Clinical Research]. 119: 2160-2170, 2009). These studies indicate that HIF-2α promotes tumor growth and progression of lung cancer and is also negatively correlated with clinical prognosis.
[0400] In mouse models, in addition to lung cancer, HIF-2αs activity has been associated with the progression of chronic obstructive pulmonary disease (COPD) (see Karoor et al., Cancer Prev. Res. [Clinical Cancer Research] 5: 1061-1071, 2012). HIF-2α activity has also been shown to be important in cancers of the central nervous system (see Holmquist-Mengelbier, et al. Cancer Cell [Cancer Cell] 10: 413-423, 2006 and Li, et al. Cancer Cell [Cancer Cell] 15: 501-513, 2009). HIF-2α attenuation reduces tumor growth in preclinical animal models of neuroblastoma, while increased HIF-2α content is associated with advanced disease, poor prognosis, and higher VEGF content, which may contribute to poor clinical outcomes. Similarly, higher HIF-2α expression is associated with low survival rates in gliomas. Experimentally, inhibition of HIF-2α in glioma stem cells reduces cell proliferation and survival in vitro and tumorigenesis in vivo. While HIF-1α is expressed in both neural progenitor cells and brain tumor stem cells, HIF-2α is found only in the latter. Moreover, the survival of patients with gliomas is correlated with HIF-2α levels, but not with HIF-1α levels.
[0401] One of the downstream HIF-2α effectors is cyclin D, an essential partner for the activation of CDK4 and CDK6. Therefore, administration of HIF-2α inhibitors together with CDK4 / 6 inhibitors, including abemaciclib Palbociclib and ribociclib This should lead to downregulation of cyclin D, thereby augmenting the antiproliferative effect of CDK4 / 6 inhibitors. Recent studies (Nicholson et al. Sci Signal. 2019 Oct 1;12(601)) have shown that the antiproliferative effect of CDK4 / 6 inhibition is synergistic with HIF-2α inhibition in HIF-2α-dependent VHL- / -ccRCC cells.
[0402] Radiotherapy is frequently used in about 50% of cancer patients alone or in combination with other therapies. However, for a long time, the hypoxic microenvironment in the tumor has been associated with resistance to radiotherapy. Bhatt and collaborators found that reduced HIF-2α levels lead to increased sensitivity to ionizing radiation in renal cell carcinoma cells (see Bhatt et al., BJU Int. [British International Journal of Urology] 102: 358-363, 2008). In addition, mechanistic studies from Bertout et al. have confirmed that HIF-2α inhibition enhances the effectiveness of radiation through increased p53-dependent apoptosis (see Bertout et al., PNAS [Proceedings of the National Academy of Sciences of the United States] 106: 14391-14396, 2009). Therefore, HIF-2α targeted therapy can improve the response of various cancers to radiotherapy.
[0403] Somatostatinoma is a rare neuroendocrine tumor that produces somatostatin, but it is often malignant. It has been found that HIF-2α mutations lead to the destruction of the prolyl hydroxylation domain (PHD) of HIF-2α, thereby eliminating the modification of PHD and subsequently reducing the degradation of HIF-2α mediated by VHL (see Yang, et al. Blood [blood]. 121: 2563-2566, 2013). Then, stable HIF-2α can be translocated to the nucleus, thereby driving the increased expression of hypoxia-related genes, leading to somatostatinoma. Therefore, HIF-2α inhibitors will provide an alternative method for treating somatostatinoma.
[0404] Polycythaemia is a blood disorder characterized by an elevated hematocrit (volume percentage of red blood cells in the blood), also known as erythrocytosis. Gain-of-function mutations in HIF-2α are associated with autosomal dominant erythrocytosis (see Percy et al., N. Engl. J. Med. [New England Journal of Medicine] 358: 162-8, 2008 and Wilson et al., Case Rep Hematol. [Hematology Case Report] 6373706, 2016). In addition, mutations in the PHD of HIF-2α (which is responsible for signaling HIF-2α for ubiquitination and degradation by VHL) have been found to drive polycythemia. Therefore, inhibition of HIF-2αn (which is stabilized by HIF-2α inhibitors through gain-of-function HIF-2α mutations or through loss-of-function mutations of PHD, VHL) should be able to inhibit HIF-2α downstream genes (such as EPO) and thereby reduce the hematocrit of polycythemia.
[0405] Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumors that usually develop in the context of susceptibility gene mutations, including loss of function of VHL or PHD2 or activating mutations of HIF-2α, all of which lead to HIF-2α protein, followed by high expression of downstream genes to promote carcinogenic progression (see Dahia, Nat Rev Cancer [Cancer Nature Review]. 14: 108-19, 2014). In addition, germline heterozygous mutations of genes encoding succinate dehydrogenase (SDH) subunits and SDH complex assembly factor 2 protein (SDHAF2) have been described in patients with hereditary pheochromocytoma and paraganglioma (PPGL). These mutations can lead to the accumulation of succinate, which in turn leads to the inhibition of prolyl-hydroxylases, which is essential for mediating the ubiquitination / degradation of HIF proteins by the VHL complex. Pituitary adenomas are often found to coexist with PPGL. Therefore, inhibition of HIF-2α should be useful for treating both PPGL and pituitary tumors. Succinate dehydrogenase subunit mutations are also associated with gastrointestinal stromal tumors (GIST), thus supporting the exploration of HIF-2α inhibitors for the treatment of GIST (see Janeway, et al. Proc. Natl Acad. Sci. USA 108:314-318, 2011).
[0406] Function loss mutations in fumarate hydratase (FH) predispose patients to an autosomal dominant syndrome of skin and uterine leiomyoma. It has been shown that activation of HIF proteins promotes FH-related tumor development by activating hypoxia pathways. (See O'Flaherty et al., Hum Mol Genet. [Human Molecular Genetics] 19: 3844-3851, 2010 and Wei et al., J Med Genet. [Journal of Medical Genetics] 43: 18-27, 2006). In addition, high expression of HIF-2α has been found in leiomyosarcoma (a rare neoplasm of smooth muscle origin) (see Mayer, et al. Cancer Res [Cancer Research]. 68: 4719, 2008). Therefore, inhibition of HIF-2α may be beneficial in treating both leiomyoma and leiomyosarcoma.
[0407] Retinal capillary hemangioblastoma may be an ocular manifestation of VHL disease, which is caused by the loss of the tumor suppressor VHL. The upregulation of HIF-2α after VHL loss has been detected in patients with retinal hemangioblastoma, and this upregulation indicates that it promotes the aggressive course of retinal hemangioblastoma, leading to resistance to multiple anti-VEGF and radiotherapy (see Wang et al. Graefes Arch. Clin. Exp. Ophthalmol [Graefes Clinical and Experimental Ophthalmology Literature]. 252: 1319-1327, 2014). In addition, uncontrolled vascular growth is a central pathological component of many human blindness disorders (including diabetic retinopathy, age-related macular degeneration, glaucoma and premature retinopathy). Neuronal cell death and visual loss observed in these diseases are often caused by abnormal, leaky blood vessels (the result of pathological new blood vessel formation) (see Krock et al., Genes Cancer [Gene and Cancer]. 2: 1117-1133, 2011). Given the causal role of HIF in new blood vessel formation, inhibitors of HIF-2α may have potential utility in treating various blindness diseases. In fact, systemic reduction of HIF-2α expression using hypomorphic Hif-2α alleles results in a significant reduction in retinal new blood vessel formation and a concomitant defect in EPO expression (see Morita et al., EMBO J. [Journal of the European Molecular Biology Association] 22: 1134-46, 2003).
[0408] In addition to its direct role in promoting the occurrence, progression and metastasis of tumor cells (e.g., ccRCC), HIF-2α also indirectly promotes tumorigenesis by enhancing the immunosuppressive effects of hypoxia in the tumor microenvironment. The expression of HIF-2α has been detected in myeloid cells (see Talks KL et al., Am J Pathol. [American Journal of Pathology]. 2000; 157 (2): 411-421). For example, it is shown that HIF-2α facilitates the polarization of macrophages into an immunosuppressive M2 phenotype and enhances the migration and invasion of tumor-associated macrophages (see Imtiyaz HZ et al., J Clin Invest. [Clinical Research Journal] 2010; 120 (8): 2699-2714). Therefore, increased levels of HIF-2α in tumor-associated macrophages (TAMs) are associated with high-grade human tumors and are associated with poor prognosis. Furthermore, HIF-2α can indirectly promote other immunosuppressive pathways (e.g., adenosine and arginase, etc.) by modulating the expression of key signaling regulators (e.g., adenosine A2B / A2A receptors and arginase, etc.). These data support HIF-2α as a potential therapeutic target for the treatment of a wider range of inflammatory disorders and cancer, either as a single agent or in combination with other therapeutic agents (e.g., immunotherapy).
[0409] Due to the key role of HIF-2α proteins in regulating the physiological response to fluctuations in oxygen content, they are also associated with many hypoxia-related pathological processes in addition to cancer. One such disease is PAH, a debilitating and life-threatening disease with a very poor prognosis. Recent studies have confirmed that HIF-2α contributes to the process of hypoxic pulmonary vascular remodeling, reduces the plasticity of the vascular bed, and ultimately weakens PAH (see Andrew S. et al., Proc Natl Acad Sci USA. [Proceedings of the National Academy of Sciences of the United States] August 2, 2016; 113 (31): 8801-8806, Tang H et al., Am J Physiol Lung Cell Mol Physiol. [American Journal of Physiology-Lung Cell and Molecular Physiology] February 1, 2018; 314 (2): L256-L275). These studies provide new insights into the role of pulmonary endothelial HIF-2α in regulating the pulmonary vascular response to hypoxia, and provide many new therapeutic strategies required by targeting HIF-2α. Another example of a hypoxia-related pathological process is IBD, a chronic relapsing inflammatory bowel disease. It was found that when dysregulated epithelial oxygen tension occurs and epithelial villi across the intestine are enhanced, intestinal inflammation and subsequent IBD occur (see Shah YM, Molecular and Cellular Pediatrics, December 2016; 3(1):1). HIF-2α activation contributes to IBD, while HIF-1α in intestinal epithelial cells is considered to be a major protective factor for IBD (see Karhausen J et al., J Clin Invest. 2004; 114(8):1098-1106; Furuta GT et al., J Exp Med. 2001; 193(9):1027-1034). Mechanistically, HIF-2α activation not only leads to the upregulation of proinflammatory cytokines, which directly promote IBD, but also leads to the loss of intestinal barrier integrity, thus indirectly contributing to the expression of IBD. (See Xue X et al., Gastroenterology. 2013; 145(4):831-841; Glover LE et al., Proc Natl Acad Sci US A. 2013; 110(49):19820-19825.) Thus, HIF-2α inhibitors are expected to restore pro-inflammatory conditions and increase intestinal barrier integrity, thereby alleviating symptoms of IBD.
[0410] HIF-2α inhibitors also represent a novel treatment for NASH, for which limited treatment options are available. Recent studies have shown that intestinal-specific destruction of HIF-2α leads to a significant reduction in hepatic steatosis and obesity induced by a high-fat diet. Mechanistically, intestinal HIF-2α actively regulates genes encoding neuraminidase 3, thereby regulating ceramide metabolism, which contributes to the development of NASH (see Xie C et al., Nat Med.. [Natural Medicine] November 2017; 23 (11): 1298-1308.). Therefore, HIF-2α inhibitors should have preventive and therapeutic effects on metabolic disorders such as NASH.
[0411] Several links between HIF-2α levels and iron homeostasis have been identified (see Peyssonnaux C et al., Cell Cycle. 2008; 7(1): 28-32). Multiple studies have demonstrated the important role of HIF-2α in iron overload disorders. HIF-2α (not HIF-1α) has emerged as an important "local" regulator of intestinal iron status, regulating various genes essential for iron transport and absorption (see Mastrogiannaki M et al., J Clin Invest. 2009; 119(5): 1159-1166). Therefore, small molecule inhibitors targeting HIF-2α hold promise for improving iron homeostasis in patients with iron disorders.
[0412] Thus, the present invention provides a method of treating or lessening the severity of a disease, condition or disorder wherein activation or overactivation of HIF-2α is implicated in the disease state. In another aspect, the present disclosure provides a method of treating renal cell carcinoma in a subject using a compound disclosed herein or a pharmaceutically acceptable salt thereof.
[0413] HIF-2α inhibitors also have therapeutic potential for a wide range of non-cancer indications, including but not limited to NASH, IBD, PAH, and iron overload.
[0414] test
[0415] Compounds of the present disclosure can be tested for HIF2α inhibitory activity using the in vitro assay described in Biological Example 1 below.
[0416] Pharmaceutical composition
[0417] In general, the compounds of the present disclosure will be administered in a therapeutically effective amount by any of the acceptable modes of administration for medicaments for similar utilities. The therapeutically effective amount range of the compounds of the present disclosure can be from about 0.01 to about 500 mg / kg patient weight / day, which can be administered in a single dose or multiple doses. Suitable dosage levels can be from about 0.1 to about 250 mg / kg / day; about 0.5 to about 100 mg / kg / day. Suitable dosage levels can be from about 0.01 to about 250 mg / kg / day, about 0.05 to about 100 mg / kg / day, or about 0.1 to about 50 mg / kg / day. Within this range, the dosage can be about 0.05 to about 0.5, about 0.5 to about 5, or about 5 to about 50 mg / kg / day. For oral administration, the composition can be provided in the form of tablets containing about 1.0 to about 1000 mg of active ingredient, particularly about 1, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 400, 500, 600, 750, 800, 900 and 1000 mg of active ingredient. The actual amount of the disclosed compound (i.e., active ingredient) will depend on many factors, such as the severity of the disease to be treated, the age and relative health of the patient, the efficacy of the compound being utilized, the route and form of administration and other factors.
[0418] In general, the compounds of the present disclosure will be administered as pharmaceutical compositions by any of the following routes: oral, systemic (e.g., transdermal, intranasal or by suppository), or parenteral (e.g., intramuscular, intravenous or subcutaneous). The preferred mode of administration is oral administration using a convenient daily dosage regimen, which can be adjusted according to the degree of illness. The composition can take the form of tablets, pills, capsules, semisolids, powders, sustained-release formulations, solutions, suspensions, elixirs, aerosols or any other suitable composition.
[0419] The choice of formulation depends on factors such as the mode of drug administration (eg, for oral administration, formulations in the form of tablets, pills or capsules are preferred, including enteric-coated or sustained-release tablets, pills or capsules) and the bioavailability of the drug substance.
[0420] These compositions are generally composed of a combination of the compounds of the present disclosure and at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, facilitate administration, and do not adversely affect the therapeutic benefits of the compounds of the present disclosure. Such excipients can be any solid, liquid, semisolid, or in the case of aerosol compositions, a gaseous excipient commonly available to those of ordinary skill in the art.
[0421] Solid pharmaceutical excipients include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glyceryl monostearate, sodium chloride, skim milk powder, etc. Liquid and semisolid excipients can be selected from glycerol, propylene glycol, water, ethanol and various oils, including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, etc. Preferred liquid carriers (especially for injectable solutions) include water, saline, aqueous dextrose and glycerol.
[0422] The compound can be formulated for parenteral administration by injection (e.g., by push injection or continuous infusion). Injectable preparations can be provided in unit dosage form, for example, in ampoules with preservatives added or in multi-dose containers. The composition can take the form of a suspension, solution or emulsion, for example, in an oily or aqueous vehicle, and can contain a preparaton (such as a suspending agent, a stabilizer and / or a dispersant). The preparation can be present in a unit dose or multi-dose container (e.g., sealed ampoules and vials), and can be stored in powder form or stored under freeze drying (lyophilization) conditions, requiring only the immediate addition of a sterile liquid carrier (e.g., saline or sterile pyrogen-free water) before use. Temporary injection solutions and suspensions can be prepared by sterile powders, granules and tablets of the aforementioned types.
[0423] Preparations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compound, which may contain antioxidants, buffers, bacteriostats, and solutes that make the preparation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions, which may include suspending agents and thickening agents. Suitable lipophilic solvents or vehicles include fatty oils (such as sesame oil), or synthetic fatty acid esters (such as ethyl oleate or triglycerides), or liposomes. Aqueous injection suspensions may include substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain a suitable stabilizer or an agent that increases the solubility of the compound to allow the preparation of a highly concentrated solution.
[0424] In addition to the aforementioned formulations, the compound can also be formulated into a depot preparation. Such long-acting formulations can be administered by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Thus, for example, the compound can be formulated with a suitable polymeric or hydrophobic material (e.g., formulated into an emulsion in an acceptable oil) or with an ion exchange resin, or formulated into a poorly soluble derivative, such as a poorly soluble salt.
[0425] For buccal or sublingual administration, the composition may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner. Such compositions may comprise the active ingredient in a flavored base such as sucrose and acacia or tragacanth.
[0426] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, eg, containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
[0427] Certain compounds disclosed herein can be administered topically, i.e., by non-systemic administration. This includes external application of compounds disclosed herein to the epidermis or oral cavity and instillation of such compounds into the ears, eyes, and nose, so that the compound does not significantly enter the bloodstream. In contrast, systemic administration refers to oral, intravenous, intraperitoneal, and intramuscular administration.
[0428] Preparations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the inflamed area, such as gels, wipes, lotions, creams, ointments or pastes and drops suitable for application to the eyes, ears or nose. The active ingredient for topical administration may comprise, for example, 0.001% to 10% w / w (by weight) of the preparation. In certain embodiments, the active ingredient may comprise up to 10% w / w. In other embodiments, it may comprise less than 5% w / w. In certain embodiments, the active ingredient may comprise 2% w / w to 5% w / w. In other embodiments, it may comprise 0.1% to 1% w / w of the preparation.
[0429] For administration by inhalation, the compound can be conveniently delivered from an insufflator, a nebulizer pressurized bag, or other convenient methods of delivering an aerosol spray. The pressurized bag may contain a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gases. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. Alternatively, for administration by inhalation or insufflation, the compound according to the present disclosure may be in the form of a dry powder composition, such as a powder mixture of the compound and a suitable powder base (such as lactose or starch). The powder composition may be in a unit dosage form, such as in a capsule, cartridge, gelatin, or blister package, from which the unit dosage powder may be administered by means of an inhaler or insufflator. Other suitable pharmaceutical excipients and formulations thereof are described in Remington's Pharmaceutical Sciences edited by EWMartin (Mack Publishing Company, 20th edition, 2000).
[0430] The level of the compound in the formulation can vary within the full range employed by those skilled in the art. Typically, the formulation will contain (based on weight percentage (wt.%)) about 0.01 to 99.99 wt.% of the compound of the disclosure based on the total formulation, with the remainder being one or more suitable pharmaceutical excipients. For example, the compound is present at a level of about 1 to 80 wt.%.
[0431] Combination and combination therapies
[0432] The compound of the present disclosure can be used in combination with one or more other drugs for the treatment of diseases or conditions, and the compound of the present disclosure or other drugs for these diseases or conditions may have utility. Such one or more other drugs can be administered simultaneously or sequentially with the compound of the present disclosure by a route and its commonly used amount. When the compound of the present disclosure is used simultaneously with one or more other drugs, a pharmaceutical composition containing such other drugs and a unit dosage form of the compound of the present disclosure is preferred. However, combination therapy can also include a therapy in which the compound of the present disclosure and one or more other drugs are administered with different overlapping schedules. It is also expected that when used in combination with one or more other active ingredients, the compound of the present disclosure and other active ingredients can be used with a lower dosage than when each is used alone.
[0433] Thus, pharmaceutical compositions of the present disclosure also include those containing one or more additional drugs in addition to the compounds of the present disclosure.
[0434] The above combination includes not only the combination of the compound of the present disclosure and a kind of other medicine, but also includes the combination with two or more other active drugs. Similarly, the compound of the present disclosure can be used in combination with other medicines for preventing, treating, controlling, improving diseases or illnesses (for which the compound of the present disclosure is useful) or reducing its risk. Such other medicines can be applied simultaneously or sequentially with the compound of the present disclosure by a way and its commonly used amount. When the compound of the present disclosure is used simultaneously with one or more other medicines, a pharmaceutical composition containing these other medicines except the compound of the present disclosure can be used. Therefore, the pharmaceutical composition of the present disclosure also includes those containing one or more other active ingredients except the compound of the present disclosure. The weight ratio of the compound of the present disclosure to the second active ingredient can vary, and will depend on the effective dose of each component. Usually, respective effective doses will be used.
[0435] In the case where a subject in need suffers from cancer or is at risk of developing cancer, the subject can be treated with any combination of the compounds disclosed herein and one or more other anticancer agents. In some embodiments, one or more of the anticancer agents are pro-apoptotic agents. Examples of anticancer agents include, but are not limited to, any of the following: gossypol, genatrix, polyphenol E, chlorofusion protein, all trans-retinoic acid (all trans-retinoic acid, ATRA), bryostatin, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), 5-aza-2'-deoxycytidine, all trans-retinoic acid, doxorubicin, vincristine, etoposide, gemcitabine, imatinib (Gleevec TM), geldanamycin, 17-N-allylamino-17-demethoxygeldanamycin (17-AAG), flavopiridol, LY294002, bortezomib, trastuzumab, BAY 11-7082, PKC412, or PD184352, Taxol TM (also known as "paclitaxel," which is a well-known anticancer drug that works by enhancing and stabilizing microtubule formation), and Taxol TM Analogues (such as Taxotere TM Compounds having the basic taxane backbone as a common structural feature have been shown to have the ability to arrest cells in the G2-M phase due to stabilizing microtubules and may be used in combination with the compounds described herein to treat cancer.
[0436] Suitable anticancer agents also include inhibitors of kinase-related cell proliferation disorders. These kinases include, but are not limited to, Aurora-A, BTK, CDK1, CDK2, CDK3, CDK4, CDK6, CDK5, CDK7, CDK8, CDK9, ephrin receptor kinases, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes, Syk, Itk, Bmx, GSK3, JNK, MEK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC, RAF, Rsk, and SGK.In particular, inhibitors of CDK4 / 6, including abemaciclib (Verzenio), palbociclib (Ibrance), and ribociclib (Kisqali), have the potential to synergize with HIF-2α inhibitors and reverse resistance to HIF-2α inhibition; mitogen-activated protein kinase signaling, e.g., U0126, PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY 43-9006, wortmannin, or LY294002; Syk inhibitors; antibodies (e.g., rituximab); MET inhibitors (e.g., foretinib, carbozantinib, or crizotinib); VEGFR inhibitors (e.g., sunitinib, sorafenib, regorafinib, lenvatinib, vandetanib); ndetanib, cabozantinib, axitinib); EGFR inhibitors (such as afatinib, brivanib, carbozatinib, erlotinib, gefitinib, neratinib, lapatinib); PI3K inhibitors (such as XL147, XL765, BKM120 (buparlisib), GDC- 0941, BYL719, IPI145, BAY80-6946. BEX235 (dactolisib), CAL101 (idelalisib), GSK2636771, TG100-115; MTOR inhibitors (such as rapamycin (sirolimus), temsirolimus, everolimus), XL388, XL765, AZD2013, PF 04691502, PKI-587, BEZ235, GDC0349); MEK inhibitors (such as AZD6244, trametinib, PD184352, pimasertinib, GDC-0973, AZD8330); CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-054, RG7155, etc.); TGFβ receptor kinase inhibitors (such as LY2157299); BTK inhibitors (such as ibrutinib).
[0437] Other anticancer agents include proteasome inhibitors (such as carfilzomib, MLN9708, delanzomib, or bortezomib); BET inhibitors (such as INCB054329, OTX015, CPI-0610); LSD1 inhibitors (such as GSK2979552, INCB059872); HDAC inhibitors (such as panobinostat, vorinostat); DNA methyltransferase inhibitors (such as azacytidine, decitabine) and other epigenetic regulators; SHP-2 inhibitors (such as TNO155); Bcl2 inhibitor ABT-199 and other Bcl-2 family protein inhibitors; HIF-2α inhibitors (such as PT2977 and PT2385); β-catenin pathway inhibitors, notch pathway inhibitors, and hedgehog pathway inhibitors. Antibodies or other therapeutic proteins to VEGF include bevacizumab and aflibercept
[0438] Other anticancer agents / drugs that can be used in combination with the compounds of the present invention include, but are not limited to, liver X receptor (LXR) modulators (including LXR agonists and LXRβ-selective agonists); aryl hydrocarbon receptor (AhR) inhibitors;
[0439] Other anticancer agents that can be used in combination with the compounds of the present disclosure include adriamycin, dactinomycin, bleomycin, vinblastine, cisplatin, acivicin; aclarubicin; acodazole hydrochloride; aclonine; adolesin; aldesleukin; hexamethylmelamine; ambromycin; ametrine acetate; aminoglutethimide; amsacrine anastrozole; anthramycin; asparaginase; tricholin; azacitidine; azatepa; azomycin; batimastat; benzotepa; bicalutamide; bisantrene hydrochloride; binefad dimesylate; bierexin; bleomycin sulfate; brequinar sodium; bropiridamine; busulfan; actinomycin; caprotestosterone; caracetamide; carbetim; carboplatin; carmustine; carrubicin hydrochloride; carzeresin; cedifingol; chlorambucil; siromycin; cladribine; cristal mesylate mesylate); cyclophosphamide; cytarabine; dacarbazine; daunorubicin hydrochloride; decitabine; dextromaplatin; dezaguanine; dezaguanine mesylate; diazocone; doxorubicin; doxorubicin hydrochloride; droloxifene; droloxifene citrate; drolostanone propionate; dazomicin; edatrexamate; eflornithine hydrochloride; elsamitrucin; enloplatin; enprobamate; epipipridine; epirubicin hydrochloride; erbulazole; isorubicin hydrochloride; estramustine; estramustine sodium phosphate; estramustine Tanidazole; etoposide; etoposide phosphate; clofenac; fadrozole hydrochloride; fazarabine; fenretinide; floxuridine; fludarabine phosphate; fluorouracil; flucitabine; fosquatone; fostramoxine sodium; gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin hydrochloride; ifosfamide; imofosine; interleukin II (including recombinant interleukin II, or Ril2), interferon α-2a; interferon α-2b; interferon α-n1; interferon α-n3; interferon beta-1a; interferon gamma-1b; iproplatin; irinotecan hydrochloride; lanreotide acetate; letrozole; leuprolide acetate; lirazo hydrochloride; lometrexol sodium; lomustine; losoxantrone hydrochloride; masoprofen; maytansine; mechlorethamine hydrochloride; megestrol acetate; melengestrol acetate; melphalan; menolipir; mercaptopurine; methotrexate; methotrexate sodium; chlorpheniramine; metodepa; mibutidamide; mitoxine; mitoclocycline; mitoxine; mitomasin; mitoxine; mitoxine Pe; mitotane; mitoxantrone hydrochloride; mycophenolic acid; nocodazole; noramycin; ormaplatin; oxysulam; pegaspargase; pelimycin; pentamidine; pelimycin sulfate; perfosfamide; piperobroman; piperosulfan; pyroxantrone hydrochloride; plicamycin; plomestane; porfimer sodium; methyl mitomycin; prednimustine; procarbazine hydrochloride; puromycin; puromycin hydrochloride; pyraclostrobin; riboadenylate; roglutimide; safinol; safinol hydrochloride; semustine; sintrazine;Sodium spalfosate; sparmyn; spirogermanium hydrochloride; spiromustine; spiroplatin; streptozocin; streptozotocin; sulfaquinoxaline; talithromycin; tecogalan sodium; tegafur; tiloxantrone hydrochloride; temoporfin; teniposide; tiroxilon; testolactone; thiabendazole; thioguanine; thiotepa; thiazofurine; tirapazamine; toremifene citrate; triptolan acetate; Triciribine phosphate; Trimetrexate; Trimetrexate glucuronide; Triptorelin; Tobradazole hydrochloride; Uramustine; Uredepa; Vapreotide; Verteporfin; Vinblastine sulfate; Vincristine sulfate; Vindesine; Vindesine sulfate; Vinpitidine sulfate; Vingolide sulfate; Vinpoline sulfate; Vinorelbine tartrate; Vinprodine sulfate; Vinpoptidine sulfate; Vorozole; Zoniplatin; Zoloft; Zorubicin hydrochloride. ;
[0440] Other anticancer agents that can be used in combination with the compounds of the present disclosure include: 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adenosine; adolesin; aldesleukin; ALL-TK antagonists; hexamethylmelamine; aminomustine; amidox; amifostine; aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole; andrographolide ; angiogenesis inhibitor; antagonist D; antagonist G; antarelix; anti-dorsal morphogenetic protein-1; antiandrogen, prostate cancer; antiestrogens; antineoplastons; antisense oligonucleotides; glycine aphidicolin; apoptosis gene modulator; apoptosis modulator; apurinic nucleic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; amustine; axinastatin 1; amustine 2; amustine 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR / ABL antagonist; benzochlorin; benzoylstaurosporine; beta-lactam derivatives; beta-alethine; aclarubicin B; betulinic acid; Bfg f inhibitor; bicalutamide; bisantrene; diazinonespermine; binefad; bistratene A; biszelesin; breflate; bropiridamine; budotitan; butyrosine sulfenyl imine; calcipotriol; carvstatin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage-derived inhibitor; cardzelesin; casein kinase inhibitor (ICOS); castanespermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cisporphyrin; cladribine; clomiphene analogs; clotrimazole; collismycin A; collismycin B; conagenin A4; conagenin analogs; conagenin; crambescidin )816; Clinato; Nostoc cyclotide 8; Nostoc cyclotide A derivative; Curacao A; Cyclopentanthraquinone; Cycloplatam; Cypemycin; Cytarabine octadecyl phosphate; Cytolytic factor; Hexylestradiol phosphate; Dacilizumab; Decitabine; Dehydroaspartate B; Deslorelin; Dexamethasone; Dexifosfamide; Dexrazoxane; Dexverapamil; Diazocone; Aspartate B; Didox; Diethylnorspermine;dihydro-5-azacytidine; 9-dioxazolidinone; biphenylspiromustine; docosinol; dolasetron; deoxyfluridine; droloxifene; dronabinol; duocamisin SA; ebselen; ecomustine; edilfosine; edrecolomab; eflornithine; elemene; ethidium bromide; epirubicin; eristeride; estramustine analogs; estrogen agonists; estrogen antagonists; etaninazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride; flavin; fluasterone; fludarabine; fluorodaunorunicin hydrochloride hydrochloride); fofolmek; formestane; fostramcin; fostramustine; gadotisalen; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylenediethylamide; hyperforin; ibandronic acid; idarubicin; idoxifene; idemenone; imofosine; ilomastat; imidazoacridone; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitors; Interferon agonists; interferon; interleukin; iodobenzylguanidine; iodoxorubicin; ipomeanol, 4-; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide; kahalalide F; lamellarin-N triacetate triacetate; lanreotide; leinamycin; leigostim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibitory factor; interferon-alpha; leuprolide + estrogen + progesterone; leuprolide; levamisole; lirozole; linear polyamine analogs; lipophilic disaccharide peptides; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; earthworm phospholipids; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lutetone; tessarin lutetium; lisofylline; lytic peptide ; Metansine; mannostatin A; Marimastat; Masoprofen; Masospin; Matrix lytic factor inhibitor; Matrix metalloproteinase inhibitor; Menoliol; Mebaron; Metirelin; Methioninase; Metoclopramide; MIF inhibitor; Mifepristone; Miltefosine; Miregrastim; Mismatched double-stranded RNA; Mitoguanazone; Dibromodulanol; Mitomycin analog; Mitoxantrone; Mitotoxin fibroblast growth factor-saponin; Mitoxantrone; Mofaroten; Moragrastim; Monoclonal antibody, human chorionic gonadotropin; Mopidarol; Multidrug resistance gene inhibitor;Multiple tumor suppressor 1-based therapy; mustard anticancer agent; Indian sea sponge (mycaperoxide) B; mycobacterial cell wall extract; myriaporone; N-acetyl pyridazine; N-substituted benzamides; nafarelin; naritipen; naloxone + pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin (nis amycin; nitric oxide modulators; nitric oxide antioxidants; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducers; oramaplatin; oxatrome; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoctonia hizoxin; pamidronate; panaxytriol; panomifen; paracoccin; pazeptine; pegaspargase; perdecan; sodium polysulfide; pentostatin; pentozole; perflurane; perphosphamide; perillyl alcohol; benzodiazepine; phenylacetate; phosphatase inhibitors; sapelloline; pilocarpine hydrochloride; pirarubicin; pirexine; placetin A; placetin B; plasminogen activator inhibitors; platinum complex; platinum compound; platinum-triamine complex; porphine sodium; methyl mitomycin; prednisone; propyl bis-acridone; prostaglandin J2; proteasome inhibitors; protein A-based immunomodulators; protein kinase C inhibitors, microalgae; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; hydroxyrubiacin; pyrazoline acridine; pyridoxalyl hemoglobin polyoxyethylene conjugates; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitors; demethylated retiptine; etidronate rhenium Re 186; Gentomycin; Ribozyme; R.sub.11 retinoic acid amide; Roglulimide; Roxitocin; Romotide; Roquineme; Rubiginone B1; Ruboxyl; Safingol; Saintopin; SarCNU; Myophylline A; Sargramostim; Sdi 1 mimetic; Semustine; Senescence-derived 1; Sense oligonucleotide; Signal transduction inhibitor; Signal transduction regulator; Single-chain antigen binding protein; Sizoran; Sobuzosine; Borca sodium; Sodium phenylacetate; Solvorol; Somatomedin binding protein; Sonamin; Fospartate; Spiromycin D; Spiromustine; Snapantin; Spongin 1; Squalamine; Stem cell inhibitor; Stem cell division inhibitor; Stipiamide; Matrix degrading inhibitor;sulfinosine; potent vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycan; tamustine; tamoxifen methyl iodide; tauromustine; tazarotene; tecogalan sodium; fluridine; tellurapyrylium; telomerase inhibitor; temoporfin; temozolomide; teniposide; tetrachlorodecoxide; tetrazomine; thaliblastine; thiopoietin; thrombopoietin mimetic; thymofasin; thymopoietin receptor agonist; thymosin; thyroid stimulating hormone; tin ethyl porphyrin etiopurpurin; tirapazamine; bis-cyclopentyl titanium dichloride; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; retinoic acid; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; torosterol; tyrosine kinase inhibitors; tyrosine phosphorylation inhibitors; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector systems, erythrocyte gene therapy; vilarezo; veratramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoteron; zeniplatin; zilascorb; and zestatin.
[0441] Still other anticancer agents that can be used in combination with the compounds of the present disclosure include alkylating agents, antimetabolites, natural products, or hormones, for example, nitrogen mustards (e.g., mechloroethamine, cyclophosphamide, chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, etc.), or triazenes (decarbazine, etc.). Examples of antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate), or pyrimidine analogs (e.g., cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[0442] Examples of natural products that can be used in combination with the compounds of the present disclosure include, but are not limited to, vinca alkaloids (e.g., vincristine), epipodophyllotoxins (e.g., etoposide), antibiotics (e.g., daunorubicin, doxorubicin, bleomycin), enzymes (e.g., L-asparaginase), or biological response modifiers (e.g., interferon alpha).
[0443] Examples of alkylating agents that can be used in combination with the compounds of the present disclosure include, but are not limited to, nitrogen mustards (e.g., dichloromethyldiethylamine, cyclophosphamide, chlorambucil, melphalan, etc.), ethyleneimine and methylmelamine (e.g., hexamethylmelamine, thiotepa), alkyl sulfonates (e.g., busulfan), nitrosoureas (e.g., carmustine, lomustine, semustine, streptozotocin, etc.), or triazenes (oxadiazine, etc.). Examples of antimetabolites include, but are not limited to, folic acid analogs (e.g., methotrexate), or pyrimidine analogs (e.g., fluorouracil, floxuridine, cytarabine), purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).
[0444] Examples of hormones and antagonists that can be used in combination with the compounds of the present disclosure include, but are not limited to, adrenocortical steroids (e.g., prednisone), progesterone (e.g., hydroxyprogesterone caproate, megestrol acetate, medroxyprogesterone acetate), estrogen (e.g., ethinyl estradiol, ethinyl estradiol), antiestrogens (e.g., tamoxifen), androgens (e.g., testosterone propionate, fluoxymesterone), antiandrogens (e.g., flutamide), gonadotropin-releasing hormone analogs (e.g., leuprolide). Other agents for treating or preventing cancer that can be used in the methods and compositions described herein include platinum coordination complexes (e.g., cisplatin, carboplatin), anthracenediones (e.g., mitoxantrone), substituted ureas (e.g., hydroxyurea), methylhydrazine derivatives (e.g., procarbazine), adrenocortical suppressants (e.g., mitotane, aminoglutethimide).
[0445] Other anticancer agents that can be used in combination with the compounds of the present disclosure include: Anticancer agents that work by arresting cells in the G2-M phase due to stabilized microtubules include Erbuclozole (also known as R-55104), Aplysia 10 (also known as DLS-10 and NSC-376128), Mivobulin isethionate (also known as CI-980), Vincristine, NSC-639829, Discodermolide (also known as NVP-XX-A-296), ABT-751 (Abbott, also known as E-7010), Altorhyrtine (such as Atorhyrtine A and Atorhyrtine C), Spongistatin (such as Spongistatin 1, Spongistatin 2, Spongistatin 3, Spongistatin 4 , spongotoxin 5, spongotoxin 6, spongotoxin 7, spongotoxin 8, and spongotoxin 9), cytomedin hydrochloride (also known as LU-103793 and NSC-D-669356), epothilones (such as epothilone A, epothilone B, epothilone C (also known as deoxyepothilone A or dEpoA), epothilone D (also known as KOS-862, dEpoB, and deoxyepothilone B), epothilone E, epothilone F, epothilone B N-oxide, epothilone AN-oxide, 16-aza-epothilone B , 21-aminoepothilone B (also known as BMS-310705), 21-hydroxyepothilone D (also known as deoxyepothilone F and dEpoF), 26-fluoroepothilone), auristatin PE (also known as NSC-654663), solidotin (also known as TZT-1027), LS-4559-P (Pharmacia, also known as LS-4577), LS-4578 (Pharmacia, also known as LS-477-P), L S-4477 (Pharmacia), LS-4559 (Pharmacia), RPR-112378 (Aventis), vincristine sulfate, DZ-3358 (Daiichi), FR-182877 (Fujisawa, also known as WS-9885B), GS-164 (Takeda), GS-198 (Takeda), KAR-2 (Hungarian Academy of Sciences), BSF-223651 (BASF,Also known as ILX-651 and LU-223651), SAH-49960 (Lilly / Novartis), SDZ-268970 (Eli Lilly / Novartis), AM-97 (Armad / Kyowa Hakko), AM-132 (Armad), AM-138 (Armad / Kyowa Hakko), IDN-5005 (Indena), Nostoc 52 (also known as LY-355703), AC-7739 (Ajinomoto, also known as AVE-8063A and CS-39.HCl), AC-7700 (Ajinomoto, also known as AVE-8062, AVE-8062A, CS-39-L-Ser. Cl, and RPR-258062A), Vitilevuamide, Tubulysin A, Canadensol, Centaureidin (also known as NSC-106969), T-138067 (Tularik, also known as T-67, TL-138067 and TI-138067), COBRA-1 (Parker Hughes Institute, also known as DDE-261 and WHI-261), H10 (Kansas State University), H16 (Kansas State University), Oncocidin A1 (also known as BTO-956 and DIME), DDE-313 (Park Hughes Institute), Fijianolide B. Laulimalide, SPA-2 (Park Hughes Institute), SPA-1 (Park Hughes Institute, also known as SPIKET-P), 3-IAABU (Cytoskeleton / Mt. Sinai School of Medicine, also known as MF-569), Narcosine (also known as NSC-5366), Nascapine, D-24851 (Asta Medica), A-105972 (Abbott), Hemiasterlin, 3-BAABU (Cytoskeleton / Mt. Sinai School of Medicine,Also known as MF-191), TMPN (Arizona State University), Vanadoceneacetylacetonate, T-138026 (Tularik), Monsatrol, Inanocine (also known as NSC-698666), 3-1AABE (Cytoskeleton / Mount Sinai), A-204197 (Abbott), T-607 (Tularik, also known as T-900607), RPR-115781 (Annette), Eleutherobin (as Desmethyleleutherobin, Desaetyleleutherobin, Isoeleutherobin A), and Z-Eleutherobin), Caribaeolin, Halichondrin B, D-64131 (Astar Pharmaceuticals), D-68144 (Astar Pharmaceuticals), Diazonamide A, A-293620 (Abbott), NPI-2350 (Nereus), Taccalonolide A, TUB-245 (Annette), A-259754 (Abbott), Diozostatin, (-)-Phenylahistin (also known as NSCL-96F037), D-68838 (Astar Pharmaceuticals), D-68836 (Astar Pharmaceuticals), Myoseverin B B), D-43411 (Zentaris, also known as D-81862), A-289099 (Abbott), A-318315 (Abbott), HTI-286 (also known as SPA-110, trifluoroacetate) (Wyeth), D-82317 (Zentaris), D-82318 (Zentaris), SC-12983 (NCI), Resverastatin sodium phosphate, BPR-OY-007 (National Health Research Institutes), and SSR-250411 (Sanofi).
[0446] One or more other immune checkpoint inhibitors can be used in combination with compounds as described herein for treating diseases, disorders or conditions associated with HIF-2α. Exemplary immune checkpoint inhibitors include inhibitors (smack molecules or biological products) for immune checkpoint molecules (such as CD27, CD28, CD40, CD122, CD96, CD73, CD39, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, A2BR, SHP-2, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2). In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, OX40, GITR, CD137 and STING. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from B7-H3, B7-H4, BTLA, CTLA-4, IDO, TDO, arginase, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRβ inhibitors.
[0447] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-1, for example, an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.
[0448] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of PD-L1, for example, an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).
[0449] In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of CTLA-4, for example, an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of LAG3, for example, an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of GITR, for example, an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, or MK-4166, INCAGN01876 or MK-1248. In some embodiments, the inhibitor of the immune checkpoint molecule is an inhibitor of OX40, for example, an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562 or INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600, or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383.
[0450] The compounds of the present invention can also be used to increase or enhance immune responses, including increasing immune responses to antigens; improving immunization, including increasing vaccine efficacy; and increasing inflammation. In some embodiments, the compounds of the present invention can be used to enhance immune responses to vaccines, including but not limited to Listeria vaccines, oncolytic virus vaccines, and cancer vaccines, such as (Tumor cell vaccines transfected with granulocyte-macrophage colony stimulating factor (GM-CF) gene). Anticancer vaccines include dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses. Other immunomodulators also include those that block the migration of immune cells, such as antagonists of chemokine receptors (including CCR2 and CCR4), Sting agonists, and Toll receptor agonists.
[0451] Other anticancer agents also include those that enhance the immune system (such as adjuvants or recipient T cell transfer). The compounds of the present application can be effective in combination with CAR (chimeric antigen receptor) T cell therapy as a booster for T cell activation.
[0452] Examples
[0453] The following preparations of compounds of formula (IA) / (I) are given to enable those skilled in the art to more clearly understand and practice the present disclosure. They should not be considered to limit the scope of the present disclosure, but merely as an illustration and representation thereof.
[0454] Example 1
[0455] 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopentadienyl
[0456] Synthesis of [cd] (inden-7-yl) (oxy) benzonitrile
[0457]
[0458] Step 1: Ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-hydroxypropanoate
[0459]
[0460] At room temperature, under nitrogen atmosphere, to zinc (6.97g, 106.56mmol, 1.03 equivalents), 1,2-dibromoethane (388.71mg, 2.069mmol, 0.02 equivalents) and chlorotrimethylsilane (1.12g, 10.31mmol, 0.10 equivalents) in THF (200mL) in a stirred mixture was added dropwise ethyl 2-bromo-2,2-difluoroacetate (21.0g, 103.45mmol, 1.0 equivalents) and 2-bromo-4-fluorobenzaldehyde (21.0g, 103.45mmol, 1.0 equivalents) in THF (100mL). At 75 ° C, under nitrogen atmosphere, the resulting mixture was stirred for 16h. The reaction was cooled and quenched with ice / water. The organic solvent was removed under vacuum, and the resulting mixture was extracted with EtOAc. The combined organic layers were washed with water, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (18 g, 53.2%) as a yellow oil.
[0461] Step 2: Ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-oxopropanoate
[0462]
[0463] At room temperature, 2-iodoacylbenzoic acid (27.4 g, 97.83 mmol, 2.0 equiv) was added to a stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-hydroxypropanoate (16 g, 48.9 mmol, 1.0 equiv) in CH3CN (200 mL), and the resulting mixture was stirred for 3 h at 80 ° C. The reaction solution was then cooled to room temperature, filtered, and the filter cake was washed with EtOAc. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (10: 1) to give the title compound (10.3 g, 64.8%) as a yellow oil.
[0464] Step 3: Ethyl 3-(2-bromo-4-fluorophenyl)-2,2,3,3-tetrafluoropropionate
[0465]
[0466] At room temperature, DAST (30.25 g, 187.6 mmol, 10.0 equiv) was added dropwise to a stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2-difluoro-3-oxopropanoate (6.1 g, 18.8 mmol, 1.0 equiv) in CHCl (6 mL), and the resulting mixture was stirred for 16 h at 70 ° C under a nitrogen atmosphere. The reaction solution was allowed to cool to room temperature and quenched with ice / water. The mixture was extracted with DCM. The organic layer was dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (10: 1) to give the title compound (2.4 g, 36.8%) as a yellow oil.
[0467] Step 4: 2,2,3,3,6-Pentafluoro-2,3-dihydro-1H-inden-1-one
[0468]
[0469] To a stirred solution of ethyl 3-(2-bromo-4-fluorophenyl)-2,2,3,3-tetrafluoropropanoate (4.20 g, 12.10 mmol, 1.0 equiv) in THF (50 mL) was added n-BuLi (2.5 M, 7.26 mL, 18.15 mmol, 1.5 equiv) dropwise at -78 °C under a nitrogen atmosphere, and the resulting mixture was stirred for 2 h between -70 °C and -80 °C under a nitrogen atmosphere. The reaction was quenched with saturated NH4Cl(aq) and extracted with EtOAc. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (20:1) to give the title compound (2.25 g, 83.7%).
[0470] Step 5: 2,2,3,3,6-Pentafluoro-2,3-dihydro-1H-inden-1-ol
[0471]
[0472] To a stirred solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (300 mg, 1.35 mmol, 1.0 equiv) and triethylamine (273.35 mg, 2.70 mmol, 2.0 equiv) in DCM (3 mL) was added formic acid (186.49 mg, 4.05 mmol, 3.0 equiv) dropwise at 0°C, followed by RuCl(p-cymene)[(S,S)-Ts-DPEN] (8.59 mg, 0.014 mmol, 0.01 equiv). The resulting mixture was stirred at room temperature under nitrogen atmosphere for 3 h and then washed with water. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with PE / EtOAc (5:1) to give the title compound (300 mg, 99.1%).
[0473] Step 6: 7-Bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol
[0474]
[0475] To a stirred solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (2500 mg, 11.154 mmol, 1.00 equiv) in tetrahydrofuran (60 mL) was added LDA (2.0 M, 16.73 mL, 33.463 mmol, 3.00 equiv) dropwise at -78 °C under a nitrogen atmosphere. The resulting mixture was warmed to -30 °C over 30 min and stirred at -30 °C for another 30 min. A solution of carbon tetrabromide (3699.05 mg, 11.154 mmol, 1.00 equiv) in THF was added dropwise at -78 °C. The resulting mixture was allowed to warm to -30 °C over 30 min and stirred at -30 °C for another 30 min. The reaction was quenched with saturated NH4Cl (aqueous solution) at -30 °C. The resulting mixture was extracted with EtOAc, and the organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (10:1) to give the title compound (2600 mg, 76.9%) as a light yellow oil. MS (ES, m / z): [MH] - =300.9,302.9.
[0476] Step 7: 7-Bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one
[0477]
[0478] To a stirred mixture of 7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-indene-1-ol (2.63 g, 8.679 mmol, 1.00 equiv) in CH3CN (45 mL) was added IBX (4.86 g, 17.356 mmol, 2.00 equiv) at room temperature. The resulting mixture was stirred for 3 h at 80 ° C, then cooled and filtered. The filter cake was washed with EtOAc. The combined filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (10: 1) to give the title compound (1.8 g, 68.9%) as an off-white solid.
[0479] Step 8: 1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol
[0480]
[0481] At -78 ° C, under a nitrogen atmosphere, to a stirred solution of 7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (100 mg, 0.332 mmol, 1.00 equiv) in THF (3 mL) was added dropwise allylmagnesium bromide (1.0 M, 0.50 mL, 0.50 mmol, 1.50 equiv). At -78 ° C, under a nitrogen atmosphere, the resulting mixture was stirred for 1 h. The reaction was quenched with saturated NH4Cl (aqueous solution). The resulting mixture was extracted with EtOAc, and the organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (5: 1) to obtain the title compound (90 mg, 79.0%) as a yellow oil. MS (ES, m / z): [MH] - =340.9,342.9.
[0482] Step 9: 3,3,4,4,7-Pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol
[0483]
[0484] To a stirred mixture of 1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (1050 mg, 3.060 mmol, 1.00 equiv) in DMF (25 mL) was added AcONa (753.17 mg, 9.181 mmol, 3.00 equiv) and Pd(dppf)Cl2·CH2Cl2 (249.93 mg, 0.306 mmol, 0.10 equiv) at room temperature. The resulting mixture was stirred for 3 h at 100 ° C under a nitrogen atmosphere. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5:1) to give the title compound (370 mg, 46.1%) as a light yellow oil.
[0485] Step 10: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0486]
[0487] To a stirred mixture of 3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol (40 mg, 0.15 mmol, 1.00 equiv) and 3-fluoro-5-hydroxybenzonitrile (20.92 mg, 0.153 mmol, 1.00 equiv) in DMF (1 mL) was added CsCO (49.71 mg, 0.15 mmol, 1.00 equiv) at room temperature. The resulting mixture was stirred at 100 °C for 24 h. The resulting mixture was filtered and the filtrate was purified by preparative HPLC to give (16.77 mg, 29.0%). MS (ES, m / z): [MH] - =378.1.
[0488] Example 2
[0489] 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]
[0490] Synthesis of (7-indenyl)oxy)benzonitrile
[0491]
[0492] Step 1: 3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one
[0493]
[0494] To a stirred mixture of 3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]indene-2a-ol (320 mg, 1.22 mmol, 1.00 equiv) in a mixed solvent (DCM / CH3CN / H2O=3mL / 3mL / 4.50mL) was added NaIO4 (1044.25 mg, 4.882 mmol, 4.00 equiv) and RuCl3·H2O (13.76 mg, 0.061 mmol, 0.05 equiv) at room temperature. The resulting mixture was stirred for 6 h at room temperature. The resulting mixture was diluted with water and extracted with DCM. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (3:1) to give the title compound (250 mg, 77.5%) as a white solid. MS (ES, m / z): [MH] - =263.0.
[0495] Step 2: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0496]
[0497] To a stirred mixture of 3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (200 mg, 0.757 mmol, 1.00 equiv) and 3-fluoro-5-hydroxybenzonitrile (103.81 mg, 0.757 mmol, 1.0 equiv) in DMF (3 mL) was added Cs2CO3 (246.69 mg, 0.76 mmol, 1.0 equiv) at room temperature. The resulting mixture was stirred for 16 h at room temperature. The resulting mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (3: 1) to give the title compound (200 mg, 69.3%) as a white semi-solid. MS(ES,m / z):[MH] - =380.0.
[0498] Example 3
[0499] 3-Fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]indene
[0500] Synthesis of benzonitrile
[0501]
[0502] To a solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (40 mg, 0.105 mmol, 1.00 equiv) in MeOH (1 mL) was added NaBH4 (7.94 mg, 0.210 mmol, 2.0 equiv) at room temperature. The resulting mixture was stirred for 3 h at room temperature. The reaction was quenched with aqueous HCl (2.0 M) to pH = 7 at room temperature. The resulting mixture was concentrated under vacuum. The residue was diluted with water and extracted with EtOAc. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC eluting with PE / EtOAc (3:1) to give the title compound (40 mg, 99.5%) as a colorless oil. MS (ES, m / z): [MH] - =382.0.
[0503] Example 4
[0504] 3-Fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]indene-7-
[0505] Synthesis of (4-(2-(4-yl)oxy)benzonitrile
[0506]
[0507] To a stirred solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (20 mg, 0.05 mmol, 1.00 equiv) in DCM (0.5 mL) was added DAST (6.73 mg, 0.04 mmol, 0.80 equiv) dropwise at -50 °C. The resulting mixture was stirred for 30 min at -50 °C to -40 °C. The reaction mixture was quenched with NaHCO3(aq) and extracted with DCM. The organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound (4.3 mg, 21.3%) as a white solid. MS (ES, m / z): [MH] - =384.1.
[0508] Example 5
[0509] Synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (5) and 3-fluoro-5-(((1R,2aS)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (6)
[0510]
[0511] Step 1: (R)-1-allyl-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol
[0512]
[0513] To a stirred solution of t-BuONa (21.6 mg, 0.225 mmol, 0.10 equiv) in toluene (3.0 mL) was added a solution of (S)-2-((3-(tert-butyl)-2-hydroxybenzyl)amino)-N,N,3-trimethylbutanamide (275.8 mg, 0.90 mmol, 0.40 equiv) in toluene (0.5 mL) followed by a solution of MeOH (90.2 mg, 2.8 mmol, 1.25 equiv) in toluene (0.5 mL) followed by a solution of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (0.50 g, 2.25 mmol, 1.00 equiv) in toluene (0.5 mL). After stirring at room temperature for 15 min, a solution of 4,4,5,5-tetramethyl-2-(prop-2-ene-1-yl)-1,3,2-dioxaborane (416.1 mg, 2.48 mmol, 1.10 equiv) in toluene (0.5 mL) was slowly added. The resulting mixture was stirred at 60 ° C for 6.5 h, cooled and diluted with ethyl acetate. After separation, the organic layer was washed with water and brine and dried over Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography, eluted with DCM / PE (0-40%) to give the title compound (0.52 g, 87.4%) as a light yellow oil. MS (ES, m / z): [M-1]-=263.0.
[0514] Step 2: (1R)-7-Bromo-2,2,3,3,6-pentafluoro-1-(prop-2-en-1-yl)inden-1-ol
[0515]
[0516] At -40 ° C, under a nitrogen atmosphere, to a stirred solution of (R)-1-allyl-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (5.0 g, 18.93 mmol, 1.00 equiv) in tetrahydrofuran (60 mL) was added dropwise 2.0 M LDA (28.4 mL, 56.8 mmol, 3.0 equiv). After stirring at -40 ° C for 1 h, a solution of carbon tetrabromide (7.53 g, 22.71 mmol, 1.20 equiv) in THF was added dropwise at -40 ° C. The resulting mixture was stirred at -40 ° C for another 10 min and then quenched with 1.0 M HCl (aq.) (100 mL) at -40 ° C. The resulting mixture was extracted with MTBE. The organic layer was washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography, eluting with EtOAc / PE (0-30%) to give a crude product as a light yellow oil. The crude product was further purified by a reverse phase C18 silica gel column (mobile phase, ACN in water, gradient: 50% to 95% in 12 min) to give the title compound (3.5 g, 53.9%) as a light yellow oil. MS (ES, m / z): [M-1] - =340.9.
[0517] Step 3: (R)-3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol
[0518]
[0519] To a stirred mixture of (R)-1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ol (3.50 g, 10.20 mmol, 1.00 equiv) in DMF (5.0 mL) was added AcONa (2.51 g, 30.60 mmol, 3.00 equiv) and Pd(dppf)Cl2.CH2Cl2 (0.83 g, 1.02 mmol, 0.10 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 100 ° C. under nitrogen atmosphere for 3 h, cooled and diluted with water, and then extracted with ethyl acetate. The organic layer was washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluted with EtOAc / PE (0-40%) to give the title compound (2.0 g, 74.8%) as a light yellow solid. MS (ES, m / z): [M-1] - =260.9.
[0520] Step 4: (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one
[0521]
[0522] To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]indene-2a-ol (2.00 g, 7.63 mmol, 1.00 equiv) in a mixed solvent (DCM / MeCN / H2O=1 / 1 / 1.5, 70.0 mL) was added RuCl3·H2O (86.0 mg, 0.38 mmol, 0.05 equiv) at room temperature. To the resulting mixture was added NaIO4 (6.53 g, 30.53 mmol, 4.0 equiv) in portions at room temperature. After stirring at room temperature for 1 h, the reaction mixture was diluted with water and then extracted with DCM. The organic layer was washed with saturated Na2S2O3 (aq.), water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated to give the crude title compound (1.85 g, 91.8%) as a light yellow solid, which was used in the next step without further purification. MS (ES, m / z): [M-1] - =262.9.
[0523] Step 5: (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0524]
[0525] To a stirred solution of (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (1.85 g, 7.0 mmol, 1.00 equiv) and 3-fluoro-5-hydroxybenzonitrile (0.86 g, 6.30 mmol, 0.90 equiv) in DMF (20.0 mL) was added CsCO (2.28 g, 7.00 mmol, 1.00 equiv) at room temperature. After stirring at room temperature for 16 h, the reaction mixture was quenched with water at 0 ° C and then extracted with EtOAc. The organic layer was washed with water and brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated and purified by silica gel column chromatography, eluted with EtOAc / PE (0-40%) to give the title compound (1.95 g, 73.0%) as a white solid. MS (ES, m / z): [M-1]-=380.1. Step 6: 3-Fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0526]
[0527] To a stirred solution of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (1.95 g, 5.12 mmol, 1.00 equiv) in MeOH (20.0 mL) was added NaBH4 (0.29 g, 7.67 mmol, 1.50 equiv) in portions at room temperature. After stirring at room temperature for 3 hours, the reaction mixture was quenched with 2.0 M HCl(aq) at 0 °C, diluted with water, and extracted with EtOAc. The organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (1.80 g, 91.8%) as a white solid. MS (ES, m / z): [M-1] - =382.0.
[0528] Step 7: 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0529]
[0530] To a stirred solution of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (384.8 mg, 1.04 mmol, 1.00 equiv) in DCM (5.0 mL) was added DAST (185.05 mg, 1.148 mmol, 1.10 equiv) dropwise at -50 °C. The resulting mixture was stirred at -50 °C for 30 min, then quenched with NaHCO (aq) and extracted with DCM. The organic layer was washed with water and brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated and purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the crude product (ca. 80% ee), which was purified by preparative chiral HPLC to give products 5 and 6 as white solids.
[0531] 5: MS (ES, m / z): [M-1] - =384.1. R :1.36min;
[0532] 6: MS (ES, m / z): [M-1] - =384.1. R : 1.54min.
[0533] Instrument: Shimadzu LC-20AD; column: CHIRALPAK IA-3, 50*4.6 mm, 3 um; mobile phase A: n-hexane (0.1% TFA); mobile phase B: ethanol; flow rate: 1.0 mL / min; concentration of phase B: 20.0%.
[0534] Example 7
[0535] Synthesis of 3-fluoro-5-(((1R,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0536]
[0537] Step 1: (1S,2aR)-7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl 4-nitrobenzoate
[0538]
[0539] To a stirred solution of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (150 mg, 0.39 mmol, 1.00 equiv), 4-nitrobenzoic acid (131 mg, 0.78 mmol, 2.00 equiv) and PPh3 (205 mg, 0.78 mmol, 2.00 equiv) in THF (4.0 mL) was added DEAD (136 mg, 0.78 mmol, 2.00 equiv) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 2 h, then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (5 / 1) to give the title compound (160 mg, 76.8%) as a light yellow solid. MS (ES, m / z): [MH] - =531.0.
[0540] Step 2: 3-Fluoro-5-(((1S,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0541]
[0542] To a stirred mixture of (1S,2aR)-7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl 4-nitrobenzoate (130 mg, 0.24 mmol, 1.00 equiv), H2O (0.4 mL) and THF (2.0 mL) was added LiOH HO (15 mg, 0.36 mmol, 1.50 equiv) at room temperature. The resulting mixture was stirred at room temperature overnight and then concentrated under reduced pressure. The residue was dissolved in water, and the mixture was acidified to pH = 5 with 1.0 M HCl (aq). The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the title compound (80 mg, 85.5%) as an off-white solid. MS(ES,m / z):[MH] - =382.0.
[0543] Step 3: 3-Fluoro-5-(((1R,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0544]
[0545] To a stirred solution of 3-fluoro-5-(((1S,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (50 mg, 0.13 mmol, 1.00 equiv) in DCM (2.0 mL) was added a solution of DAST (21 mg, 0.13 mmol, 1.00 equiv) in DCM (0.5 mL) dropwise at -50 °C. The resulting mixture was stirred at -40 °C to -50 °C for 30 min and then quenched with NaHCO3(aq). The mixture was extracted with DCM and the combined organic layers were washed with water and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by preparative HPLC to give the title compound (2.2 mg, 4.4%) as a white solid. MS(ES,m / z):[MH] - =384.1.
[0546] Example 8
[0547] 1,3,3,4,4-Pentafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopentadienyl
[0548] Synthesis of [cd]inden-2a-ol
[0549]
[0550] Step 1: 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one
[0551]
[0552] At room temperature, under a nitrogen atmosphere, to a stirred mixture of 3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (95 mg, 0.36 mmol, 1.00 equiv) and 5-fluoropyridine-3-ol (41 mg, 0.36 mmol, 1.00 equiv) in DMF (2.00 mL) was added CsCO (128.90 mg, 0.40 mmol, 1.10 equiv). After stirring at room temperature for 4 h, the reaction mixture was quenched with water at 0 ° C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous NaSO. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc=3 / 1) to give the title compound (85 mg, 66%) as a white solid. MS (ES, m / z): [M+1] + =358.1.
[0553] Step 2: 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta-[cd]indene-1,2a-diol
[0554]
[0555] To a stirred solution of 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (85 mg, 0.24 mmol, 1.00 equiv) in MeOH (1.50 mL) was added NaBH4 (18 mg, 0.48 mmol, 2.00 equiv) at room temperature. After stirring at room temperature for 1 h, the reaction mixture was quenched with saturated NH4Cl (aqueous solution) at 0 ° C. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-60%) to give the title compound (80 mg, 93.7%) as a light yellow solid. MS (ES, m / z): [M+1] + =360.1.
[0556] Step 3: 1,3,3,4,4-Pentafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol
[0557]
[0558] At -50 ° C, under a nitrogen atmosphere, DAST (20 mg, 0.12 mmol, 1.50 equiv) was added to a stirred solution of 3,3,4,4-tetrafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]indene-1,2a-diol (30 mg, 0.08 mmol, 1.00 equiv) in THF (1.00 mL). After stirring for 2 h at -50 ° C to -30 ° C, the reaction mixture was quenched with saturated NaHCO3 (aqueous solution) at 0 ° C. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The crude product was purified by preparative HPLC to give the title compound (3 mg, 10%) as a white solid. MS (ES, m / z): [M+1] + =362.1.
[0559] Example 9
[0560] 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydrospiro[cyclopenta[cd]indene-1,1'-
[0561] Synthesis of [cyclopropane]-7-yl)oxy)benzonitrile
[0562]
[0563] To a stirred mixture of diethylzinc (0.53 mL, 0.53 mmol, 1.0 M in hexanes) in DCM (3 mL) was added TFA (60 mg, 0.526 mmol, 4.00 equiv) dropwise at 0°C under nitrogen atmosphere. The resulting mixture was stirred for 10 min at 0°C. CH2I2 (141 mg, 0.53 mmol, 4.0 equiv) was added dropwise to the above mixture at 0°C. The resulting mixture was stirred for another 10 min at 0°C, followed by the addition of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (50 mg, 0.132 mmol, 1.00 equiv). The reaction mixture was stirred for 10 min at 0°C, and then stirred for another 1 h at room temperature. The reaction mixture was quenched with water and extracted with CH2Cl2. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the crude product was purified by preparative HPLC to give the title compound (5.6 mg, 10.8%) as a white solid. MS (ES, m / z): [MH]-=392.1.
[0564] Example 10
[0565] 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopentadienyl
[0566] Synthesis of [cd] (inden-7-yl) (oxy) benzonitrile
[0567]
[0568] To a stirred mixture of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (30 mg, 0.08 mmol, 1.00 equiv) and phenyl sulfide (1.47 mg, 0.008 mmol, 0.10 equiv) in ethyl acetate (3 mL) and CH3OH (3 mL) was added 10% Pd / C (20 mg) at room temperature. The resulting mixture was stirred at room temperature under a hydrogen atmosphere for 48 h and then filtered. The filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (9 mg, 30%) as a white solid. MS (ES, m / z): [MH]-=380.1.
[0569] Example 11
[0570] Synthesis of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0571]
[0572] To a stirred solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (20 mg, 0.05 mmol, 1.00 equiv) in THF (0.60 mL) was added bromo(methyl)magnesium (1.0 M, 0.16 mL, 0.16 mmol, 3.05 equiv) dropwise at -78 °C under nitrogen atmosphere. The resulting mixture was stirred at -78 °C under nitrogen atmosphere for 1 h and then quenched with saturated NH4Cl(aq) (2 mL) at -78 °C. The resulting mixture was extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative HPLC to give the title compound as a white solid (10 mg, 48.0%). MS (ES, m / z): [MH]-=396.2.
[0573] Example 12
[0574] 3-Fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopentadienyl
[0575] Synthesis of [cd] (inden-7-yl) (oxy) benzonitrile
[0576]
[0577] To a stirred mixture of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (30 mg, 0.07 mmol, 1.00 equiv) in DCM (1.5 mL) was added DAST (12 mg, 0.07 mmol, 1.00 equiv) dropwise at -50 °C under nitrogen atmosphere. The resulting mixture was stirred at -50 °C to -40 °C under nitrogen atmosphere for 1.5 h and then quenched with saturated NaHCO3(aq) at 0 °C. The resulting mixture was extracted with DCM and the combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (4.3 mg, 14.3%) as a white solid. MS(ES,m / z):[MH] - =398.1.
[0578] Example 13
[0579] 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]indene-7-
[0580] Synthesis of (4-(2-(4-(2-yl)oxy)benzonitrile
[0581]
[0582] Step 1: O-(7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl)1H-imidazole-1-carbothioate
[0583]
[0584] To a stirred solution of 3-fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (100 mg, 0.26 mmol, 1.00 equiv) and DMAP (6 mg, 0.05 mmol, 0.20 equiv) in DCE (2.0 mL) was added di(1H-imidazole-1-yl)methanethione (56 mg, 0.31 mmol, 1.20 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred for 3 h at room temperature. The reaction mixture was concentrated and the residue was purified by preparative TLC (PE / EtOAc 2:1) to give the title compound (80 mg, 62%). MS (ES, m / z): [M+H] + =494.1.
[0585] Step 2: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0586]
[0587] To a stirred solution of O-(7-(3-cyano-5-fluorophenoxy)-3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-yl)1H-imidazole-1-carbothioate (65 mg, 0.13 mmol, 1.00 equiv) and Bu3SnH (115 mg, 0.40 mmol, 3.00 equiv) in toluene (2.0 mL) was added AIBN (65 mg, 0.40 mmol, 3.00 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 50°C for 16 h, cooled and diluted with water, and extracted with EtOAc. The combined organic layers were washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by preparative TLC (PE / EtOAc=2 / 1) and preparative HPLC to give the title compound (12 mg, 25%) as a white solid. MS (ES, m / z): [MH]-=366.2.
[0588] Example 14
[0589] Synthesis of 3-((2a-amino-1,3,3,4,4-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile
[0590]
[0591] Step 1: N-(7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfenamide
[0592]
[0593] To a stirred mixture of 7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-one (1.00 g, 3.32 mmol, 1.00 equiv) and 2-methylpropane-2-sulfinamide (0.81 g, 6.64 mmol, 2.00 equiv) in THF (20.0 mL) was added Ti(OEt)4 (3.03 g, 13.29 mmol, 4.00 equiv) at room temperature. After stirring at 75 ° C for 4 h, the reaction mixture was cooled and concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-60%) to give the title compound (900 mg, 67.0%) as a brown oil. MS (ES, m / z): [M+1] + =404.0.
[0594] Step 2: N-(1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfenamide
[0595]
[0596] At 0 ° C, to a stirred solution of N-(7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-ylidene)-2-methylpropane-2-sulfinamide (900 mg, 2.23 mmol, 1.00 equiv) in THF (15.0 mL) was added allylmagnesium bromide (2.0 M, 1.34 mL, 2.70 mmol, 1.20 equiv). After stirring at 0 ° C for 1.5 h, the reaction mixture was quenched with saturated NH4Cl (aqueous solution) at 0 ° C and then extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with EtOAc / PE (0-50%) to give the title compound (750 mg, 75.5%) as a light yellow oil. MS (ES, m / z): [M+1] + =446.1.
[0597] Step 3: 2-Methyl-N-(3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]-inden-2a-yl)propane-2-sulfenamide
[0598]
[0599] To a stirred mixture of N-(1-allyl-7-bromo-2,2,3,3,6-pentafluoro-2,3-dihydro-1H-inden-1-yl)-2-methylpropane-2-sulfinamide (750 mg, 1.68 mmol, 1.00 equiv) and Pd(dppf)Cl2.CH2Cl2 (137 mg, 0.17 mmol, 0.10 equiv) in DMF (15.0 mL) was added NaOAc (414 mg, 5.05 mmol, 3.00 equiv) at room temperature under nitrogen atmosphere. After stirring at 100°C for 1.5 h, the reaction mixture was cooled to room temperature, quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (10%-40%) to give the title compound (450 mg, 73.3%) as a light yellow solid. MS (ES, m / z): [M+1] + =366.1.
[0600] Step 4: 3,3,4,4,7-Pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-amine
[0601]
[0602] At room temperature, to a stirred solution of 2-methyl-N-(3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopentadien [cd] indene-2a-yl) propane-2-sulfinamide (150 mg, 0.41 mmol, 1.00 equivalent) in 1,4-dioxane (1.0 mL) was added a solution of HCl in 1,4-dioxane (4.0 M, 1.00 mL, 4.0 mmol, 9.74 equivalent). After stirring at room temperature for 5 h, the reaction mixture was quenched with NaHCO3 (aqueous solution) at room temperature and extracted with EtOAc. The combined organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-60%) to give the title compound (85 mg, 79.3%) as a light yellow oil. MS (ES, m / z): [M+1] + =262.1.
[0603] Step 5: 2a-Amino-3,3,4,4,7-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one
[0604]
[0605] To a stirred mixture of 3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]indene-2a-amine (85 mg, 0.325 mmol, 1.00 equiv) and NaIO4 (278 mg, 1.30 mmol, 4.00 equiv) in CH3CN (0.50 mL) and DCM (0.50 mL) was added water (0.75 mL) and RuCl3.HO (7.34 mg, 0.03 mmol, 0.10 equiv) at room temperature. After stirring at room temperature for 1 h, the resulting mixture was diluted with DCM. The organic layer was washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by preparative TLC (PE / EtOAc=3 / 1) to give the title compound (45 mg, 52.5%) as a light yellow oil. MS (ES, m / z): [M-1] - =261.9.
[0606] Step 6: 3-((2a-amino-3,3,4,4-tetrafluoro-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile
[0607]
[0608] To a stirred mixture of 2a-amino-3,3,4,4,7-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-1-one (40 mg, 0.15 mmol, 1.00 equiv) and 3-fluoro-5-hydroxybenzonitrile (21 mg, 0.15 mmol, 1.00 equiv) in DMF (1.00 mL) was added Cs2CO3 (50 mg, 0.15 mmol, 1.00 equiv) at room temperature. After stirring at room temperature for 1.5 h, the reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by preparative TLC (PE / EtOAc=3 / 1) to give the title compound (35 mg, 60.3%) as a white solid. MS (ES, m / z): [M+1] + =381.1.
[0609] Step 7: 3-((2a-amino-3,3,4,4-tetrafluoro-1-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile
[0610]
[0611] To a stirred solution of 3-((2a-amino-3,3,4,4-tetrafluoro-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile (35 mg, 0.09 mmol, 1.00 equiv) in MeOH (0.50 mL) was added NaBH4 (5 mg, 0.13 mmol, 1.4 equiv) at room temperature. After stirring at room temperature for 0.5 h, the reaction mixture was quenched with saturated NH4Cl(aq) at 0 °C and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluted with EtOAc / PE (0-60%) to give the title compound (30 mg, 85.3%) as a light yellow oil. MS (ES, m / z): [M+1] + =383.1.
[0612] Step 8: 3-((2a-amino-1,3,3,4,4-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile
[0613]
[0614] To a stirred solution of 3-((2a-amino-3,3,4,4-tetrafluoro-1-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile (25 mg, 0.07 mmol, 1.00 equiv) in DCM (1.0 mL) was added DAST (16 mg, 0.10 mmol, 1.5 equiv) at room temperature. After stirring for 2 h at room temperature, the reaction mixture was quenched with saturated NaHCO3(aq) at 0 °C and extracted with DCM. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative HPLC to give the title compound (6 mg, 24%) as a white solid. MS (ES, m / z): [M+1] + =385.1.
[0615] Example 15
[0616] Synthesis of 3-fluoro-5-((1,1,2a,3,3,4,4-heptafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0617]
[0618] To a stirred mixture of 3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (30 mg, 0.08 mmol, 1.00 equiv) in DCM (1.0 mL) was added 4-tert-butyl-2,6-dimethylphenylsulfur trifluoride (59 mg, 0.24 mmol, 3.00 equiv) and pyridine hydrofluoride (0.05 mL, 65%-70%) at room temperature. The resulting mixture was stirred at room temperature under a nitrogen atmosphere for 24 h, then diluted with water and extracted with DCM. The combined organic layers were washed with water and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative HPLC to give the title compound (9.9 mg, 31.1%) as a white solid. MS (ES, m / z): [MH] - =404.1.
[0619] Example 16
[0620] 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]indene-5-
[0621] Synthesis of 5-fluorobenzonitrile
[0622]
[0623] Step 1: 3-Fluoro-5-((7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile
[0624]
[0625] 3-Fluoro-5-((1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile (28 g, 104.77 mmol, 1.00 equiv), F-TEDA-BF4 (33 g, 93.15 mmol, 0.89 equiv) and CH3CN (840 mL) were added to a 2L round-bottom flask. A solution of I2 (24 g, 94.56 mmol, 0.90 equiv) in CH3CN (560 mL) was added dropwise to the stirred solution at 60 °C. The resulting mixture was stirred for 3 h at 60 °C. The mixture was cooled to room temperature and then concentrated under vacuum. Ethyl acetate (250 mL) was added to the residue, and the resulting mixture was stirred at 80 °C for 1 h. The mixture was cooled to room temperature, and the precipitated solid was collected by filtration and washed with Et2O to give the title compound (16.8 g, 40.8%) as an off-white solid. MS (ES, m / z): [M+H] + =394.0.
[0626] Step 2: 3-((2,2-difluoro-7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile
[0627]
[0628] To a stirred mixture of 3-fluoro-5-((7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-benzonitrile (3.600 g, 9.15 mmol, 1.00 equiv) and butan-1-amine (6.7 g, 91.57 mmol, 10.00 equiv) in toluene (90 mL) was added TFA (209 mg, 1.83 mmol, 0.20 equiv) dropwise at room temperature. The resulting mixture was stirred at 100 °C under nitrogen atmosphere for 16 h and then concentrated under vacuum. The residue was dissolved in CH3CN (90 mL) and then Na2SO4 (5.2 g, 36.62 mmol, 4.00 equiv) and F-TEDA-BF4 (6.5 g, 18.31 mmol, 2.00 equiv) were added at room temperature. The resulting mixture was stirred at 80 °C for 2 h, diluted with water, and extracted with EtOAc. The combined organic layers were washed with water, brine, and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with PE / EtOAc (10:1) to give the title compound (1.60 g, 40.7%) as a yellow solid.
[0629] Step 3: 3-((1-allyl-2,2-difluoro-1-hydroxy-7-iodo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile
[0630]
[0631] To a stirred mixture of 3-((2,2-difluoro-7-iodo-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (449 mg, 1.05 mmol, 1.00 equiv) and allyl bromide (253.15 mg, 2.093 mmol, 2.00 equiv) in THF (10 mL) at room temperature was added pyridine (165.52 mg, 2.09 mmol, 2.00 equiv) and (1S,2R)-2-amino-1,2-diphenylethanol (446.30 mg, 2.09 mmol, 2.00 equiv). Indium powder (240.26 mg, 2.09 mmol, 2.00 equiv) was then added to the solution, and the resulting mixture was stirred at room temperature under a nitrogen atmosphere for 8 h. The resulting mixture was filtered, and the filter cake was washed with EtOAc. The filtrate was concentrated and purified by silica gel column chromatography eluting with PE / EtOAc (9:1) to give the title compound (430 mg, 87.2%) as a yellow oil. MS (ES, m / z): [MH]-=470.0.
[0632] Step 4: 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile
[0633]
[0634] To a stirred solution of 3-((1-allyl-2,2-difluoro-1-hydroxy-7-iodo-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (430 mg, 0.91 mmol, 1.00 equiv) and NaOAc (225 mg, 2.74 mmol, 3.00 equiv) in DMF (10 mL) was added Pd(dppf)Cl2.CH2Cl2 (75 mg, 0.09 mmol, 0.10 equiv) at room temperature under nitrogen atmosphere. The resulting mixture was stirred at 100 °C under nitrogen atmosphere for 3 h and then filtered. The filter cake was washed with EtOAc, and the filtrate was washed with H2O, dried over anhydrous Na2SO4 and concentrated. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc (5:1) to give the title compound (223 mg, 71.2%) as a yellow oil.
[0635] Example 17
[0636] Synthesis of 3-((3,3-difluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile
[0637]
[0638] To a 25 mL 2-necked round bottom flask was added 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (210 mg, 0.61 mmol, 1.00 equiv), DCM (2.0 mL), MeCN (2.0 mL) and H2O (3.0 mL) at room temperature. RuCl3.H2O (7 mg, 0.03 mmol, 0.05 equiv) was then added to the solution. To the above mixture was added NaIO4 (523 mg, 2.45 mmol, 4.00 equiv) in portions over 2 min at room temperature and the resulting mixture was stirred at room temperature for 3 h. The resulting mixture was extracted with DCM and the combined organic layers were washed with Na2S2O3 (aq.), H2O and brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluting with PE / EtOAc (5:1) to give the title compound (107 mg, 50.7%) as a yellow oil. MS (ES, m / z): [2M-H]-=689.1.
[0639] Example 18
[0640] Synthesis of 3-((3,3-difluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile
[0641]
[0642] 3-((3,3-difluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (100 mg, 0.29 mmol, 1.00 equiv) and MeOH (2.00 mL) were added to an 8 mL sealed tube at room temperature. NaBH4 (22 mg, 0.58 mmol, 2.0 equiv) was added to the above mixture in batches at 0°C, and the resulting mixture was stirred at room temperature for 1 h. The reaction was quenched with water at 0°C and neutralized to pH=7 with aqueous HCl (1.0 M). The resulting mixture was extracted with DCM, and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative TLC (PE / EtOAc=5 / 1) to give the title compound (78 mg, 77.6%) as a white solid.
[0643] Example 19
[0644] Synthesis of 3-fluoro-5-((1,3,3-trifluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile
[0645]
[0646] To a stirred solution of 3-((3,3-difluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (20 mg, 0.06 mmol, 1.00 equiv) in THF (0.50 mL) was added a solution of DAST (9.35 mg, 0.06 mmol, 1.00 equiv) in DCM (0.2 mL) dropwise at -50 °C under a nitrogen atmosphere. The resulting mixture was stirred at -50 °C under a nitrogen atmosphere for 1 h and then quenched with water at -40 °C. The mixture was neutralized to pH = 7 with saturated NaHCO3(aq) and then extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by preparative HPLC to give the title compound (5.7 mg, 28.3%) as a white solid. MS (ES, m / z): [2M-H]-=697.2.
[0647] Example 20
[0648] 3-Fluoro-5-((1,1,2,2,3,3,4-heptafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]
[0649] Synthesis of (5-(inden-5-yl)oxy)benzonitrile
[0650]
[0651] Step 1: Ethyl 2,2-difluoro-2-(2,2,3,3,6-pentafluoro-1-hydroxy-2,3-dihydro-1H-inden-1-yl) acetate
[0652]
[0653] At 60 ° C, under N2 atmosphere, a mixture of 2,2,3,3,6-pentafluoro-2,3-dihydro-1H-indene-1-one (10.0 g, 45.02 mmol, 1.00 equivalent), In (7.7 g, 67.06 mmol, 1.5 equivalents) and ethyl 2-bromo-2,2-difluoroacetate (13.7 g, 67.5 mmol, 1.50 equivalents) in THF (150 mL) was stirred for 16 h. The reaction was quenched with HCl aqueous solution (2.0 M, 50 mL) at room temperature, and the resulting mixture was extracted with ethyl acetate. The combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (5 / 1) to obtain the title compound (8.0 g, 51.3%) as a light yellow oil. MS (ES, m / z): [M-1]-=345.0
[0654] Step 2: 1,1,2,2,3,3,5-Heptafluoro-2a-hydroxy-1,2,2a,3-tetrahydro-4H-cyclopenta[cd]inden-4-one
[0655]
[0656] At -78 ° C, under N2 atmosphere, to ethyl 2,2-difluoro-2-(2,2,3,3,6-pentafluoro-1-hydroxy-2,3-dihydro-1H-inden-1-yl) acetate (500 mg, 1.44 mmol, 1.00 equiv) in THF (10 mL) was added dropwise LDA (2.2 mL, 4.40 mmol, 2.0 M, 3.06 equiv). The resulting mixture was stirred at -78 ° C for 1 h, then quenched with saturated NH4Cl aqueous solution (10 mL) at -78 ° C. The resulting mixture was extracted with ethyl acetate, and the combined organic layer was dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated and purified by silica gel column chromatography, eluted with PE / EA (3 / 1) to obtain a crude product. The crude product was purified by preparative HPLC to obtain the title product (34 mg, 7.8%) as a light yellow oil. MS (ES, m / z): [M-1]-=298.9
[0657] Step 3: 3-Fluoro-5-((1,1,2,2,3,3-hexafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile
[0658]
[0659] A mixture of 1,1,2,2,3,3,5-heptafluoro-2a-hydroxy-1,2,2a,3-tetrahydro-4H-cyclopenta-[cd]inden-4-one (100 mg, 0.33 mmol, 1.00 equiv), CsCO (217 mg, 0.67 mmol, 2.00 equiv) and 3-fluoro-5-hydroxybenzonitrile (50 mg, 0.36 mmol, 1.10 equiv) in DMF (2 mL) was stirred at -10 °C under N2 atmosphere for 1 h. The crude reaction mixture was used directly in the next step without further purification. MS (ES, m / z): [M-1]-=416.0.
[0660] Step 4: 3-Fluoro-5-((1,1,2,2,3,3-hexafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile
[0661]
[0662] To a stirred solution of crude 3-fluoro-5-((1,1,2,2,3,3-hexafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (0.33mmol, 1.00 equiv) in MeOH (2mL) was added NaBH4 (25mg, 0.66mmol, 2.00 equiv) in batches at -10°C under N2 atmosphere. The resulting mixture was stirred at -10°C for 1h and then quenched with saturated NH4Cl aqueous solution. The resulting mixture was extracted with ethyl acetate, and the combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EA (3 / 1) to give the title compound (90mg, 63.6%) as a light yellow oil for two steps. MS (ES, m / z): [M-1]-=418.0.
[0663] Step 5: 3-Fluoro-5-((1,1,2,2,3,3,4-heptafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile
[0664]
[0665] To a stirred solution of 3-fluoro-5-((1,1,2,2,3,3-hexafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (50 mg, 0.12 mmol, 1.00 equiv) in DCM (1.0 mL) was added DAST (38 mg, 0.24 mmol, 2.00 equiv) dropwise at -20 °C under N2 atmosphere. The resulting mixture was stirred at room temperature for 2 h and quenched with saturated aqueous NaHCO3. The resulting mixture was extracted with DCM and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the crude product was purified by preparative HPLC to give the title compound (14 mg, 27.5%) as a light yellow solid. MS (ES, m / z): [M-1] - =420.0.
[0666] Example 21
[0667] Synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile
[0668]
[0669] Step 1: (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-2,2-d2)oxy)benzonitrile
[0670]
[0671] To a stirred mixture of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (3.0 g, 7.87 mmol, 1.00 equiv) in THF (60 mL) was added a solution of NaOD (645 mg, 15.737 mmol, 2.00 equiv) in D2O (24 mL) dropwise at room temperature. The resulting mixture was stirred at room temperature for 4 h, then diluted with D2O and extracted with MTBE. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography, eluting with PE / EA (3:1) to give the title compound (2.3 g, 76.3%) as a white solid. MS (ES, m / z): [MH] - =382.1.
[0672] Step 2: 3-Fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile
[0673]
[0674] To a stirred mixture of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-2,2-d2)oxy)benzonitrile (1.5 g, 3.883 mmol, 1.00 equiv) in CD3OD (15 mL) was added NaBD4 (329 mg, 7.827 mmol, 2.00 equiv) at 5 °C. The resulting mixture was stirred at room temperature for 2 h and then quenched with D2O at room temperature. The resulting mixture was extracted with MTBE and the combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography eluted with PE / EA (3:1) to give the title compound (1.5 g, 99.2%) as a light yellow solid. MS (ES, m / z): [MH]-=385.1.
[0675] Step 3: 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile
[0676]
[0677] To a stirred mixture of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile (1.5 g, 3.88 mmol, 1.00 equiv) in THF (21 mL) was added DBU (1.18 g, 7.77 mmol, 2.00 equiv) and pyridine-2-sulfonyl fluoride (814 mg, 5.05 mmol, 1.30 equiv) in THF (2 mL) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 16 h and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography with PE / EA (4:1). The resulting product was further purified by chiral preparative HPLC to give the optically pure title compound (740 mg, 49.1%) as a white solid. MS (ES, m / z): [MH]-=387.1.
[0678] Example 22
[0679] Synthesis of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3
[0680]
[0681] Step 1: 3-Bromo-5-fluorobenzene-2,4,6-d3-ol
[0682]
[0683] At room temperature in D2O, 3-bromo-5-fluorophenol (5.00 g, 26.18 mmol, 1.00 equiv) and 60% D2SO4 (13.09 g, 78.53 mmol, 3.00 equiv) were added to a 40 mL sealed tube. The resulting mixture was stirred at 75 ° C for 18 h and then slowly poured into ice. The resulting mixture was extracted with EtOAc, and the combined organic layer was washed with water, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to give the product. Under D2O, the product was added into 60% D2SO4, and the above procedure was repeated 4 more times to give the title compound (4.20 g, 82.7% yield) as a yellow oil. MS (ES, m / z): [MH]-=191.9.
[0684] Step 2: 3-Fluoro-5-hydroxybenzonitrile-2,4,6-d3
[0685]
[0686] At room temperature, under nitrogen atmosphere, to a stirred solution of 3-bromo-5-fluorobenzene-2,4,6-d3-ol (100 mg, 0.515 mmol, 1.00 equiv) and Zn(CN)2 (121 mg, 1.03 mmol, 2.0 equiv) in DMF (2.0 mL) was added Pd(PPh3)4 (60 mg, 0.05 mmol, 0.10 equiv). The resulting mixture was stirred at 100 ° C under nitrogen atmosphere for 3 h, then quenched with water at room temperature. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with water, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography, eluted with PE / EtOAc (1: 1) to obtain the title compound (37 mg, 51.2%) as a white solid. MS (ES, m / z): [MH]-=139.0. Step 3: (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile-2,4,6-d3
[0687]
[0688] To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]indene-1-one (179 mg, 0.68 mmol, 1.00 equiv) and 3-fluoro-5-hydroxybenzonitrile-2,4,6-d3 (95 mg, 0.68 mmol, 1.00 equiv) in DMF (3.5 mL) was added CsCO (221 mg, 0.68 mmol, 1.00 equiv) at room temperature. After stirring at room temperature for 16 h, the reaction mixture was quenched with water at 0 °C. The resulting mixture was extracted with EtOAc, and the combined organic layers were washed with H2O, brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography eluting with EtOAc / PE (0-40%) to give the title compound (170 mg, 65.3%) as a white solid. MS (ES, m / z): [MH]-=383.0.
[0689] Step 4: 3-Fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3
[0690]
[0691] To a stirred mixture of (R)-3-fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile-2,4,6-d3 (170 mg, 0.442 mmol, 1.00 equiv) in CD3OD (3.5 mL) was added NaBD4 (37 mg, 0.885 mmol, 2.00 equiv) in portions at room temperature. The resulting mixture was stirred at room temperature for 3 h, diluted with D2O (3.0 mL) and extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated and the residue was purified by silica gel column chromatography eluted with EtOAc / PE (0-40%) to give the title compound (120 mg, 70.0%) as a white solid. MS (ES, m / z): [2M-H]-=773.1.
[0692] Step 5: 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3
[0693]
[0694] To a stirred mixture of 3-fluoro-5-(((1R,2aR)-3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3 (125 mg, 0.32 mmol, 1.00 equiv) in THF (1.6 mL) was added DBU (98 mg, 0.65 mmol, 2.00 equiv) and pyridine-2-sulfonyl fluoride (68 mg, 0.42 mmol, 1.30 equiv) in THF (0.4 mL) dropwise at room temperature under nitrogen atmosphere. The resulting mixture was stirred at room temperature under nitrogen atmosphere for 16 h. The reaction solution was purified by silica gel column chromatography eluting with PE / EtOAc (4:1) and then purified by preparative HPLC to give the title compound (10 mg, 8.0%) as a white solid. MS (ES, m / z): [MH]-=388.1.
[0695] Example 23
[0696] (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile [23a] and (S)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0697] Synthesis of [23b]
[0698]
[0699] To a stirred mixture of (R)-3,3,4,4,7-pentafluoro-1-methylene-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]indene-2a-ol (400 mg, 1.53 mmol, 1.0 equiv., about 80% ee) and 3-fluoro-5-hydroxybenzonitrile (209 mg, 1.53 mmol, 1.0 equiv.) in DMF (10 mL) was added CsCO (497 mg, 1.53 mmol, 1.0 equiv.) at room temperature, and the resulting mixture was stirred at 100 ° C for 24 h. After the reaction mixture was cooled to room temperature, it was filtered. The filtrate was purified by preparative HPLC to give 131 mg of the product as a mixture of enantiomers. The enantiomers were separated by chiral preparative HPLC [column: CHIRALPAK OD-3, 50*4.6 mm, 3um OD30CC-QE001, flow rate: 1.0 mL / min; oven temperature: 25°C; mobile phase A: n-hexane; mobile phase B: ethanol; concentration of phase B: 10%) to give 23a (65 mg, 11.2%) MS (ES, m / z): [MH]-=378.0.tR: 1.34 min and 23b (6 mg, 1.0%); MS (ES, m / z): [MH]-=378.0.tR: 1.77 min.
[0700] Example 24
[0701] Synthesis of 3-fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile[24a] and 3-fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile[24b]
[0702]
[0703] Step 1: (R)-3-((4-(butylimino)-1,1,2,2-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile
[0704]
[0705] A solution of (R)-3-fluoro-5-((1,1,2,2-tetrafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (700 mg, 1.84 mmol, 1.0 equiv, ca. 80% ee), TFA (42 mg, 0.37 mmol, 0.2 equiv) and butylamine (1343 mg, 18.36 mmol, 10.0 equiv) in toluene (15 mL) was stirred at 100 °C under N2 atmosphere for 16 h. The resulting mixture was concentrated under vacuum to give the title compound (1.0 g, crude) as a light brown oil, which was used directly in the next step. MS (ES, m / z): [M+1] + =437.2.
[0706] Step 2: 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and 3-Fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile
[0707]
[0708] A mixture of (R)-3-((4-(butylimino)-1,1,2,2-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile (1.0 g crude, 1.84 mmol, 1.0 eq), sodium sulfate (651 mg, 4.58 mmol, 2.5 eq) and Selectfluor (1.05 g, 2.96 mmol, 1.6 eq) in MeCN (15 mL) was stirred at 60 °C under N2 atmosphere for 4 h. The crude product was purified by preparative HPLC to give 150 mg of one isomer and 300 mg of the other isomer. MS (ES, m / z): [M-1] - =397.9.
[0709] Step 3: 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and 3-Fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile
[0710]
[0711] 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile is separated The 2-hydroxy-2-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and the 2-hydroxy-2-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile were respectively converted as follows.
[0712] To a stirred solution of 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a-hydroxy-4-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (1.0 equiv) in MeOH was added NaBH4 (2.0 equiv) in portions at 0°C under N2 atmosphere. The resulting mixture was stirred at room temperature for 1 h and quenched with saturated aqueous NH4Cl solution. The resulting mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous Na2SO4. After filtration, the filtrate was concentrated under reduced pressure to obtain 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile as a light yellow oil. MS (ES, m / z): [2M-1] - =801.2.
[0713] Step 4: 3-Fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or 3-Fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile
[0714]
[0715] 3-Fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile and 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile were prepared as follows: Respectively converted into 3-fluoro-5-(((2aS,3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile:
[0716] To a stirred solution of 3-fluoro-5-(((2aS,3S)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS,3R)-1,1,2,2,3-pentafluoro-2a,4-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile (1.0 equiv) in DCM was added DAST (1.5 equiv) dropwise at -40 °C under N2 atmosphere. The resulting mixture was stirred at -40 °C for 2 h and quenched with saturated aqueous NH4Cl solution. The resulting mixture was extracted with DCM. The combined organic layers were dried over anhydrous Na2SO4. After filtration, the filtrate is concentrated under reduced pressure. The crude product is purified by preparative HPLC to give 3-fluoro-5-(((2aS, 3S)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile or 3-fluoro-5-(((2aS, 3R)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile as a light yellow solid. MS (ES, m / z): [M-1] - =402.0.
[0717] Since the stereochemistry at *C of compounds 24a and 24b has not been determined, compound 24a is either compound 24a1 or 24a2.
[0718]
[0719] Similarly, compound 24b is compound 24b1 or 24b2.
[0720]
[0721] Example 25
[0722] Synthesis and Polymorphic Characterization of 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (Compound 5)
[0723]
[0724] To a 3000 mL 3-neck round bottom flask was added 3-fluoro-5-(((lR,2aR)-3,3,4,4-tetrafluoro-l,2a-dihydroxy-2,2a,3,4-tetrahydro-lH-cyclopenta[cd]inden-7-yl)oxy)benzonitrile (350 g, 0.762 mol, 1.0 eq) and DBU (232.1 g, 1.53 mol, 2.0 eq) in THF (3.5 L) at room temperature. To this solution was added a solution of pyridine-2-sulfonyl fluoride (159.7 g, 0.991 mmol, 1.3 eq) in THF (700 mL) dropwise at 10-15°C. The resulting mixture was stirred at room temperature for 12 hours and then diluted with water and EtOAc. The suspension was filtered through silica gel and the phases were separated. The aqueous layer is extracted with EtOAc and the combined organic layer is washed with water and brine, dried over anhydrous Na2SO4 and concentrated. The residue is purified by silica gel column chromatography (petroleum ether / ethyl acetate=20 / 1 to 7 / 1) to give a crude product (400g) as an off-white solid. The crude product is separated by SFC (column: DAICEL CHIRALPAK AS (250mm*50mm, 10um)) to give 250g of crude product. Heptane (1.0L) is added to the crude product and the mixture is stirred at 40°C for 2 hours. The mixture is filtered to give a pure title product (230g).
[0725] SFC conditions: Column: Chiralpak AD-350×4.6 mm ID, 3 μm Mobile phase: Phase A, CO2; Phase B, EtOH (0.05% DEA) Gradient elution: B in A, from 5% to 40%; Flow rate: 3 mL / min
[0726] Column temperature: 35°C; back pressure: 100 bar; t R :0.904min.
[0727] Polymorph Characterization:
[0728] Compound 5 (15.5 mg) was added to a mixture of 0.4 mL of n-pentanol / heptane (9:1) at 50° C. After the mixture was stirred for 3 days, the solid was collected by filtration to give Form A. X-ray diffractometer (Bruker D8 advance) was used with Cu Ka from a generator operating at 40 kV and 40 mA. The XRPD pattern was obtained with incident light of . The system was equipped with a LynxEye detector. 5 The sample was scanned from 3 to 40° 2θ with a step size of 0.02° 2θ. The data were analyzed using DIFFRAC plus Evaluation Package Release 2010. The XRPD spectrum of Form A is shown in Figure 1 A peak listing for the XRPD spectra is provided in Table A below, with diffraction angles reported in degrees (2-θ).
[0729] Table A. Peak list of crystalline compounds obtained from n-pentanol / heptane
[0730]
[0731]
[0732] Crystallization of compound 5 under the following conditions also gave Form A.
[0733] Method A
[0734] Compound 5 (15 mg / ml) was dissolved in MeOH, IPA, MTBE, EtOAc, IPAc or toluene, and the solution was allowed to evaporate at room temperature to give Compound 5 as a crystalline solid. XRPD analysis showed the crystalline solid to be Form A.
[0735] Method B
[0736] Compound 5 (about 10 mg) was added to 0.5 mL of antisolvent at 50°C and then solvent was added to dissolve the solid as shown in Table B below. The mixture was filtered and the solution was slowly cooled to room temperature and stirred at room temperature for one day. The crystals were filtered and subjected to XRPD analysis.
[0737] Table B
[0738] Antisolvent Solvents Crystal form water EtOH Type A water IPA Type A Heptane EtOH Type A Heptane IPA Type A Heptane Toluene Type A
[0739] Method C
[0740] Compound 5 was dissolved in a solvent and anti-solvent was added with stirring at room temperature, 50°C or an ice bath as shown in the following Table C. The crystalline solid was filtered and characterized by XRPD.
[0741] Table C
[0742]
[0743] Method D
[0744] Compound 5 (about 10 mg) was dissolved in a solvent, and the resulting solution was then added to 0.5 mL of an antisolvent. The mixture was kept stirring at room temperature for one day. The crystalline solid was analyzed by XRPD. The results are shown in Table D below.
[0745] Table D
[0746]
[0747] Biological Examples
[0748] Example 1
[0749] VEGF ELISA assay
[0750] The ability of the disclosed compounds to inhibit HIF-2α was measured by measuring VEGF expression in 786-O cells. Approximately 7500 786-O cells were seeded into each well of a 96-well white transparent bottom plate (07-200-566, Fisher Scientific) containing 200ul growth medium. Four hours later, the compound was dispensed into the wells by a Tecan D300e digital dispenser, with a starting concentration of 10uM and a 1 / 2 log dilution to 1nM as a final concentration. The treatment of each concentration was performed in duplicate. After about 20 hours, the culture medium was removed and fresh culture medium was added, followed by the treatment of the compound as described above. After 24 hours, the cell culture medium was collected to determine the VEGF concentration using an ELISA kit (R&D systems, catalog number DVE00) according to the manufacturer's instructions.
[0751] EC was calculated using the dose-response-inhibition (four-parameter) equation by GraphPad Prism. 50 Plates containing cells were then subjected to the CellTiter-Glo luminescent cell viability assay (Promega) to determine the effects of these compounds on cell numbers following the above treatments.
[0752]
[0753] Preparation Examples
[0754] The following are representative pharmaceutical formulations containing compounds of the disclosure.
[0755] Tablet formulations
[0756] The following ingredients are intimately mixed and compressed into single slot tablets.
[0757]
[0758] Capsule preparations
[0759] The following ingredients are mixed intimately and filled into hard shell gelatin capsules.
[0760]
[0761] Injectable preparations
[0762] Compounds of the disclosure (e.g., compounds of Formula I) in 2% HPMC, 1% Tween 80 in DI water, q.s. to at least 20 mg / mL
[0763] Inhalation composition
[0764] To prepare a pharmaceutical composition for inhalation delivery, 20 mg of a compound disclosed herein is mixed with 50 mg of anhydrous citric acid and 100 mL of 0.9% sodium chloride solution. The mixture is incorporated into an inhalation delivery device suitable for inhalation administration, such as a nebulizer.
[0765] Topical gel composition
[0766] To prepare a pharmaceutical topical gel composition, 100 mg of a compound disclosed herein is mixed with 1.75 g of hydroxypropylcellulose, 10 mL of propylene glycol, 10 mL of isopropyl myristate, and 100 mL of purified alcohol USP. The resulting gel mixture is then incorporated into a container (such as a tube) suitable for topical administration.
[0767] Ophthalmic solution composition
[0768] To prepare a pharmaceutical ophthalmic solution composition, 100 mg of a compound disclosed herein is mixed with 0.9 g NaCl in 100 mL of purified water and filtered with a 0.2 micron filter. The resulting isotonic solution is then incorporated into an ophthalmic delivery device (such as an eye drop container) suitable for ophthalmic administration.
[0769] Nasal spray solution
[0770] To prepare a pharmaceutical nasal spray solution, 10 g of a compound disclosed herein was mixed with 30 mL of 0.05 M phosphate buffer solution (pH 4.4). The solution was placed in a nasal applicator designed to deliver 100 ul of spray for each administration.
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt thereof: in: X 1 is CH or N; R 1 is hydroxy, halo or amino; R 2 It is hydrogen, deuterium, C 1-6 Alkyl, halo or C 1-6 Haloalkyl; R 3 and R 4 are independently hydrogen, deuterium, C 1-6 Alkyl, C 3-10 Cycloalkyl, halo, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl or C 1-6 Alkoxyalkyl; R 5 It is hydrogen, deuterium, C 1-6 Alkyl, halo, C 1-6 Haloalkyl, hydroxyl or C 1-6 Alkoxy; R 6 It is hydrogen, deuterium, C 1-6 Alkyl, C 3-10 Cycloalkyl or halo; or R 5 and R 6 Together with the carbon to which it is attached, it forms an oxo, C 1-6 alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene; provided that R 5 With R 6 and R 3 With R 4 together with the carbon to which it is attached, do not simultaneously form oxo, cycloalkylene, or optionally substituted 4- to 6-membered heterocyclylene; R 7 It is hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, cyano, halo, C 1-6 Haloalkyl or C 1-6 Haloalkoxy; L is O; R 8 It is C 6-10 Aryl or 5- to 10-membered heteroaryl, wherein C 6-10 Aryl or 5- to 10-membered heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl group, a , R b and R c Replace the R a , R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy, halo, cyano, C 1-6 Hydroxyalkyl, C 1-6 Alkoxyalkyl or C 1-6 aminoalkyl; R 9 It is hydrogen, C 1-6 Alkyl, C 3-10 Cycloalkyl, hydroxyl, C 1-6 Alkoxy, cyano, halo, C 1-6 Haloalkyl or C 1-6 haloalkoxy; or When R 9 and R 2 When attached to the same carbon atom, they can combine to form oxo, C 1-6 alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered heterocyclylene.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 3 and R 4 are independently halogenated; or, R 3 is halogenated and R 4 is hydrogen; or, R 3 is fluorine; or, R 3 and R 4 It's fluorine.
3. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is hydroxyl; or, R 1 It's amino.
4. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 6 is halogenated; or, R 6 It is C 1-6 Alkyl, hydrogen or deuterium.
5. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 5 is halogenated; or, R 5 It is C 1-6 Alkyl, hydrogen or C 1-6 Alkoxy.
6. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 5 and R 6 Together with the carbon to which it is attached, it forms a 3- to 6-membered cycloalkylene group.
7. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein X 1 Yes CR 7 .
8. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which has a structure of formula (IIa) or (IIb):
9. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, which has a structure of formula (IIa') or (IIb'):
10. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 8 It is R a , R b or R c substituted phenyl, and wherein R a , R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy, halo, cyano, C 1-6 Hydroxyalkyl, C 1-6 Alkoxyalkyl or C 1-6 aminoalkyl; Preferably, R 8 is 3-chloro-5-fluorophenyl, 3,5-difluorophenyl, 3-fluoro-5-methoxyphenyl, 3-cyano-5-fluorophenyl, 3-chloro-5-cyanophenyl, 3-cyano-5-methylphenyl, 3-chloro-4-fluorophenyl, 3-chloro-5-fluorophenyl, 3-fluoro-5-methyl, 3-cyanophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3-chloro-2-methylphenyl, 3,5-dichlorophenyl, 3,5-dimethylphenyl, 2-chloro-6-methylphenyl, 2,6-difluorophenyl, 3,4,5-trifluorophenyl, 3,4-difluorophenyl, 4-fluoro-3-methylphenyl, 3-cyano-4-fluorophenyl, 3-cyano-5-difluoromethylphenyl or 3-cyano-5-fluoro-2,4,6-trideuteratedphenyl; Or, R 8 It is R a , R b and R c substituted 5-membered or 6-membered heteroaryl, the R a , R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy, halo, cyano, C 1-6 Hydroxyalkyl, C 1-6 Alkoxyalkyl or C 1-6 aminoalkyl; Preferably, R 8 It is R a , R b and R c Substituted 5-membered or 6-membered heteroaryl, wherein R a and R b are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Alkoxy, hydroxy, halogen, C 1-6 Haloalkyl, C 1-6 haloalkoxy and cyano, and R c Selected from hydrogen, C 1-6 Alkyl, halo, C 1-6 Haloalkyl and C 1-6 Haloalkoxy; More preferably, R 8 is pyridin-3-yl, pyridin-2-yl, pyridazin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, pyrimidin-2-yl, thien-2-yl, furan-2-yl, thiazol-5-yl, oxazol-5-yl, imidazol-5-yl, furan-3-yl, thien-3-yl, thiazol-4-yl, pyridin-4-yl, oxazol-2-yl, imidazol-2-yl, pyridin-2-yl, pyrazin-2-yl or thiazol-2-yl, and R a , R b and R c Substitution, where R a and R b are independently selected from hydrogen, methyl, methoxy, hydroxy, chlorine, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy, and R c is selected from the group consisting of hydrogen, methyl, cyano, chlorine, fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy and trifluoromethoxy.
11. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 7 is hydrogen, methyl, ethyl, methoxy, fluorine, trifluoromethyl or trifluoromethoxy.
12. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen, fluorine, methyl or ethyl, and R 9 It is hydrogen, C 1-6 Alkyl, halo, hydroxy or C 1-6 Alkoxy; Or, R 2 and R 9 attached to the same carbon atom; Preferably, R 2 and R 9 Attached to a ring carbon atom that is attached to R 1 The ring carbon of is in the meta position; Or, R 2 and R 9 is attached to the same carbon atom and together with the carbon atom to which it is attached forms an oxo group and is attached to a ring carbon atom that is the same as the carbon atom attached to R 1 The ring carbon is in the meta position.
13. The compound according to claim 9 or a pharmaceutically acceptable salt thereof, which has the structure of formula (VIIIa) or (VIIIb):
14. The compound according to claim 13 or a pharmaceutically acceptable salt thereof, which has a structure of formula (VIIIb), wherein R 2 is hydrogen and R 9 is hydrogen, fluorine or methyl.
15. The compound of claim 1, which is selected from: 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-(((1R,2aS)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-(((1R,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 1,3,3,4,4-Pentafluoro-7-((5-fluoropyridin-3-yl)oxy)-1,2,3,4-tetrahydro-2aH-cyclopenta[cd]inden-2a-ol; 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydrospiro[cyclopenta[cd]-indene-1,1'-cyclopropane]-7-yl)oxy)benzonitrile; 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-((3,3,4,4-tetrafluoro-1,2a-dihydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-((1,3,3,4,4-pentafluoro-2a-hydroxy-1-methyl-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-((2a-amino-1,3,3,4,4-pentafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-5-fluorobenzonitrile; 3-Fluoro-5-((1,1,2a,3,3,4,4-heptafluoro-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-((3,3-difluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile; 3-((3,3-difluoro-2a-hydroxy-1-oxo-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile; 3-((3,3-difluoro-1,2a-dihydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)-5-fluorobenzonitrile; 3-Fluoro-5-((1,3,3-trifluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-5-yl)oxy)benzonitrile; 3-Fluoro-5-((1,2,2,3,3,4,4-heptafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy); 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1,2,2-d3)oxy)benzonitrile; 3-Fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl-1-d)oxy)benzonitrile-2,4,6-d3; (R)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; (S)-3-Fluoro-5-((3,3,4,4-tetrafluoro-2a-hydroxy-1-methylene-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-(((2S,2aS)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; 3-Fluoro-5-(((2R,2aS)-1,2,3,3,4,4-hexafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)benzonitrile; or or pharmaceutically acceptable salts thereof.
16. The compound of claim 1, wherein the compound is a crystalline form of 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile; Preferably, the crystalline form is a Form A polymorph; More preferably, the Form A polymorph has an X-ray powder diffraction pattern comprising peaks at angular positions 15.8 and 18.6, wherein these angular positions may vary. + 0.2°2θ; Further preferably, the Form A polymorph has an X-ray powder diffraction pattern comprising peaks at angular positions 15.8, 18.6 and 20.1, wherein these angular positions may vary. + 0.2°2θ; Still further preferably, the Form A polymorph has an X-ray powder diffraction pattern comprising peaks at angular positions 12.9, 15.8, 18.6 and 20.1, wherein these angular positions may vary. + 0.2°2θ; Still further preferably, the Form A polymorph has an X-ray powder diffraction pattern comprising peaks at angular positions 11.4, 12.9, 15.8, 18.6 and 20.1, wherein these angular positions may vary. + 0.2°θ; Most preferably, the Form A polymorph of the compound 3-fluoro-5-(((1S,2aR)-1,3,3,4,4-pentafluoro-2a-hydroxy-2,2a,3,4-tetrahydro-1H-cyclopenta[cd]inden-7-yl)oxy)-benzonitrile has an X-ray powder diffraction pattern comprising peaks at angular positions substantially as shown in Figure 1.
17. A pharmaceutical composition comprising the compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof, or the crystalline form according to claim 16; and a pharmaceutically acceptable excipient.
18. Use of a compound according to any one of claims 1 to 15 or a pharmaceutically acceptable salt thereof or a crystalline form according to claim 16 in the preparation of a medicament for treating cancer, inflammatory disease, liver disease, iron overload or lung disease in a patient; Preferably, the cancer is selected from renal cancer, glioblastoma, neuroblastoma, paraganglioma, pheochromocytoma, pancreatic neuroendocrine tumor, liver cancer, colorectal cancer, somatostatinoma, hemangioblastoma, gastrointestinal stromal tumor, pituitary tumor, leiomyoma, leiomyosarcoma, polycythemia vera, retinal cancer, Hippel-Lindau disease, astrocytoma, lung cancer, non-small cell lung cancer, melanoma, breast cancer, cervical cancer, head and neck cancer, ovarian cancer, prostate cancer, esophageal squamous cell carcinoma and uterine fibroids; the inflammatory disease or lung disease is selected from NASH, pulmonary hypertension or inflammatory bowel disease; More preferably, the cancer is clear cell renal cell carcinoma or hepatocellular carcinoma.
19. The use according to claim 18, wherein the disease is cancer, and the compound according to claims 1 to 15 or a pharmaceutically acceptable salt thereof or the crystalline form according to claim 16 can be optionally administered in combination with at least one other anticancer agent; Preferably, the at least one additional anticancer agent is selected from sunitinib, sorafenib, regorafenib, lenvatinib, vandetanib, cabozantinib, axitinib, aflibercept, bevacizumab, pazopanib, rapamycin (sirolimus), temsirolimus, everolimus, XL388, XL765, AZD2013, PF04691502, PKI-587, BEZ235, GDC0349 (atezolizumab), MED14736 (durvalumab), pomacetinib, palbociclib and ribociclib.
20. The compound shown below:
21. A method for preparing a compound of formula (1-4) or a pharmaceutically acceptable salt thereof: Treating the compound of formula (1-3) with a fluorinating agent to obtain a compound of formula (1-4); the fluorinating agent is preferably DAST; Preferably, the preparation method of the compound of formula (1-3) is as follows: Treating the compound of formula (1-2) with a reducing agent to obtain a compound of formula (1-3); the reducing agent is preferably sodium borohydride; More preferably, the preparation method of the compound of formula (1-2) is as follows: Using R 8 -LH treatment of the compound of formula (1-1) to obtain the compound of formula (1-2); More preferably, the preparation method of the compound of formula (1-1) is as follows: Treating the compound of formula (1-k) with an oxidative cleavage reagent to obtain a compound of formula (1-1); the oxidative cleavage reagent is preferably NaIO4 or RuCl3; Alternatively, a method for preparing a compound of formula (1-5) or a pharmaceutically acceptable salt thereof: Using R 8 -LH treatment of the compound of formula (1-k) to obtain a compound of formula (1-5); Preferably, the preparation method of the compound of formula (1-k) is as follows: Treating the compound of formula (1-j) with a Pd catalyst to obtain a compound of formula (1-k); the Pd catalyst is preferably Pd(dppf)Cl2CH2Cl2 or Pd(PPh3)2Cl2; in, R 3 and R 4 are independently hydrogen, deuterium, C 1-6 Alkyl, C 3-10 Cycloalkyl, halo, C 1-6 Haloalkyl, C 1-6 Hydroxyalkyl or C 1-6 Alkoxyalkyl; or R 3 and R 4 together with the carbon to which it is attached, form oxo, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene; R 5 It is hydrogen, deuterium, C 1-6 Alkyl, halo, C 1-6 Haloalkyl, hydroxyl or C 1-6 Alkoxy; R 6 It is hydrogen, deuterium, C 1-6 Alkyl, C 3-10 Cycloalkyl or halo; or R 5 and R 6 Together with the carbon to which it is attached, it forms an oxo, C 1-6 alkyldienyl, 3- to 6-membered cycloalkylene, or 4- to 6-membered optionally substituted heterocyclylene; provided that R 5 With R 6 and R 3 With R 4 together with the carbon to which it is attached, do not simultaneously form oxo, cycloalkylene, or optionally substituted 4- to 6-membered heterocyclylene; R 7 It is hydrogen, deuterium, C 1-6 Alkyl, C 1-6 Alkoxy, cyano, halo, C 1-6 Haloalkyl or C 1-6 Haloalkoxy; L is O; R 8 It is C 6-10 Aryl or 5- to 10-membered heteroaryl, wherein C 6-10 Aryl or 5- to 10-membered heteroaryl, each by itself or as part of an aralkyl or heteroaralkyl group, a , R b and R c Replace the R a , R b and R c are independently selected from hydrogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Halogenated alkoxy, C 1-6 Alkoxy, hydroxy, halo, cyano, C 1-6 Hydroxyalkyl, C 1-6 Alkoxyalkyl or C 1-6 Aminoalkyl.
